{"questions": [{"id": "5a67a049b750ff4455000007", "body": "Does echinacea increase anaphylaxis risk?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/9507713", "http://www.ncbi.nlm.nih.gov/pubmed/11814277", "http://www.ncbi.nlm.nih.gov/pubmed/28731887", "http://www.ncbi.nlm.nih.gov/pubmed/18831749", "http://www.ncbi.nlm.nih.gov/pubmed/17085774", "http://www.ncbi.nlm.nih.gov/pubmed/25784510", "http://www.ncbi.nlm.nih.gov/pubmed/23024696", "http://www.ncbi.nlm.nih.gov/pubmed/26895223", "http://www.ncbi.nlm.nih.gov/pubmed/26633727", "http://www.ncbi.nlm.nih.gov/pubmed/21923308"], "snippets": [{"offsetInBeginSection": 1292, "offsetInEndSection": 1505, "text": "Echinacea was associated with a borderline increased risk of having at least one episode of acute otitis media during 6-month follow-up compared to placebo (65% versus 41%; relative risk, 1.59, 95% CI 1.04, 2.42).", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/18831749"}, {"offsetInBeginSection": 1618, "offsetInEndSection": 1785, "text": "CONCLUSION: In otitis-prone young children, treating colds with this form of echinacea does not decrease the risk of acute otitis media, and may in fact increase risk.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/18831749"}, {"offsetInBeginSection": 187, "offsetInEndSection": 555, "text": "Regular ingestion of echinacea by up to 5% of surveyed patients with atopy, combined with detection of echinacea-binding IgE in atopic subjects (19% by skin testing; 20% with moderate to strong reactivity by RAST testing), raises the possibility of severe allergic reactions, even with first-time use, due to cross-reactivity with other structurally similar allergens.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/9507713"}, {"offsetInBeginSection": 540, "offsetInEndSection": 676, "text": "SUMMARY: Knowing the factors that increase the risk of anaphylaxis allows reactions to be recognized, reported and further investigated.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28731887"}, {"offsetInBeginSection": 261, "offsetInEndSection": 433, "text": "Therefore, modulation of the immune system and antiviral interventions such as echinacea might reduce the risk of recurrences and possibly the development of complications.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25784510"}, {"offsetInBeginSection": 588, "offsetInEndSection": 776, "text": "RESULTS: There is good scientific evidence from a prospective cohort study that oral consumption of echinacea during the first trimester does not increase the risk for major malformations.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17085774"}, {"offsetInBeginSection": 0, "offsetInEndSection": 136, "text": "Echinacea reduces the risk of recurrent respiratory tract infections and complications: a meta-analysis of randomized controlled trials.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25784510"}, {"offsetInBeginSection": 1040, "offsetInEndSection": 1167, "text": "Use of echinacea extracts was associated with reduced risk of recurrent respiratory infections (RR 0.649, 95% CI 0.545-0.774; P", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25784510"}, {"offsetInBeginSection": 1256, "offsetInEndSection": 1366, "text": "The use of echinacea was not associated with an increased risk of malformations or adverse pregnancy outcomes.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26895223"}, {"offsetInBeginSection": 1366, "offsetInEndSection": 1503, "text": "CONCLUSION: This study revealed no increased risk of malformations or adverse pregnancy outcomes after the use of echinacea in pregnancy.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26895223"}]}, {"id": "58e8a2fc3e8b6dc87c00000c", "body": "Do cephalopods use RNA editing less frequently than other species?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/29048557", "http://www.ncbi.nlm.nih.gov/pubmed/28388405", "http://www.ncbi.nlm.nih.gov/pubmed/28855414", "http://www.ncbi.nlm.nih.gov/pubmed/8939811", "http://www.ncbi.nlm.nih.gov/pubmed/22044752", "http://www.ncbi.nlm.nih.gov/pubmed/25347917", "http://www.ncbi.nlm.nih.gov/pubmed/26169954", "http://www.ncbi.nlm.nih.gov/pubmed/18567816", "http://www.ncbi.nlm.nih.gov/pubmed/8467802", "http://www.ncbi.nlm.nih.gov/pubmed/2480644"], "snippets": [{"offsetInBeginSection": 1066, "offsetInEndSection": 1489, "text": "Some features of the chimeric molecules are at odds with current models of RNA editing: (i) U residues are completely absent from the connecting sequence of a number of these molecules, (ii) the ND7 gRNAs are frequently hooked up to the wrong editing domain of ND7 RNA, although other gRNAs are not found at these positions and (iii) in some chimeric molecules the gRNA appears to be linked to the 5' end of pre-edited RNA.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/8467802"}, {"offsetInBeginSection": 0, "offsetInEndSection": 161, "text": "The adenosine-to-inosine (A-to-I) RNA editomes have been systematically characterized in various metazoan species, and many editing sites were found in clusters.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/29048557"}, {"offsetInBeginSection": 532, "offsetInEndSection": 749, "text": "Several instances show that the genomic arginine codon CGG is edited in the mRNA to the tryptophan codon TGG in amino acid positions that are highly conserved as tryptophan in the homologous proteins of other species.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/2480644"}, {"offsetInBeginSection": 928, "offsetInEndSection": 1104, "text": "The apparently frequent and non-species-specific equivalency of CGG and TGG codons in particular suggests that RNA editing is a common feature of all higher plant mitochondria.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/2480644"}, {"offsetInBeginSection": 278, "offsetInEndSection": 491, "text": "By adopting a method originally designed to detect linkage disequilibrium of DNA mutations, we examined the editomes of ten metazoan species and detected extensive linkage of editing in Drosophila and cephalopods.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/29048557"}, {"offsetInBeginSection": 1170, "offsetInEndSection": 1363, "text": "Moreover, more than half of these edited amino acids are genomically encoded in the orthologs of other species; an example of a conversion model of the nonconservative edited site is addressed.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/18567816"}, {"offsetInBeginSection": 153, "offsetInEndSection": 516, "text": "We analyzed the RNA editing of the Kv2 K(+) channel from different insects spanning more than 300 million years of evolution: Drosophila melanogaster, Culex pipiens (Diptera), Pulex irritans (Siphonaptera), Bombyx mori (Lepidoptera), Tribolium castaneum (Coleoptera), Apis mellifera (Hymenoptera), Pediculus humanus (Phthiraptera), and Myzus persicae (Homoptera).", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/18567816"}, {"offsetInBeginSection": 517, "offsetInEndSection": 655, "text": "RNA editing was detected across all Kv2 orthologs, representing the most highly conserved RNA editing event yet reported in invertebrates.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/18567816"}, {"offsetInBeginSection": 477, "offsetInEndSection": 640, "text": "Comparison analysis of the published editotypes of these 25 transcripts in eight species showed that RNA editing events gradually disappear during plant evolution.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22044752"}, {"offsetInBeginSection": 1101, "offsetInEndSection": 1280, "text": "Even for the subset of RNA editing sites shared by deeply divergent cephalopod lineages, the primary effect of nuclear editing is an increase-not a decrease-in protein divergence.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28855414"}]}, {"id": "5a6a3335b750ff4455000025", "body": "Which algorithm is available for computing minimal absent words using external memory?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/28407038", "http://www.ncbi.nlm.nih.gov/pubmed/25526884", "http://www.ncbi.nlm.nih.gov/pubmed/22974263", "http://www.ncbi.nlm.nih.gov/pubmed/19426495", "http://www.ncbi.nlm.nih.gov/pubmed/18366790", "http://www.ncbi.nlm.nih.gov/pubmed/28293277", "http://www.ncbi.nlm.nih.gov/pubmed/21386877", "http://www.ncbi.nlm.nih.gov/pubmed/22220210", "http://www.ncbi.nlm.nih.gov/pubmed/27004958", "http://www.ncbi.nlm.nih.gov/pubmed/26953874"], "snippets": [{"offsetInBeginSection": 903, "offsetInEndSection": 1230, "text": "RESULTS: Our contribution in this article is twofold: first, we bridge this unpleasant gap by presenting an [Formula: see text]-time and [Formula: see text]-space algorithm for computing all minimal absent words based on the construction of suffix arrays; and second, we provide the respective implementation of this algorithm.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25526884"}, {"offsetInBeginSection": 1067, "offsetInEndSection": 1616, "text": "We stress that our implementation, despite making use of external memory, is fast; indeed, even on relatively smaller datasets when enough RAM is available to hold all necessary data structures, it is less than two times slower than state-of-the-art internal-memory implementations.Availability and implementation: https://github.com/solonas13/maw (free software under the terms of the GNU GPL).Contact: alice.heliou@lix.polytechnique.fr or solon.pissis@kcl.ac.uk.Supplementary information: Supplementary data are available at Bioinformatics online.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28407038"}, {"offsetInBeginSection": 531, "offsetInEndSection": 740, "text": "Such memory requirements are a significant hurdle to the computation of minimal absent words in large datasets.Results: We present emMAW, the first external-memory algorithm for computing minimal absent words.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28407038"}, {"offsetInBeginSection": 346, "offsetInEndSection": 563, "text": "There exists an [Formula: see text]-time and [Formula: see text]-space algorithm for computing all minimal absent words on a fixed-sized alphabet based on the construction of suffix automata (Crochemore et al., 1998).", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25526884"}, {"offsetInBeginSection": 1150, "offsetInEndSection": 1431, "text": "We have analyzed our implementation on a 875-million read whole-genome dataset, on which LSG has built the string graph using only 1GB of main memory (reducing the memory occupation by a factor of 50 with respect to SGA), while requiring slightly more than twice the time than SGA.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26953874"}, {"offsetInBeginSection": 2, "offsetInEndSection": 57, "text": "MAW: computing minimal absent words in external memory.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28407038"}, {"offsetInBeginSection": 541, "offsetInEndSection": 709, "text": "This method outputs the whole set of minimal absent words and furthermore our technique provides a linear-time algorithm with less memory usage than previous solutions.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22974263"}, {"offsetInBeginSection": 569, "offsetInEndSection": 687, "text": "We have developed a disk-based algorithm for computing string graphs in external memory: the light string graph (LSG).", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26953874"}, {"offsetInBeginSection": 232, "offsetInEndSection": 399, "text": "There exists an O(n) -time and O(n) -space algorithm for computing all minimal absent words of a sequence of length n on a fixed-sized alphabet based on suffix arrays.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28407038"}, {"offsetInBeginSection": 0, "offsetInEndSection": 99, "text": "LSG: An External-Memory Tool to Compute String Graphs for Next-Generation Sequencing Data Assembly.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26953874"}]}, {"id": "5a7357e63b9d13c708000001", "body": "Is there an RNAi drug being developed to treat amyloidosis?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/23432579", "http://www.ncbi.nlm.nih.gov/pubmed/27033334", "http://www.ncbi.nlm.nih.gov/pubmed/28389707", "http://www.ncbi.nlm.nih.gov/pubmed/19495687", "http://www.ncbi.nlm.nih.gov/pubmed/26458571", "http://www.ncbi.nlm.nih.gov/pubmed/28430919", "http://www.ncbi.nlm.nih.gov/pubmed/20307511", "http://www.ncbi.nlm.nih.gov/pubmed/17456035", "http://www.ncbi.nlm.nih.gov/pubmed/25670385", "http://www.ncbi.nlm.nih.gov/pubmed/20024842"], "snippets": [{"offsetInBeginSection": 1112, "offsetInEndSection": 1344, "text": "Pioneering clinical studies include RNAi drugs targeting liver synthesis of PCSK9 resulting in highly significant lowering of LDL cholesterol or targeting liver transthyretin (TTR) synthesis for treatment of cardiac TTR amyloidosis.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28430919"}, {"offsetInBeginSection": 115, "offsetInEndSection": 246, "text": "RNA interference (RNAi) is a clinically validated technology that may be a promising approach to the treatment of ATTR amyloidosis.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27033334"}, {"offsetInBeginSection": 443, "offsetInEndSection": 706, "text": "As neurological disorder related amyloidosis, systemic amyloidosis, such as AL amyloidosis, AA amyloidosis, dialysis related amyloidosis, FAP, senile systemic amyloidosis, and brain localized amyloidosis, such as Alzheimer's disease, and prion disease are listed.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26458571"}, {"offsetInBeginSection": 0, "offsetInEndSection": 85, "text": "Preclinical evaluation of RNAi as a treatment for transthyretin-mediated amyloidosis.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27033334"}, {"offsetInBeginSection": 168, "offsetInEndSection": 593, "text": "This conference report highlights selected presentations on the reversal of drug resistance using targeted siRNA or small-hairpin RNA and EnGeneIC drug delivery vehicles, the development of siRNA therapeutics for lung diseases, siRNA-based topical microbicides, locked nucleic acid-based oligonucleotides, and company-specific approaches to the development of RNAi therapeutics from Alnylam Pharmaceuticals Inc and MDRNA Inc.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20024842"}, {"offsetInBeginSection": 224, "offsetInEndSection": 442, "text": "In addition to these amyloidosis, in transthyretin (TTR) related familial amyloidotic polyneuropathy (FAP), liver transplantation, tertial structure stabilizing drugs, and gene silencing drugs have been developing now.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26458571"}, {"offsetInBeginSection": 0, "offsetInEndSection": 64, "text": "[Amyloidosis and neurological disorders: Treatable amyloidosis].", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26458571"}, {"offsetInBeginSection": 1098, "offsetInEndSection": 1286, "text": "Together, the data presented herein support the therapeutic hypothesis behind TTR lowering and highlight the potential of RNAi in the treatment of patients afflicted with ATTR amyloidosis.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27033334"}, {"offsetInBeginSection": 882, "offsetInEndSection": 1111, "text": "Particularly advanced is the development of RNA interference (RNAi) drugs which use recently discovered pathways of endogenous short interfering RNAs and are becoming versatile tools for efficient silencing of protein expression.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28430919"}, {"offsetInBeginSection": 0, "offsetInEndSection": 167, "text": "The RNAi for Developing Targeted Therapeutics meeting, held in Boston, included topics covering new therapeutic developments in the field of RNAi-based drug discovery.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20024842"}]}, {"id": "5a87d73861bb38fb2400000b", "body": "Which main ribotype of Clostridium difficile is responsible of the recent outbreak?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/21998885", "http://www.ncbi.nlm.nih.gov/pubmed/20621236", "http://www.ncbi.nlm.nih.gov/pubmed/24916866", "http://www.ncbi.nlm.nih.gov/pubmed/24739945", "http://www.ncbi.nlm.nih.gov/pubmed/26238868", "http://www.ncbi.nlm.nih.gov/pubmed/26341328", "http://www.ncbi.nlm.nih.gov/pubmed/28782647", "http://www.ncbi.nlm.nih.gov/pubmed/27533048", "http://www.ncbi.nlm.nih.gov/pubmed/28169013", "http://www.ncbi.nlm.nih.gov/pubmed/28989415"], "snippets": [{"offsetInBeginSection": 1103, "offsetInEndSection": 1249, "text": "CONCLUSION: Our findings sustain the hypothesis of a recent emerged outbreak of C. difficile PCR ribotype 027 infections in the area of Bucharest.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24916866"}, {"offsetInBeginSection": 0, "offsetInEndSection": 200, "text": "Epidemiology of Clostridium difficile is characterized by worldwide increase of C. difficile infections (CDI) and the emergence of new epidemic outbreak strains with the capacity for global spreading.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26341328"}, {"offsetInBeginSection": 0, "offsetInEndSection": 139, "text": "BACKGROUND: An outbreak of Clostridium difficile ribotype 027 infection (CDI) occurred at an university hospital, involving 19 departments.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27533048"}, {"offsetInBeginSection": 0, "offsetInEndSection": 97, "text": "Outbreak of Clostridium difficile PCR ribotype 027--the recent experience of a regional hospital.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24739945"}, {"offsetInBeginSection": 0, "offsetInEndSection": 190, "text": "An Outbreak of Clostridium difficile Ribotype 027 Associated with Length of Stay in the Intensive Care Unit and Use of Selective Decontamination of the Digestive Tract: A Case Control Study.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27533048"}, {"offsetInBeginSection": 0, "offsetInEndSection": 109, "text": "Cost analysis of an outbreak of Clostridium difficile infection ribotype 027 in a Dutch tertiary care centre.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28169013"}, {"offsetInBeginSection": 0, "offsetInEndSection": 152, "text": "Clostridium difficile strain ribotype 027 is a hypervirulent pathogen that is responsible for recent, severe outbreaks of serious nosocomial infections.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21998885"}, {"offsetInBeginSection": 1039, "offsetInEndSection": 1215, "text": "Interestingly, all trf isolates were toxin A-negative, toxin B-positive, but they did not correspond to PCR-ribotype 017, thus being assigned a new ribotype (PCR-ribotype 369).", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26238868"}, {"offsetInBeginSection": 378, "offsetInEndSection": 502, "text": "METHODS: A retrospective analysis was performed to estimate the costs of a one-year-long C.\u00a0difficile ribotype 027 outbreak.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28169013"}, {"offsetInBeginSection": 175, "offsetInEndSection": 344, "text": "A second strain associated with hypervirulence is ribotype 078 and the prevalence of Clostridium difficile infection (CDI) due to this ribotype appears to be increasing.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20621236"}]}, {"id": "5a67a550b750ff4455000009", "body": "Is there an association between carcinoid syndrome and mitral valve disease?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/11568027", "http://www.ncbi.nlm.nih.gov/pubmed/7453210", "http://www.ncbi.nlm.nih.gov/pubmed/21316509", "http://www.ncbi.nlm.nih.gov/pubmed/26564596", "http://www.ncbi.nlm.nih.gov/pubmed/14626739", "http://www.ncbi.nlm.nih.gov/pubmed/7236050", "http://www.ncbi.nlm.nih.gov/pubmed/22364692", "http://www.ncbi.nlm.nih.gov/pubmed/27278349", "http://www.ncbi.nlm.nih.gov/pubmed/24812331", "http://www.ncbi.nlm.nih.gov/pubmed/146456"], "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 253, "text": "A 53-year-old woman is described who underwent mitral and aortic valve replacement and tricuspid valve annuloplasty for pure regurgitation at all 3 valve sites for unrecognized carcinoid heart disease without the carcinoid syndrome 22 days before death.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21316509"}, {"offsetInBeginSection": 1214, "offsetInEndSection": 1379, "text": "Recent evidence suggests that degenerative aortic and mitral valve disease may involve pathologic processes that mimic osteogenesis and chondrogenesis, respectively.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22364692"}, {"offsetInBeginSection": 282, "offsetInEndSection": 406, "text": "Degenerative (myxomatous) mitral valve disease (DMVD) is an important disease associated with aging in both dogs and humans.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22364692"}, {"offsetInBeginSection": 379, "offsetInEndSection": 542, "text": "RESULTS: Eleven patients (7 men, 4 women) with symptomatic carcinoid heart disease underwent surgery for left- and right-sided valve disease between 1989 and 1999.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/11568027"}, {"offsetInBeginSection": 0, "offsetInEndSection": 166, "text": "BACKGROUND: Symptoms and survival of patients with carcinoid syndrome have improved, but development of carcinoid heart disease (CaHD) continues to decrease survival.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26564596"}, {"offsetInBeginSection": 815, "offsetInEndSection": 1066, "text": "Of the patients who were identified to have carcinoid heart disease in different studies, 193 patients had valve procedure, mainly replacements at tricuspid, mitral and aortic valve positions and either valvuloplasty or replacement at pulmonary valve.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24812331"}, {"offsetInBeginSection": 0, "offsetInEndSection": 133, "text": "Carcinoid heart disease without the carcinoid syndrome but with quadrivalvular regurgitation and unsuccessful operative intervention.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21316509"}, {"offsetInBeginSection": 1111, "offsetInEndSection": 1246, "text": "The diagnosis of carcinoid syndrome should be discussed in patients with organic tricuspid regurgitation without left valvular disease.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/14626739"}, {"offsetInBeginSection": 0, "offsetInEndSection": 97, "text": "We present a case of a 54-year-old man with carcinoid heart disease and mitral valve involvement.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27278349"}, {"offsetInBeginSection": 0, "offsetInEndSection": 160, "text": "A 53-year-old man with a pancreatic carcinoid tumor and liver metastases had the carcinoid syndrome with involvement of the tricuspid valve by carcinoid plaque.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/7453210"}]}, {"id": "58eb99f3eda5a57672000009", "body": "Do origins of replication close to yeast centromeres fire early or late?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/15294892", "http://www.ncbi.nlm.nih.gov/pubmed/18093330", "http://www.ncbi.nlm.nih.gov/pubmed/9783589", "http://www.ncbi.nlm.nih.gov/pubmed/22589733", "http://www.ncbi.nlm.nih.gov/pubmed/17304213", "http://www.ncbi.nlm.nih.gov/pubmed/22081599", "http://www.ncbi.nlm.nih.gov/pubmed/20865002", "http://www.ncbi.nlm.nih.gov/pubmed/20808889", "http://www.ncbi.nlm.nih.gov/pubmed/22081107", "http://www.ncbi.nlm.nih.gov/pubmed/12167157"], "snippets": [{"offsetInBeginSection": 2031, "offsetInEndSection": 2515, "text": "CONCLUSION: The fact that approximately 97% of fission yeast replication origins - both early and late - are not significantly affected by replication checkpoint mutations in HU-treated cells suggests that (i) most late-firing origins are restrained from firing in HU-treated cells by at least one checkpoint-independent mechanism, and (ii) checkpoint-dependent slowing of S phase in fission yeast when DNA is damaged may be accomplished primarily by the slowing of replication forks.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/18093330"}, {"offsetInBeginSection": 610, "offsetInEndSection": 913, "text": "The block to late origin firing is an active process and is defective in yeast with mutations in the rad53 and mec1 checkpoint genes, indicating that regulation of late origin firing may also be an important component of the 'intra-S-phase' checkpoint and may aid cell survival under adverse conditions.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/9783589"}, {"offsetInBeginSection": 0, "offsetInEndSection": 191, "text": "DNA replication in eukaryotic cells initiates from many replication origins which fire throughout the S phase of the cell cycle in a predictable pattern: some origins fire early, others late.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/9783589"}, {"offsetInBeginSection": 1064, "offsetInEndSection": 1369, "text": "We found (consistent with the three previous studies after appropriate interpretation) that, in surprising contrast to budding yeast, most fission yeast origins, including both early- and late-firing origins, are not significantly affected by checkpoint mutations during replication in the presence of HU.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/18093330"}, {"offsetInBeginSection": 0, "offsetInEndSection": 209, "text": "Origins of replication are activated throughout the S phase of the cell cycle such that some origins fire early and others fire late to ensure that each chromosome is completely replicated in a timely fashion.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20865002"}, {"offsetInBeginSection": 942, "offsetInEndSection": 1144, "text": "Furthermore, functional analysis also reveals that catabolic genes cluster around early firing origins, whereas anabolic genes can rather be found in the proximity of late firing origins of replication.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22081599"}, {"offsetInBeginSection": 336, "offsetInEndSection": 504, "text": "Here we show that, in budding yeast, hydroxyurea, which blocks the progression of replication forks from early-firing origins, also inhibits the firing of late origins.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/9783589"}, {"offsetInBeginSection": 0, "offsetInEndSection": 113, "text": "Different groups of metabolic genes cluster around early and late firing origins of replication in budding yeast.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22081599"}, {"offsetInBeginSection": 1327, "offsetInEndSection": 1576, "text": "Upon exposure to DNA-damaging agents, cells expressing non-phosphorylatable alleles of SLD3 and DBF4 (SLD3-m25 and dbf4-m25, respectively) proceed through the S phase faster than wild-type cells by inappropriately firing late origins of replication.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20865002"}, {"offsetInBeginSection": 801, "offsetInEndSection": 1079, "text": "Because the activation time of individual origins is not an intrinsic property of S. cerevisiae origins, but is influenced by surrounding sequences, we sought to test the hypothesis that centromeres influence replication time by moving a centromere to a late replication domain.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22589733"}]}, {"id": "5a6d0727b750ff445500002b", "body": "Is there any role of 5hmC in T-cell development and differentiation?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/25071199", "http://www.ncbi.nlm.nih.gov/pubmed/27252783", "http://www.ncbi.nlm.nih.gov/pubmed/22956496", "http://www.ncbi.nlm.nih.gov/pubmed/27346350", "http://www.ncbi.nlm.nih.gov/pubmed/26363184", "http://www.ncbi.nlm.nih.gov/pubmed/26115768", "http://www.ncbi.nlm.nih.gov/pubmed/21750410", "http://www.ncbi.nlm.nih.gov/pubmed/25200796", "http://www.ncbi.nlm.nih.gov/pubmed/24615693", "http://www.ncbi.nlm.nih.gov/pubmed/23958281"], "snippets": [{"offsetInBeginSection": 786, "offsetInEndSection": 927, "text": "Our data constitute a valuable resource that will facilitate detailed analysis of the role of 5hmC in T-cell development and differentiation.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25071199"}, {"offsetInBeginSection": 173, "offsetInEndSection": 319, "text": "We have mapped 5-hydroxymethylcytosine (5hmC) at different stages of T-cell development in the thymus and T-cell differentiation in the periphery.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25071199"}, {"offsetInBeginSection": 167, "offsetInEndSection": 311, "text": "5hmC plays important roles in regulation of gene expression and differentiation and has been implicated in T\u00a0cell malignancies and autoimmunity.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27346350"}, {"offsetInBeginSection": 312, "offsetInEndSection": 484, "text": "Here, we report early and widespread 5mC/5hmC remodeling during human CD4(+) T\u00a0cell differentiation ex\u00a0vivo at genes and cell-specific enhancers with known T\u00a0cell function.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27346350"}, {"offsetInBeginSection": 0, "offsetInEndSection": 100, "text": "Dissecting the dynamic changes of 5-hydroxymethylcytosine in T-cell development and differentiation.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25071199"}, {"offsetInBeginSection": 940, "offsetInEndSection": 1119, "text": "Our results support 5hmC-mediated DNA de-methylation as a key component of CD4(+) T\u00a0cell biology in humans, with important implications for gene regulation and lineage commitment.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27346350"}, {"offsetInBeginSection": 640, "offsetInEndSection": 808, "text": "Underscoring their important function, 5hmC loci were highly enriched for genetic variants associated with T\u00a0cell diseases and\u00a0T-cell-specific chromosomal interactions.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27346350"}, {"offsetInBeginSection": 394, "offsetInEndSection": 590, "text": "RESULTS: We used reduced representation of 5-hydroxymethylcytosine profiling (RRHP) to characterize 5hmC distribution in CD34+ cells, CD4+ T cells, CD19+ B cells, CD14+ monocytes and granulocytes.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27252783"}, {"offsetInBeginSection": 484, "offsetInEndSection": 781, "text": "Although most of the work on TET enzymes and 5hmC has been carried out in embryonic stem (ES) cells, the highest levels of 5hmC occur in the brain and in neurons, pointing to a role for this epigenetic modification in the control of neuronal differentiation, neural plasticity and brain functions.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25200796"}, {"offsetInBeginSection": 674, "offsetInEndSection": 845, "text": "Based on these studies of 5hmC levels and reports of tissue-specific TET expression, these enzymes are thought to play a role in mammalian development and differentiation.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22956496"}]}, {"id": "5a74a4be0384be9551000004", "body": "Are there RNAi approaches considered for the treatment of kidney injury?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/20588055", "http://www.ncbi.nlm.nih.gov/pubmed/27009268", "http://www.ncbi.nlm.nih.gov/pubmed/20217562", "http://www.ncbi.nlm.nih.gov/pubmed/27253415", "http://www.ncbi.nlm.nih.gov/pubmed/23627598", "http://www.ncbi.nlm.nih.gov/pubmed/27867451", "http://www.ncbi.nlm.nih.gov/pubmed/23968852", "http://www.ncbi.nlm.nih.gov/pubmed/28389707", "http://www.ncbi.nlm.nih.gov/pubmed/24090239", "http://www.ncbi.nlm.nih.gov/pubmed/23035592"], "snippets": [{"offsetInBeginSection": 900, "offsetInEndSection": 1027, "text": "Both pathologic and biochemical analyses show that knockdown of CypD by RNAi protects rat kidney from I/R-induced renal injury.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20588055"}, {"offsetInBeginSection": 1020, "offsetInEndSection": 1301, "text": "p53, caspase 2, PKN3, \u03b22-adrenergic receptor, mutated KRAS, microRNAs); (ii) therapeutic conditions, including ophthalmic diseases, kidney injury, amyloidosis, pancreatic cancer, viral hepatitis; and (iii) routes of administration (ocular, intravenous, subcutaneous, intratumoral).", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28389707"}, {"offsetInBeginSection": 0, "offsetInEndSection": 68, "text": "Targeted fibrillar nanocarbon RNAi treatment of acute kidney injury.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27009268"}, {"offsetInBeginSection": 1267, "offsetInEndSection": 1430, "text": "Above all, DGL-PEG-dermorphin/shRNA NPs were proved to be efficient and safe for brain-targeting RNAi neuroprotection against cerebral ischemia reperfusion injury.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23968852"}, {"offsetInBeginSection": 0, "offsetInEndSection": 81, "text": "Kidney in diabetic state is more sensitive to ischemic acute kidney injury (AKI).", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27867451"}, {"offsetInBeginSection": 455, "offsetInEndSection": 644, "text": "METHODS: To evaluate the role of CypD following I/R renal injury, we tested the hypothesis that knockdown of CypD gene by RNA interference (RNAi) protects rat from I/R-induced renal injury.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20588055"}, {"offsetInBeginSection": 278, "offsetInEndSection": 487, "text": "Herein, we describe ammonium-functionalized carbon nanotube (fCNT)-mediated transport of siRNA selectively and with high efficiency to renal proximal tubule cells in animal models of acute kidney injury (AKI).", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27009268"}, {"offsetInBeginSection": 167, "offsetInEndSection": 314, "text": "As one of the effective RNA interference (RNAi) approaches, short hairpin RNA (shRNA) has been proved to be promising in the field of gene therapy.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23968852"}, {"offsetInBeginSection": 0, "offsetInEndSection": 95, "text": "Brain-targeting delivery for RNAi neuroprotection against cerebral ischemia reperfusion injury.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23968852"}, {"offsetInBeginSection": 0, "offsetInEndSection": 146, "text": "Thioredoxin-Interacting Protein Mediates NLRP3 Inflammasome Activation Involved in the Susceptibility to Ischemic Acute Kidney Injury in Diabetes.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27867451"}]}, {"id": "5a87e95461bb38fb2400000c", "body": "Which is the transcriptome of RNA polymerase III?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/20413673", "http://www.ncbi.nlm.nih.gov/pubmed/17977614", "http://www.ncbi.nlm.nih.gov/pubmed/21417954", "http://www.ncbi.nlm.nih.gov/pubmed/20418882", "http://www.ncbi.nlm.nih.gov/pubmed/24564208", "http://www.ncbi.nlm.nih.gov/pubmed/28228471", "http://www.ncbi.nlm.nih.gov/pubmed/14634212", "http://www.ncbi.nlm.nih.gov/pubmed/27506977", "http://www.ncbi.nlm.nih.gov/pubmed/16166643", "http://www.ncbi.nlm.nih.gov/pubmed/15121834"], "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 235, "text": "Our view of the RNA polymerase III (Pol III) transcription machinery in mammalian cells arises mostly from studies of the RN5S (5S) gene, the Ad2 VAI gene, and the RNU6 (U6) gene, as paradigms for genes with type 1, 2, and 3 promoters.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20413673"}, {"offsetInBeginSection": 0, "offsetInEndSection": 186, "text": "The products of transcription by the multisubunit enzyme RNA polymerase III (Pol III), such as 5S rRNA, tRNAs, U6 snRNA, are important for cell growth, proliferation and differentiation.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21417954"}, {"offsetInBeginSection": 0, "offsetInEndSection": 80, "text": "RNA polymerase III (Pol III) transcribes small untranslated RNAs, such as tRNAs.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/14634212"}, {"offsetInBeginSection": 569, "offsetInEndSection": 755, "text": "A unique aspect of this work is the use of the RNA polymerase II (Pol II) inhibitor \u03b1-amanitin, which we used to define a set of RNA polymerase I and III (Pol I and Pol III) transcripts.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24564208"}, {"offsetInBeginSection": 0, "offsetInEndSection": 127, "text": "RNA polymerase III (Pol III) transcribes a limited set of short genes in eukaryotes producing abundant small RNAs, mostly tRNA.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28228471"}, {"offsetInBeginSection": 0, "offsetInEndSection": 137, "text": "Defining the RNA polymerase III transcriptome: Genome-wide localization of the RNA polymerase III transcription machinery in human cells.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20413673"}, {"offsetInBeginSection": 976, "offsetInEndSection": 1214, "text": "It does not contain any of the microRNA genes previously described as transcribed by Pol III, but reveals two other microRNA genes, MIR886 (hsa-mir-886) and MIR1975 (RNY5, hY5, hsa-mir-1975), which are genuine Pol III transcription units.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20413673"}, {"offsetInBeginSection": 769, "offsetInEndSection": 1026, "text": "This review summarizes the novel data on the regulation of RNA polymerase III transcription, including epigenetic and gene specific mechanisms and outlines recent insights into the cellular functions of the Pol III transcriptome, in particular of SINE RNAs.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21417954"}, {"offsetInBeginSection": 0, "offsetInEndSection": 47, "text": "The expanding RNA polymerase III transcriptome.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17977614"}, {"offsetInBeginSection": 0, "offsetInEndSection": 238, "text": "We used genome-wide expression analysis in Saccharomyces cerevisiae to explore whether and how the expression of protein-coding, RNA polymerase (Pol) II-transcribed genes is influenced by a decrease in RNA Pol III-dependent transcription.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16166643"}]}, {"id": "5a67a72fb750ff445500000a", "body": "Is propranolol used for treatment of infantile hemangioma?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/24346925", "http://www.ncbi.nlm.nih.gov/pubmed/21385205", "http://www.ncbi.nlm.nih.gov/pubmed/23519547", "http://www.ncbi.nlm.nih.gov/pubmed/25535459", "http://www.ncbi.nlm.nih.gov/pubmed/24352207", "http://www.ncbi.nlm.nih.gov/pubmed/24505868", "http://www.ncbi.nlm.nih.gov/pubmed/26400030", "http://www.ncbi.nlm.nih.gov/pubmed/22503260", "http://www.ncbi.nlm.nih.gov/pubmed/22299307", "http://www.ncbi.nlm.nih.gov/pubmed/21402978"], "snippets": [{"offsetInBeginSection": 274, "offsetInEndSection": 399, "text": "Since 2008, however, propranolol has been rapidly adopted as an effective pharmacological treatment for infantile hemangioma.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25535459"}, {"offsetInBeginSection": 751, "offsetInEndSection": 830, "text": "Propranolol is novel and safe medication for treatment of infantile hemangioma.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22299307"}, {"offsetInBeginSection": 1368, "offsetInEndSection": 1523, "text": "RESULTS: This study proved high efficiency of propranolol in treatment of infantile hemangioma, as assessed with the objective measures for the first time.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24352207"}, {"offsetInBeginSection": 1510, "offsetInEndSection": 1690, "text": "Our results suggest that early treatment with propranolol is remarkably effective in treating and preventing loss of visual acuity associated with periocular infantile hemangiomas.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21402978"}, {"offsetInBeginSection": 1618, "offsetInEndSection": 1819, "text": "Propranolol is the only Food and Drug Administration approved therapy for treatment of patients with this vascular anomaly and should be considered first-line therapy for genital infantile hemangiomas.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26400030"}, {"offsetInBeginSection": 171, "offsetInEndSection": 244, "text": "Propranolol has been proposed for the treatment of infantile hemangiomas.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24505868"}, {"offsetInBeginSection": 245, "offsetInEndSection": 441, "text": "The aim of this study is to explore the mechanism of action of propranolol for the treatment of infantile hemangiomas and to demonstrate its safety and efficacy through a review of the literature.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24505868"}, {"offsetInBeginSection": 0, "offsetInEndSection": 127, "text": "OBJECTIVE: To evaluate the efficacy, adverse effects, and recurrence of oral propranolol for treatment of infantile hemangioma.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23519547"}, {"offsetInBeginSection": 636, "offsetInEndSection": 723, "text": "Propranolol was a rapid and effective treatment for infantile hemangiomas at 4 weeks (p", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21385205"}, {"offsetInBeginSection": 1264, "offsetInEndSection": 1432, "text": "CONCLUSIONS: Oral propranolol for treatment of infantile hemangiomas was effective in all patients, with 33% reduction in astigmatism and 39% reduction in surface area.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21402978"}]}, {"id": "58ede257eda5a57672000010", "body": "What is the genetic basis of the Delayed Sleep-Phase Syndrome (DSPS)?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/8255922", "http://www.ncbi.nlm.nih.gov/pubmed/23250347", "http://www.ncbi.nlm.nih.gov/pubmed/17964201", "http://www.ncbi.nlm.nih.gov/pubmed/18571740", "http://www.ncbi.nlm.nih.gov/pubmed/14592284", "http://www.ncbi.nlm.nih.gov/pubmed/10875562", "http://www.ncbi.nlm.nih.gov/pubmed/11306557", "http://www.ncbi.nlm.nih.gov/pubmed/16295212", "http://www.ncbi.nlm.nih.gov/pubmed/11186112", "http://www.ncbi.nlm.nih.gov/pubmed/11763990"], "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 119, "text": "This paper presents a clinical review of delayed sleep phase syndrome (DSPS) and non-24-h sleep-wake syndrome (non-24).", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17964201"}, {"offsetInBeginSection": 0, "offsetInEndSection": 199, "text": "Recent progress in biological clock research has facilitated genetic analysis of circadian rhythm sleep disorders, such as delayed sleep phase syndrome (DSPS) and non-24-h sleep-wake syndrome (N-24).", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/11306557"}, {"offsetInBeginSection": 0, "offsetInEndSection": 255, "text": "We classified 64 patients with chronic delayed sleep phase syndrome (DSPS) into the primary (n = 53) and secondary (n = 11) group according to presence or absence of such signs as difficulty in waking up which appeared much earlier than the onset of DSPS.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/11186112"}, {"offsetInBeginSection": 0, "offsetInEndSection": 229, "text": "OBJECTIVE: Delayed sleep phase syndrome (DSPS) is a condition in which the patient is unable to reset or phase-advance his/her sleep timing properly after transient sleep delay and consequently shows persistent sleep phase delay.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/10875562"}, {"offsetInBeginSection": 0, "offsetInEndSection": 101, "text": "In human delayed sleep-phase syndrome (DSPS), sleep onset and wake times occur far later than normal.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/8255922"}, {"offsetInBeginSection": 6, "offsetInEndSection": 144, "text": "OBJECTIVE: Delayed sleep phase syndrome (DSPS) is a circadian-rhythm sleep disorder characterized by abnormally late sleep and wake times.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16295212"}, {"offsetInBeginSection": 0, "offsetInEndSection": 107, "text": "Delayed sleep-phase syndrome (DSPS) is characterized by delayed sleep onset against the desired clock time.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23250347"}, {"offsetInBeginSection": 0, "offsetInEndSection": 97, "text": "Successful use of S20098 and melatonin in an animal model of delayed sleep-phase syndrome (DSPS).", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/8255922"}, {"offsetInBeginSection": 373, "offsetInEndSection": 605, "text": "The N408 allele was previously described to be much less frequent in individuals with Delayed Sleep-Phase Syndrome (DSPS), than in the general Japanese population, suggesting a protective function for the allele against the disease.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/18571740"}, {"offsetInBeginSection": 0, "offsetInEndSection": 89, "text": "The prevalence of delayed sleep phase syndrome (DSPS) has been estimated to be quite low.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/11763990"}]}, {"id": "5a6d0b2db750ff445500002d", "body": "Which factors drive replisome disassembly during DNA replication termination and mitosis?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/28368371", "http://www.ncbi.nlm.nih.gov/pubmed/25342805", "http://www.ncbi.nlm.nih.gov/pubmed/28235849", "http://www.ncbi.nlm.nih.gov/pubmed/25835602", "http://www.ncbi.nlm.nih.gov/pubmed/28537574", "http://www.ncbi.nlm.nih.gov/pubmed/26322582", "http://www.ncbi.nlm.nih.gov/pubmed/27086594", "http://www.ncbi.nlm.nih.gov/pubmed/26255844", "http://www.ncbi.nlm.nih.gov/pubmed/15916609", "http://www.ncbi.nlm.nih.gov/pubmed/28092263"], "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 285, "text": "Initiation of bacteriophage Mu DNA replication by transposition requires the disassembly of the transpososome that catalyses strand exchange and the assembly of a replisome promoted by PriA, PriB, PriC and DnaT proteins, which function in the host to restart stalled replication forks.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15916609"}, {"offsetInBeginSection": 895, "offsetInEndSection": 1066, "text": "In this extended view we present hypothetical models of replication fork termination and discuss remaining and emerging questions in the DNA replication termination field.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25835602"}, {"offsetInBeginSection": 890, "offsetInEndSection": 1085, "text": "When the transition from transpososome to replisome was reconstituted using MRFalpha-DF and MRFalpha-PR, initiation of Mu DNA replication was strictly dependent upon added PriC and PriA helicase.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15916609"}, {"offsetInBeginSection": 764, "offsetInEndSection": 891, "text": "Altogether, our data provide insight into the mechanism of replisome disassembly during eukaryotic DNA replication termination.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25342805"}, {"offsetInBeginSection": 0, "offsetInEndSection": 86, "text": "Polyubiquitylation drives replisome disassembly at the termination of DNA replication.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25342805"}, {"offsetInBeginSection": 203, "offsetInEndSection": 373, "text": "During this process, which is known as replication termination, DNA synthesis is completed, the replication machinery is disassembled and daughter molecules are resolved.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28537574"}, {"offsetInBeginSection": 286, "offsetInEndSection": 543, "text": "Once the molecular chaperone ClpX weakens the very tight binding of the transpososome to the Mu ends, host disassembly factors (MRFalpha-DF) promote the dissociation of the transpososome from the DNA template and the assembly of a new nucleoprotein complex.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15916609"}, {"offsetInBeginSection": 1227, "offsetInEndSection": 1337, "text": "By orchestrating the spatiotemporal turnover of the replisome, p97 plays an essential role in DNA replication.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27086594"}, {"offsetInBeginSection": 0, "offsetInEndSection": 207, "text": "Disassembly of the Cdc45-MCM-GINS (CMG) DNA helicase, which unwinds the parental DNA duplex at eukaryotic replication forks, is the key regulated step during replication termination but is poorly understood.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26255844"}, {"offsetInBeginSection": 781, "offsetInEndSection": 1056, "text": "Dissociation of the replicative CMG helicase (comprising CDC45, MCM2-7 and GINS) occurs only after the final ligation step, and is not required for completion of DNA synthesis, strongly suggesting that converging CMGs pass one another and dissociate from double-stranded DNA.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26322582"}]}, {"id": "5a75fec383b0d9ea6600000b", "body": "Can the CEP290 gene mutations be targeted by AAV-mediated gene therapy?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/28109959", "http://www.ncbi.nlm.nih.gov/pubmed/28679290", "http://www.ncbi.nlm.nih.gov/pubmed/10775597", "http://www.ncbi.nlm.nih.gov/pubmed/15960597", "http://www.ncbi.nlm.nih.gov/pubmed/21257638", "http://www.ncbi.nlm.nih.gov/pubmed/9282169", "http://www.ncbi.nlm.nih.gov/pubmed/17724218", "http://www.ncbi.nlm.nih.gov/pubmed/24807808", "http://www.ncbi.nlm.nih.gov/pubmed/26325627", "http://www.ncbi.nlm.nih.gov/pubmed/22142163"], "snippets": [{"offsetInBeginSection": 278, "offsetInEndSection": 396, "text": "The large size of the CEP290 gene prevents its use in adeno-associated virus (AAV)-mediated gene augmentation therapy.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28109959"}, {"offsetInBeginSection": 1447, "offsetInEndSection": 1645, "text": "These data reveal that a specific region of the CEP290 protein is sufficient to restore visual function and this region may be a viable gene therapy target for LCA patients with mutations in CEP290.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21257638"}, {"offsetInBeginSection": 1025, "offsetInEndSection": 1422, "text": "These data suggest that intravitreal injections of SSO should be considered to bypass protein truncation resulting from the c.2991+1655A>G mutation as well as other truncating mutations in genes which like CEP290 or ABCA4 have a mRNA size that exceed cargo capacities of US Food and Drug Administration (FDA)-approved adeno-associated virus (AAV)-vectors, thus hampering gene augmentation therapy.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26325627"}, {"offsetInBeginSection": 826, "offsetInEndSection": 1049, "text": "The focus of this review is on examples of AAV-mediated gene therapy in those animal models of inherited retinal degeneration caused by mutations directly affecting the interacting unit formed by photoreceptors and the RPE.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15960597"}, {"offsetInBeginSection": 1081, "offsetInEndSection": 1268, "text": "The clinical features of MFRP-RP and our preliminary data indicating a response to gene therapy in the rd6 mouse suggest that this form of RP is a potential target for gene-based therapy.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22142163"}, {"offsetInBeginSection": 169, "offsetInEndSection": 398, "text": "Autosomal recessive CEP290-associated LCA is a good candidate for gene replacement therapy, and cells derived from affected individuals give researchers the ability to study human disease and therapeutic gene correction in vitro.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24807808"}, {"offsetInBeginSection": 1282, "offsetInEndSection": 1392, "text": "These studies should prove helpful in designing AAV gene targeting vectors for basic research or gene therapy.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/10775597"}, {"offsetInBeginSection": 225, "offsetInEndSection": 534, "text": "Towards this end, we have evaluated the efficacy of a recombinant adeno-associated virus (AAV) vector to deliver and express the correct form of the cGMP phosphodiesterase-beta (PDE-beta) gene in the retinas of rd mice, which suffer rapid retinal degeneration due to recessive mutation in the endogenous gene.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/9282169"}, {"offsetInBeginSection": 1315, "offsetInEndSection": 1506, "text": "CONCLUSIONS: RPE65 gene mutations represented a significant cause of LCA in the Italian population, whereas GUCY2D and CEP290 mutations had a lower frequency than that found in other reports.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17724218"}, {"offsetInBeginSection": 0, "offsetInEndSection": 113, "text": "Gene therapy for retinitis pigmentosa caused by MFRP mutations: human phenotype and preliminary proof of concept.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22142163"}]}, {"id": "5a87ea1861bb38fb2400000d", "body": "What is a coligo?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/24531370", "http://www.ncbi.nlm.nih.gov/pubmed/25764216", "http://www.ncbi.nlm.nih.gov/pubmed/27593562"], "snippets": [{"offsetInBeginSection": 160, "offsetInEndSection": 347, "text": "Here we randomized the 12-nucleotide larger loop (L-loop) of a well characterized coligo and found unexpectedly that in vitro transcription by FLAG-Pol III was not significantly affected.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27593562"}, {"offsetInBeginSection": 1125, "offsetInEndSection": 1261, "text": "A polymerase termination sequence embedded in the double-stranded region of a hairpin-encoding coligo stem can antagonize transcription.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24531370"}, {"offsetInBeginSection": 1125, "offsetInEndSection": 1261, "text": "A polymerase termination sequence embedded in the double-stranded region of a hairpin-encoding coligo stem can antagonize transcription.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25764216"}, {"offsetInBeginSection": 450, "offsetInEndSection": 611, "text": "By using immunoprecipitated RNA polymerase III we now report corroborating evidence that this enzyme is the sole polymerase responsible for coligo transcription.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24531370"}, {"offsetInBeginSection": 450, "offsetInEndSection": 611, "text": "By using immunoprecipitated RNA polymerase III we now report corroborating evidence that this enzyme is the sole polymerase responsible for coligo transcription.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25764216"}, {"offsetInBeginSection": 0, "offsetInEndSection": 123, "text": "RNA polymerase III initiation on coligo DNA templates containing loops of variable sequence, size and nucleotide chemistry.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27593562"}, {"offsetInBeginSection": 827, "offsetInEndSection": 1074, "text": "Transcription of a series of coligos containing twelve contiguous randomized nucleotides placed at different locations within the coligo structure provided further evidence that the stem-loop junction structure is important for precise initiation.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27593562"}, {"offsetInBeginSection": 348, "offsetInEndSection": 464, "text": "This observation allowed us to test the variable of coligo L-loop size separately from the variable of its sequence.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27593562"}, {"offsetInBeginSection": 1169, "offsetInEndSection": 1315, "text": "Overall, these experiments support structure, rather than L-loop sequence, as the major determinant of coligo transcription initiation by Pol III.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27593562"}, {"offsetInBeginSection": 0, "offsetInEndSection": 95, "text": "New insights into the promoterless transcription of DNA coligo templates by RNA polymerase III.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24531370"}]}, {"id": "5a67b2f7b750ff445500000f", "body": "Which type of urinary incontinence is diagnosed with the Q tip test?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/25966437", "http://www.ncbi.nlm.nih.gov/pubmed/3056562", "http://www.ncbi.nlm.nih.gov/pubmed/10423870", "http://www.ncbi.nlm.nih.gov/pubmed/18214136", "http://www.ncbi.nlm.nih.gov/pubmed/15195034", "http://www.ncbi.nlm.nih.gov/pubmed/3585870", "http://www.ncbi.nlm.nih.gov/pubmed/20141914", "http://www.ncbi.nlm.nih.gov/pubmed/8729187", "http://www.ncbi.nlm.nih.gov/pubmed/3368164", "http://www.ncbi.nlm.nih.gov/pubmed/3945436"], "snippets": [{"offsetInBeginSection": 1130, "offsetInEndSection": 1263, "text": "Postoperative Q tip test value in TVT group was significantly smaller than in TOT group [25\u00b0(15-45\u00b0) and 20\u00b0 (15-45\u00b0), respectively].", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25966437"}, {"offsetInBeginSection": 116, "offsetInEndSection": 257, "text": "One hundred patients were investigated with cystometergrams or videocystourethrography, and all patients underwent a standardized Q-Tip test.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/3945436"}, {"offsetInBeginSection": 0, "offsetInEndSection": 158, "text": "We evaluated the accuracy of the Q-tip test to measure uretrhovesical junction mobility in patient's histories of urinary incontinence, and pelvic relaxation.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/8729187"}, {"offsetInBeginSection": 361, "offsetInEndSection": 561, "text": "More than one-third of the patients with bladder instability and almost one-half of the patients with pelvic relaxation and no urinary incontinence had a positive Q-tip test, for low test specificity.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/3585870"}, {"offsetInBeginSection": 911, "offsetInEndSection": 1178, "text": "CONCLUSION: Clinical diagnosis and evaluation of female urinary incontinence is based on patient interview, cough stress test, clinical evaluation of uretral mobility (Q-Tip test), voiding diary, pad test and validated questionnaires for symptoms and quality of life.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20141914"}, {"offsetInBeginSection": 979, "offsetInEndSection": 1129, "text": "In both TOT and TVT groups, postoperative Q tip test values, IIQ-7 and UDI-6 scores were statistically reduced when compared with preoperative values.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25966437"}, {"offsetInBeginSection": 1366, "offsetInEndSection": 1518, "text": "Simple clinical tests for support of the urethrovesical junction, such as the Q tip test, are non-specific in patients with stress urinary incontinence.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/3056562"}, {"offsetInBeginSection": 230, "offsetInEndSection": 360, "text": "More than 90% of the patients with SUI and no previous surgery had a positive Q-tip test, with 90% test sensitivity in this group.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/3585870"}, {"offsetInBeginSection": 0, "offsetInEndSection": 65, "text": "Role of the Q-tip test in evaluating stress urinary incontinence.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/3585870"}, {"offsetInBeginSection": 1264, "offsetInEndSection": 1402, "text": "When we compared the Q-tip test value, IIQ-7 and UDI-6 scores changes, there were no statistically significant changes between the groups.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25966437"}]}, {"id": "58edf567eda5a57672000011", "body": "How many genes constitute the DosR regulon, controlled by the dormancy survival regulator (DosR) in Mycobacterium tuberculosis?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/22833514", "http://www.ncbi.nlm.nih.gov/pubmed/22759512", "http://www.ncbi.nlm.nih.gov/pubmed/19487478", "http://www.ncbi.nlm.nih.gov/pubmed/22544737", "http://www.ncbi.nlm.nih.gov/pubmed/24939385", "http://www.ncbi.nlm.nih.gov/pubmed/19795912", "http://www.ncbi.nlm.nih.gov/pubmed/20630871", "http://www.ncbi.nlm.nih.gov/pubmed/19577518", "http://www.ncbi.nlm.nih.gov/pubmed/21602344", "http://www.ncbi.nlm.nih.gov/pubmed/22719925"], "snippets": [{"offsetInBeginSection": 247, "offsetInEndSection": 374, "text": "The dormancy survival regulon (DosR regulon) is chiefly responsible for encoding dormancy related functions of M. tuberculosis.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22719925"}, {"offsetInBeginSection": 606, "offsetInEndSection": 719, "text": "DosR (Dormancy Survival Regulator, Rv3133c) regulon genes are expressed under the conditions of latency/dormancy.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19795912"}, {"offsetInBeginSection": 0, "offsetInEndSection": 228, "text": "In Mycobacterium tuberculosis, the sensor kinases DosT and DosS activate the transcriptional regulator DosR, resulting in the induction of the DosR regulon, which is important for anaerobic survival and perhaps latent infection.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19487478"}, {"offsetInBeginSection": 0, "offsetInEndSection": 124, "text": "Mycobacterium tuberculosis DosR regulon gene Rv0079 encodes a putative, 'dormancy associated translation inhibitor (DATIN)'.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22719925"}, {"offsetInBeginSection": 121, "offsetInEndSection": 398, "text": "In Mycobacterium tuberculosis, the dormancy regulon is well characterized and contains the dosR gene itself and dosS and dosT genes encoding DosR kinases, nitroreductases (acg; Rv3131), diacylglycerol acyltransferase (DGAT) (Rv3130c), and many universal stress proteins (USPs).", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21602344"}, {"offsetInBeginSection": 0, "offsetInEndSection": 252, "text": "The latency global regulator DosR regulon of Mycobacterium tuberculosis, which is stimulated by hypoxia, comprises approximately fifty genes including ctpF (Rv1997), which encodes a putative alkali/alkaline earth ion transporter of the plasma membrane.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24939385"}, {"offsetInBeginSection": 0, "offsetInEndSection": 94, "text": "Function prediction of Rv0079, a hypothetical Mycobacterium tuberculosis DosR regulon protein.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19795912"}, {"offsetInBeginSection": 0, "offsetInEndSection": 96, "text": "Unique roles of DosT and DosS in DosR regulon induction and Mycobacterium tuberculosis dormancy.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19487478"}, {"offsetInBeginSection": 314, "offsetInEndSection": 438, "text": "The dormancy survival regulator (DosR) regulon, composed of 48 co-regulated genes, is held as essential for Mtb persistence.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22833514"}, {"offsetInBeginSection": 0, "offsetInEndSection": 159, "text": "The DosR dormancy regulator of Mycobacterium tuberculosis stimulates the Na(+)/K (+) and Ca (2+) ATPase activities in plasma membrane vesicles of mycobacteria.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24939385"}]}, {"id": "5a6d1143b750ff445500002e", "body": "List the partners of budding yeast Cdc48 that are important for disassembly of ubiquitylated CMG helicase at the end of chromosome replication", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/28355556", "http://www.ncbi.nlm.nih.gov/pubmed/25342810", "http://www.ncbi.nlm.nih.gov/pubmed/26255844", "http://www.ncbi.nlm.nih.gov/pubmed/28235849", "http://www.ncbi.nlm.nih.gov/pubmed/28368371", "http://www.ncbi.nlm.nih.gov/pubmed/24307213", "http://www.ncbi.nlm.nih.gov/pubmed/16103218", "http://www.ncbi.nlm.nih.gov/pubmed/22285032", "http://www.ncbi.nlm.nih.gov/pubmed/22718908", "http://www.ncbi.nlm.nih.gov/pubmed/24121501"], "snippets": [{"offsetInBeginSection": 246, "offsetInEndSection": 380, "text": "Disassembly of CMG is likely to be a key regulated step at the end of chromosome replication, but the mechanism was unknown until now.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25342810"}, {"offsetInBeginSection": 749, "offsetInEndSection": 988, "text": "Mutation of K29 abrogates in\u00a0vitro recruitment of Ufd1-Npl4-Cdc48 to the CMG helicase, supporting a model whereby Ufd1-Npl4 recruits Cdc48 to ubiquitylated CMG at the end of chromosome replication, thereby driving the disassembly reaction.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28355556"}, {"offsetInBeginSection": 254, "offsetInEndSection": 425, "text": "Here, we employ a screen to identify partners of budding yeast Cdc48 that are important for disassembly of ubiquitylated CMG helicase at the end of chromosome replication.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28355556"}, {"offsetInBeginSection": 0, "offsetInEndSection": 107, "text": "Ufd1-Npl4 Recruit Cdc48 for Disassembly of Ubiquitylated CMG Helicase at the End of Chromosome Replication.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28355556"}, {"offsetInBeginSection": 0, "offsetInEndSection": 172, "text": "Replisome disassembly is the final step of DNA replication in eukaryotes, involving the ubiquitylation and CDC48-dependent dissolution of the CMG helicase (CDC45-MCM-GINS).", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28368371"}, {"offsetInBeginSection": 642, "offsetInEndSection": 906, "text": "In cdc20-ct1 cells carrying mutations in the C-terminal domain of Cdc20, the CMG components, RPA, Pol \u03b1, and Pol \u03b4 were loaded onto replication origins, but Cdc45 did not translocate from the origins, suggesting that Pol \u03b5 is required for CMG helicase progression.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22718908"}, {"offsetInBeginSection": 1435, "offsetInEndSection": 1637, "text": "Residual ubiquitylation of Mcm7 in dia2-\u0394TPR cells is still CMG specific, highlighting the complex regulation of the final stages of chromosome replication, about which much still remains to be learned.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26255844"}, {"offsetInBeginSection": 0, "offsetInEndSection": 245, "text": "Chromosome replication is initiated by a universal mechanism in eukaryotic cells, involving the assembly and activation at replication origins of the CMG (Cdc45-MCM-GINS) DNA helicase, which is essential for the progression of replication forks.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25342810"}, {"offsetInBeginSection": 158, "offsetInEndSection": 284, "text": "A key process of replication initiation is to convert inactive Mcm2-7 to active Cdc45-Mcm-GINS (CMG) replicative helicase [2].", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22285032"}, {"offsetInBeginSection": 147, "offsetInEndSection": 219, "text": "Sld2 is required for the initiation of DNA replication in budding yeast.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24307213"}]}, {"id": "5a76039b83b0d9ea66000010", "body": "What are jakinibs?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/26994322", "http://www.ncbi.nlm.nih.gov/pubmed/29104284", "http://www.ncbi.nlm.nih.gov/pubmed/28255960", "http://www.ncbi.nlm.nih.gov/pubmed/22819198", "http://www.ncbi.nlm.nih.gov/pubmed/26633291", "http://www.ncbi.nlm.nih.gov/pubmed/27821272", "http://www.ncbi.nlm.nih.gov/pubmed/28323260"], "snippets": [{"offsetInBeginSection": 1044, "offsetInEndSection": 1191, "text": "Jakinibs are currently being investigated for a number of new indications, and second-generation selective Jakinibs are being developed and tested.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26633291"}, {"offsetInBeginSection": 138, "offsetInEndSection": 467, "text": "Janus kinases (JAKs) are essential signalling mediators downstream of many pro-inflammatory cytokines, and small-molecule inhibitors of JAKs (jakinibs) have gained traction as safe and efficacious options for the treatment of inflammation-driven pathologies such as rheumatoid arthritis, psoriasis and inflammatory bowel disease.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/29104284"}, {"offsetInBeginSection": 748, "offsetInEndSection": 883, "text": "First generation JAK inhibitors (jakinibs) are used to treat rheumatologic disease, and second-generation jakinibs are being developed.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27821272"}, {"offsetInBeginSection": 698, "offsetInEndSection": 870, "text": "Given these promising findings, Jakinibs are expected to represent the next generation compounds for treating RA, and a number of Jakinibs are currently in clinical trials.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26994322"}, {"offsetInBeginSection": 1184, "offsetInEndSection": 1345, "text": "The safety and clinical efficacy of the Jakinibs are reviewed, starting with the FDA-approved Jakinib tofacitinib, and continuing on to next-generation Jakinibs.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28255960"}, {"offsetInBeginSection": 587, "offsetInEndSection": 735, "text": "Many other Jakinibs are likely to follow and in this brief review, we will discuss the state-of-the art of this new class of pharmacological agents.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22819198"}, {"offsetInBeginSection": 930, "offsetInEndSection": 1021, "text": "Many other Jakinibs are in preclinical development or in various phases of clinical trials.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28255960"}, {"offsetInBeginSection": 468, "offsetInEndSection": 662, "text": "Building on the clinical success of first-generation jakinibs, second-generation compounds that claim to be more selective are currently undergoing development and proceeding to clinical trials.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/29104284"}, {"offsetInBeginSection": 925, "offsetInEndSection": 1043, "text": "Adverse effects of these agents are largely related to their mode of action and include infections and hyperlipidemia.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26633291"}, {"offsetInBeginSection": 390, "offsetInEndSection": 629, "text": "Many cytokines that bind type I and type II cytokine receptors are critical regulators of immune-mediated diseases and employ the Janus kinase (JAK) and signal transducer and activator of transcription (STAT) pathway to exert their effect.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26633291"}]}, {"id": "5a87efa961bb38fb2400000e", "body": "Are mutations in the nf1 gene associated with memory?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/24334617", "http://www.ncbi.nlm.nih.gov/pubmed/25788518", "http://www.ncbi.nlm.nih.gov/pubmed/9639526", "http://www.ncbi.nlm.nih.gov/pubmed/12707950", "http://www.ncbi.nlm.nih.gov/pubmed/23047742", "http://www.ncbi.nlm.nih.gov/pubmed/8528106", "http://www.ncbi.nlm.nih.gov/pubmed/19475561", "http://www.ncbi.nlm.nih.gov/pubmed/25403449", "http://www.ncbi.nlm.nih.gov/pubmed/22207399", "http://www.ncbi.nlm.nih.gov/pubmed/22869071"], "snippets": [{"offsetInBeginSection": 925, "offsetInEndSection": 1211, "text": "Additionally, we leveraged two complementary Nf1 genetically-engineered mouse strains in which hippocampal-based learning and memory is DA-dependent to establish that neuronal DA levels and signaling as well as mouse spatial learning are controlled in an Nf1 gene dose-dependent manner.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25788518"}, {"offsetInBeginSection": 270, "offsetInEndSection": 418, "text": "As 25 % of sporadic PCCs harbor somatic neurofibromin 1 gene (NF1) mutations, NF1 has been established as the most recurrently mutated gene in PCCs.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25403449"}, {"offsetInBeginSection": 1118, "offsetInEndSection": 1370, "text": "Mice with homozygous knockout of the Spred1 gene show learning deficits and decreased synaptic plasticity in hippocampal neurons similar to those seen in Nf1 heterozygous mice, underlining the importance of the RAS-MAPK pathway for learning and memory.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24334617"}, {"offsetInBeginSection": 0, "offsetInEndSection": 164, "text": "Neurofibromatosis type 1 (NF1) and its related disorders (NF1-Noonan syndrome (NFNS) and Watson syndrome (WS)) are caused by heterozygous mutations in the NF1 gene.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23047742"}, {"offsetInBeginSection": 275, "offsetInEndSection": 386, "text": "This study investigated whether PS is associated with specific types of NF1 gene mutations in NF1, NFNS and WS.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23047742"}, {"offsetInBeginSection": 185, "offsetInEndSection": 306, "text": "Mutations in the NF1 gene, which encodes the  neurofibromin protein, have been identified as  the pathogenic gene of NF1.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22869071"}, {"offsetInBeginSection": 309, "offsetInEndSection": 718, "text": "We investigated the mutational status of the N-ras gene and the FLR exon of codons 1371-1423 of the open reading frame of the full-length NF1 cDNA, which has a strong homology with the mammalian ras GTPase-activating protein (GAP), especially for a stretch of three consecutive amino acids (F, L, R), by single-strand conformation polymorphism analysis and direct sequencing in samples from patients with AML.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/8528106"}, {"offsetInBeginSection": 326, "offsetInEndSection": 424, "text": "We hypothesized that NF1 mutations disturb the expression of genes important for memory formation.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19475561"}, {"offsetInBeginSection": 372, "offsetInEndSection": 510, "text": "The purpose of this study was to define the impact of the germline NF1 gene mutation on brain neurofibromin function relevant to learning.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25788518"}, {"offsetInBeginSection": 511, "offsetInEndSection": 743, "text": "Herein, we employ human NF1-patient primary skin fibroblasts, induced pluripotent stem cells and derivative neural progenitor cells (NPCs) to demonstrate that NF1 germline mutations have dramatic effects on neurofibromin expression.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25788518"}]}, {"id": "5a68f2bab750ff4455000017", "body": "Is tretinoin effective for photoaging?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/9703125", "http://www.ncbi.nlm.nih.gov/pubmed/25141855", "http://www.ncbi.nlm.nih.gov/pubmed/9486677", "http://www.ncbi.nlm.nih.gov/pubmed/10790815", "http://www.ncbi.nlm.nih.gov/pubmed/22538278", "http://www.ncbi.nlm.nih.gov/pubmed/2186790", "http://www.ncbi.nlm.nih.gov/pubmed/8435921", "http://www.ncbi.nlm.nih.gov/pubmed/8785463", "http://www.ncbi.nlm.nih.gov/pubmed/3534016", "http://www.ncbi.nlm.nih.gov/pubmed/28293257"], "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 82, "text": "BACKGROUND: Topical tretinoin is effective treatment for both acne and photoaging.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/9486677"}, {"offsetInBeginSection": 0, "offsetInEndSection": 74, "text": "Topical tretinoin is established as an effective treatment for photoaging.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/9703125"}, {"offsetInBeginSection": 0, "offsetInEndSection": 120, "text": "* A cream containing 0.05% tretinoin (Retinova((R)) is approved for treatment of sun-induced skin damage (\"photoaging\").", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/10790815"}, {"offsetInBeginSection": 544, "offsetInEndSection": 656, "text": "Randomized, controlled trials have shown that topical tretinoin is effective in the treatment of photoaged skin.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/2186790"}, {"offsetInBeginSection": 0, "offsetInEndSection": 153, "text": "Most topical tretinoin treatment is for acne vulgaris through the age of 44 years: an analysis of the National Ambulatory Medical Care Survey, 1990-1994.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/9486677"}, {"offsetInBeginSection": 355, "offsetInEndSection": 485, "text": "It was reported in 1969 that topical tretinoin was effective in acne vulgaris, principally by preventing and dislodging comedones.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/3534016"}, {"offsetInBeginSection": 221, "offsetInEndSection": 434, "text": "Many well constructed trials confirm the clinical efficacy of topical tretinoin for improving fine wrinkling and mild to moderate hyperpigmentation; coarse wrinkling and severe hyperpigmentation respond less well.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/8785463"}, {"offsetInBeginSection": 222, "offsetInEndSection": 319, "text": "Tretinoin is the only pharmacologic compound shown to partially reverse some signs of photoaging.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/8435921"}, {"offsetInBeginSection": 297, "offsetInEndSection": 403, "text": "CONCLUSIONS: Tretinoin can be used for photoaging treatment or combined treatment by different mechanisms.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25141855"}, {"offsetInBeginSection": 438, "offsetInEndSection": 633, "text": "Significant advances in clinical and basic research in this area have dispelled much of the confusion, clearing the way for an evidence-based medical approach to tretinoin therapy for photoaging.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/9703125"}]}, {"id": "58edfaf4eda5a57672000012", "body": "What is the function of the dormancy survival regulator (DosR) in Mycobacterium tuberculosis?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/22439727", "http://www.ncbi.nlm.nih.gov/pubmed/22833514", "http://www.ncbi.nlm.nih.gov/pubmed/22544737", "http://www.ncbi.nlm.nih.gov/pubmed/25535276", "http://www.ncbi.nlm.nih.gov/pubmed/12446625", "http://www.ncbi.nlm.nih.gov/pubmed/22372912", "http://www.ncbi.nlm.nih.gov/pubmed/28255560", "http://www.ncbi.nlm.nih.gov/pubmed/19795912", "http://www.ncbi.nlm.nih.gov/pubmed/19487478", "http://www.ncbi.nlm.nih.gov/pubmed/22759512"], "snippets": [{"offsetInBeginSection": 1335, "offsetInEndSection": 1462, "text": "Based on these two functions, dormancy survival and regulation, we named the Rv3133c gene dosR for dormancy survival regulator.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/12446625"}, {"offsetInBeginSection": 0, "offsetInEndSection": 98, "text": "How Mycobacterium tuberculosis goes to sleep: the dormancy survival regulator DosR a decade later.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22439727"}, {"offsetInBeginSection": 606, "offsetInEndSection": 719, "text": "DosR (Dormancy Survival Regulator, Rv3133c) regulon genes are expressed under the conditions of latency/dormancy.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19795912"}, {"offsetInBeginSection": 0, "offsetInEndSection": 87, "text": "DevR is a key regulator of the dormancy response in Mycobacterium tuberculosis (M.\u00a0tb).", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22372912"}, {"offsetInBeginSection": 565, "offsetInEndSection": 737, "text": "A binding motif similar to the dormancy survival regulator (DosR) binding site of M. tuberculosis has been identified in the upstream sequences of most genes in these loci.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25535276"}, {"offsetInBeginSection": 0, "offsetInEndSection": 94, "text": "Function prediction of Rv0079, a hypothetical Mycobacterium tuberculosis DosR regulon protein.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19795912"}, {"offsetInBeginSection": 521, "offsetInEndSection": 717, "text": "Antibodies to Rv1733c, Rv0081, Rv1735c, and Rv1737c DosR regulon-encoded proteins were measured in 68 uninfected individuals, 62 with LTBI, and 107 with active pulmonary tuberculosis (APTB) cases.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28255560"}, {"offsetInBeginSection": 100, "offsetInEndSection": 226, "text": "DosR/DevR of M. tuberculosis is a two component dormancy survival response regulator which induces the expression of 48 genes.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22759512"}, {"offsetInBeginSection": 0, "offsetInEndSection": 228, "text": "In Mycobacterium tuberculosis, the sensor kinases DosT and DosS activate the transcriptional regulator DosR, resulting in the induction of the DosR regulon, which is important for anaerobic survival and perhaps latent infection.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19487478"}, {"offsetInBeginSection": 139, "offsetInEndSection": 337, "text": "The dormancy survival (Dos) regulon, regulated by the response regulator DosR, appears to be essential for hypoxic survival in M. tuberculosis, but it is not known how the regulon promotes survival.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22544737"}]}, {"id": "5a6d217eb750ff4455000034", "body": "Are there ultraconserved genomic regions in the budding yeast?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/29028909", "http://www.ncbi.nlm.nih.gov/pubmed/23349633", "http://www.ncbi.nlm.nih.gov/pubmed/2118998", "http://www.ncbi.nlm.nih.gov/pubmed/20436919", "http://www.ncbi.nlm.nih.gov/pubmed/28348222", "http://www.ncbi.nlm.nih.gov/pubmed/15899965", "http://www.ncbi.nlm.nih.gov/pubmed/17072884", "http://www.ncbi.nlm.nih.gov/pubmed/25213602", "http://www.ncbi.nlm.nih.gov/pubmed/17785203", "http://www.ncbi.nlm.nih.gov/pubmed/23079418"], "snippets": [{"offsetInBeginSection": 341, "offsetInEndSection": 816, "text": "Here, we present a systematic study of ultraconserved genomic regions in the budding yeast based on the publicly available genome sequences, in order to reveal their relationship with the adaptability or fitness advantages of the budding yeast.Results: Our results indicate that, in addition to some fundamental biological functions, the UCSs play an important role in the adaptation of S. cerevisiae to the acidic environment, which is backed up by the previous observation.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/29028909"}, {"offsetInBeginSection": 464, "offsetInEndSection": 614, "text": "In contrast, herein we analyze Hi-C data for budding yeast and identify 200-kb scale TADs, whose boundaries are enriched for transcriptional activity.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28348222"}, {"offsetInBeginSection": 432, "offsetInEndSection": 613, "text": "We show that the budding yeast, Saccharomyces cerevisiae, contains 201 rTfs, which is one of the largest rTF numbers found in yeast species for which genome sequences are available.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17072884"}, {"offsetInBeginSection": 85, "offsetInEndSection": 237, "text": "We report that a large fraction of genomic ultraconserved regions (UCRs) encode a particular set of ncRNAs whose expression is altered in human cancers.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17785203"}, {"offsetInBeginSection": 0, "offsetInEndSection": 79, "text": "The systematic analysis of ultraconserved genomic regions in the budding yeast.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/29028909"}, {"offsetInBeginSection": 614, "offsetInEndSection": 776, "text": "This is a much higher number than the 129 rTFs found in the fission yeast, Schizosaccharomyces pombe, which is currently the yeast with the lowest number of rTFs.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17072884"}, {"offsetInBeginSection": 685, "offsetInEndSection": 882, "text": "Two of the Drosophila SARs have autonomously replicating sequence activity in budding yeast, and three function in fission yeast, while four flanking non-SAR sequences are totally inactive in both.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/2118998"}, {"offsetInBeginSection": 0, "offsetInEndSection": 128, "text": "Drosophila scaffold-attached regions bind nuclear scaffolds and can function as ARS elements in both budding and fission yeasts.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/2118998"}, {"offsetInBeginSection": 1105, "offsetInEndSection": 1325, "text": "However, we also showed that there are regions within the genomic landscape of budding yeast with highly specific replication rates, which cannot be explained by global properties of the replication machinery.CONCLUSION/", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20436919"}, {"offsetInBeginSection": 1044, "offsetInEndSection": 1192, "text": "However, we also show that budding yeast species that have not been affected by the WGD contain a greater number of rTFs than S. pombe (mean = 145).", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17072884"}]}, {"id": "5a7610af83b0d9ea6600001a", "body": "Which Janus kinase does decernotinib target?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/26230873", "http://www.ncbi.nlm.nih.gov/pubmed/25762693", "http://www.ncbi.nlm.nih.gov/pubmed/27253519", "http://www.ncbi.nlm.nih.gov/pubmed/28790974", "http://www.ncbi.nlm.nih.gov/pubmed/27298338", "http://www.ncbi.nlm.nih.gov/pubmed/28765121", "http://www.ncbi.nlm.nih.gov/pubmed/28158411", "http://www.ncbi.nlm.nih.gov/pubmed/23301855", "http://www.ncbi.nlm.nih.gov/pubmed/26994322", "http://www.ncbi.nlm.nih.gov/pubmed/24326567"], "snippets": [{"offsetInBeginSection": 226, "offsetInEndSection": 348, "text": "Janus kinase (JAK) inhibitors are oral synthetic DMARDs that inhibit the non-receptor tyrosine kinase family Janus kinase.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27253519"}, {"offsetInBeginSection": 871, "offsetInEndSection": 1060, "text": "Jakinibs can differ substantially in their selectivity against JAKs; tofacitinib and baricitinib target multiple JAKs, whereas the most recently developed Jakinibs target only a single JAK.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26994322"}, {"offsetInBeginSection": 589, "offsetInEndSection": 864, "text": "A detailed comparative analysis of different Janus kinase inhibitors in our quantitative assays and the subsequent characterization of additional activities demonstrated for the first time that the most potent Jak2 inhibitor in our study, CEP701, also targets Aurora kinases.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23301855"}, {"offsetInBeginSection": 1028, "offsetInEndSection": 1273, "text": "GSK2586184, a Janus kinase 1 selective inhibitor, induced clinical and endoscopic response in ulcerative colitis; however, the study was discontinued at an early stage due to liver toxicity observed in systemic lupus patients receiving the drug.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28158411"}, {"offsetInBeginSection": 648, "offsetInEndSection": 777, "text": "The targeting of the Janus kinases (JAKs) has been quite successful and two JAK inhibitors are now approved to be used in humans.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24326567"}, {"offsetInBeginSection": 1274, "offsetInEndSection": 1393, "text": "Filgotinib, a Janus kinase 1 selective inhibitor investigated in treatment of Crohn's disease, was superior to placebo.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28158411"}, {"offsetInBeginSection": 1255, "offsetInEndSection": 1554, "text": "We summarise the development and recent application of Janus kinase (JAK) inhibitors in the treatment of IMIDs, including first-generation pan-JAK inhibitors (tofacitinib, baricitinib, ruxolitinib, peficitinib) and second-generation selective JAK inhibitors (decernotinib, filgotinib, upadacitinib).", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28765121"}, {"offsetInBeginSection": 148, "offsetInEndSection": 423, "text": "Targeting the Janus tyrosine kinases (JAKs), which play essential roles in cell signaling responses and can contribute to aberrant immune function associated with disease, has emerged as a novel and attractive approach for the development of new autoimmune disease therapies.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26230873"}, {"offsetInBeginSection": 0, "offsetInEndSection": 192, "text": "Cytokines, growth factors, and other chemical messengers rely on a class of intracellular nonreceptor tyrosine kinases known as Janus kinases (JAKs) to rapidly transduce intracellular signals.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25762693"}, {"offsetInBeginSection": 0, "offsetInEndSection": 141, "text": "VX-509 (decernotinib) is a potent and selective janus kinase 3 inhibitor that attenuates inflammation in animal models of autoimmune disease.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25762693"}]}, {"id": "5a87fd0561bb38fb24000010", "body": "Is autophagy modulated in a circadian fashion?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/20833224", "http://www.ncbi.nlm.nih.gov/pubmed/24328814", "http://www.ncbi.nlm.nih.gov/pubmed/26674859", "http://www.ncbi.nlm.nih.gov/pubmed/23707790", "http://www.ncbi.nlm.nih.gov/pubmed/24751357", "http://www.ncbi.nlm.nih.gov/pubmed/26671266", "http://www.ncbi.nlm.nih.gov/pubmed/28625127", "http://www.ncbi.nlm.nih.gov/pubmed/22520961", "http://www.ncbi.nlm.nih.gov/pubmed/19377293", "http://www.ncbi.nlm.nih.gov/pubmed/23750326"], "snippets": [{"offsetInBeginSection": 1411, "offsetInEndSection": 1804, "text": "CONCLUSION: Our in vitro data suggests that basal activity of autophagy seems to be modulated by PER1, and confirms the in vivo data by showing that the autophagic machinery is depressed in Per1-/--hippocampal neurons.The implication of both autophagy and circadian dysfunction in the pathogenesis of cerebral ischemia suggests that a functional connection between the two processes may exist.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28625127"}, {"offsetInBeginSection": 352, "offsetInEndSection": 516, "text": "Here, we provide evidence that lLNvs fire in bursts both during the day and at night and that the frequency of bursting is what is modulated in a circadian fashion.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26674859"}, {"offsetInBeginSection": 146, "offsetInEndSection": 257, "text": "The release of glucocorticoids is characteristically pulsatile and is further modulated in a circadian fashion.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20833224"}, {"offsetInBeginSection": 237, "offsetInEndSection": 335, "text": "Recent work has demonstrated that autophagy is rhythmically activated in a clock-dependent manner.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22520961"}, {"offsetInBeginSection": 277, "offsetInEndSection": 337, "text": "The human cortisol response is modulated by circadian phase.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24328814"}, {"offsetInBeginSection": 403, "offsetInEndSection": 682, "text": "Although autophagy is generally accepted to be regulated in a cell-autonomous fashion, recent studies suggest that nutrients can modulate autophagy in a systemic manner by inducing the secretion of hormones and neurotransmitters that regulate G protein-coupled receptors (GPCRs).", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24751357"}, {"offsetInBeginSection": 798, "offsetInEndSection": 1012, "text": "Interestingly, autophagy is induced in a seemingly beneficial manner by many of the same perturbations that extend lifespan, including mutations in key signaling pathways such as the insulin/IGF-1 and TOR pathways.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23750326"}, {"offsetInBeginSection": 0, "offsetInEndSection": 157, "text": "The Hippocampal Autophagic Machinery is Depressed in the Absence of the Circadian Clock Protein PER1 that may Lead to Vulnerability During Cerebral Ischemia.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28625127"}, {"offsetInBeginSection": 1211, "offsetInEndSection": 1423, "text": "Here, we discuss mechanisms, functions and interactions of the circadian and glucocorticoid systems across time scales ranging from seconds (DNA binding by transcriptional regulators) to years (seasonal rhythms).", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23707790"}, {"offsetInBeginSection": 182, "offsetInEndSection": 316, "text": "Here we report that lipoprotein production, autophagy and lysosomal lipolysis are linked to modulate life span in a conserved fashion.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26671266"}]}, {"id": "5a68ff52b750ff445500001c", "body": "Which tendons are affected in the Dequervain's tenosynovitis?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/28765477", "http://www.ncbi.nlm.nih.gov/pubmed/871301", "http://www.ncbi.nlm.nih.gov/pubmed/10595881", "http://www.ncbi.nlm.nih.gov/pubmed/26752490", "http://www.ncbi.nlm.nih.gov/pubmed/4038032", "http://www.ncbi.nlm.nih.gov/pubmed/24822827", "http://www.ncbi.nlm.nih.gov/pubmed/3488531", "http://www.ncbi.nlm.nih.gov/pubmed/14507508", "http://www.ncbi.nlm.nih.gov/pubmed/11831123", "http://www.ncbi.nlm.nih.gov/pubmed/26007263"], "snippets": [{"offsetInBeginSection": 352, "offsetInEndSection": 999, "text": "Patients with flexor tendonitis (FT) had a significantly higher prevalence of rheumatoid nodules (56% vs 33%), carpal tunnel syndrome (47% vs 13%), wrist extensor tenosynovitis (47% vs 9%), and elbow epicondylitis (22% vs 7%) than patients without FT. Dupuytren's contracture, DeQuervain's tenovaginitis, flexor carpi radialis and ulnaris tendonitis, and Achilles tendonitis were found exclusively in patients with FT. A control group of 50 non-RA patients with FT had statistically fewer diseased tendons per patient (mean 1.5) and a different digital distribution, the thumb being affected more frequently (P less than 0.05) than in RA patients.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/871301"}, {"offsetInBeginSection": 758, "offsetInEndSection": 1233, "text": "The syndromes are trigger finger, dorsal radiocarpal impingement syndrome (gymnast's wrist), DeQuervain's disease, tenosynovitis of other dorsal compartments, intersection syndrome (oarsman's wrist), flexor carpi ulnaris tendinitis, flexor carpi radialis tendonitis, humeral epicondylitis (tennis elbow), posterior impingement syndrome of the elbow, medial tension and lateral compression syndrome, stress fracture in the hand, wrist, forearm and elbow, and tunnel syndromes.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/11831123"}, {"offsetInBeginSection": 648, "offsetInEndSection": 898, "text": "DeQuervain's tenosynovitis was noted in 21 patients (1.3%), local soft-tissue infection was noted in 3 patients (0.2)%, fracture through donor site was noted in 2 patients (0.1%), and superficial radial nerve neuromas were noted in 2 patients (0.1%).", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/14507508"}, {"offsetInBeginSection": 0, "offsetInEndSection": 128, "text": "AIM: To report the presentation of complex regional pain syndrome-1 (CRPS-1) as deQuervain's stenosing tenosynovitis (DQST).CASE", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26752490"}, {"offsetInBeginSection": 0, "offsetInEndSection": 89, "text": "Complex Regional Pain Syndrome-Type 1 Presenting as deQuervain's Stenosing Tenosynovitis.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26752490"}, {"offsetInBeginSection": 0, "offsetInEndSection": 90, "text": "Triggering of the abductor pollicis longus in association with deQuervain's tenosynovitis.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28765477"}, {"offsetInBeginSection": 175, "offsetInEndSection": 406, "text": "We present a case of intersection syndrome, describing its characteristic clinical and anatomic features, and highlighting differences in the areas of diagnosis and treatment relative to the better known DeQuervain's tenosynovitis.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/10595881"}, {"offsetInBeginSection": 238, "offsetInEndSection": 450, "text": "The patients were evaluated for success of bone grafting and for the following complications: fracture through donor site, local infection, DeQuervain's tenosynovitis, and neuroma of the superficial radial nerve.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/14507508"}, {"offsetInBeginSection": 0, "offsetInEndSection": 174, "text": "Intersection syndrome is a condition that should be differentiated from DeQuervain's stenosing tenosynovitis, as there are many subtle differences in treatment and prognosis.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/10595881"}, {"offsetInBeginSection": 0, "offsetInEndSection": 72, "text": "DeQuervain's tenosynovitis is a common cause of radial-sided wrist pain.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28765477"}]}, {"id": "58ee1cafeda5a57672000014", "body": "Are TAD boundaries in Drosophila depleted in highly-expressed genes?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/26518482", "http://www.ncbi.nlm.nih.gov/pubmed/28388407", "http://www.ncbi.nlm.nih.gov/pubmed/28282436", "http://www.ncbi.nlm.nih.gov/pubmed/26748519", "http://www.ncbi.nlm.nih.gov/pubmed/27111891", "http://www.ncbi.nlm.nih.gov/pubmed/25818644", "http://www.ncbi.nlm.nih.gov/pubmed/27210764", "http://www.ncbi.nlm.nih.gov/pubmed/26431028", "http://www.ncbi.nlm.nih.gov/pubmed/29077530", "http://www.ncbi.nlm.nih.gov/pubmed/28408976"], "snippets": [{"offsetInBeginSection": 625, "offsetInEndSection": 881, "text": "Contrary to previous studies, we find that regions between TADs (i.e., the inter-TADs and TAD boundaries) in Drosophila are only weakly enriched with the insulator protein dCTCF, while another insulator protein Su(Hw) is preferentially present within TADs.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26518482"}, {"offsetInBeginSection": 490, "offsetInEndSection": 892, "text": "The genome-wide H3K27me3 profile partitions into two states; very low H3K27me3 identifies Depleted (D) domains that contain housekeeping genes and their regulators such as the histone acetyltransferase-containing NSL complex, whereas domains containing moderate-to-high levels of H3K27me3 (Enriched or E domains) are associated with regulated genes, irrespective of whether they are active or inactive.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28282436"}, {"offsetInBeginSection": 756, "offsetInEndSection": 888, "text": "Furthermore, we find that these TAD boundaries are present irrespective of the expression and looping of genes located between them.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26748519"}, {"offsetInBeginSection": 449, "offsetInEndSection": 551, "text": "Early expressed genes serve as nucleation sites for topologically associating domain (TAD) boundaries.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28388407"}, {"offsetInBeginSection": 250, "offsetInEndSection": 465, "text": "We discuss how loop extrusion models can explain TAD formation and evidence that TADs are formed by the ring-shaped protein complex, cohesin, and that TAD boundaries are established by the DNA-binding protein, CTCF.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/29077530"}, {"offsetInBeginSection": 157, "offsetInEndSection": 277, "text": "Disruption of TAD boundaries results in aberrant gene expression by exposing genes to inappropriate regulatory elements.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27111891"}, {"offsetInBeginSection": 882, "offsetInEndSection": 989, "text": "However, Drosophila inter-TADs harbor active chromatin and constitutively transcribed (housekeeping) genes.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26518482"}, {"offsetInBeginSection": 620, "offsetInEndSection": 755, "text": "We find that the same TAD boundaries are present in all cell types, indicating that TADs represent a universal chromosome architecture.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26748519"}, {"offsetInBeginSection": 1404, "offsetInEndSection": 1535, "text": "Interestingly, interactions between TADs are also highly cell-type-specific and often involve loci clustered around TAD boundaries.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26748519"}, {"offsetInBeginSection": 1536, "offsetInEndSection": 1694, "text": "These data point to key roles of invariant TAD boundaries in constraining as well as mediating cell-type-specific long-range interactions and gene regulation.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26748519"}]}, {"id": "5a6d23ccb750ff4455000035", "body": "Does TUC.338 inhibit colorectal cancer?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/27914101", "http://www.ncbi.nlm.nih.gov/pubmed/28599453", "http://www.ncbi.nlm.nih.gov/pubmed/27878301", "http://www.ncbi.nlm.nih.gov/pubmed/27637778", "http://www.ncbi.nlm.nih.gov/pubmed/21187392", "http://www.ncbi.nlm.nih.gov/pubmed/19240162", "http://www.ncbi.nlm.nih.gov/pubmed/27793031", "http://www.ncbi.nlm.nih.gov/pubmed/26617747", "http://www.ncbi.nlm.nih.gov/pubmed/24468585", "http://www.ncbi.nlm.nih.gov/pubmed/25996664"], "snippets": [{"offsetInBeginSection": 894, "offsetInEndSection": 1075, "text": "In summary, miR-31 can inhibit autophagy in colorectal CAFs, affect colorectal cancer development, and increase the radiosensitivity of colorectal cancer cells co-cultured with CAF.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27793031"}, {"offsetInBeginSection": 468, "offsetInEndSection": 944, "text": "To identify additional and novel small molecules that inhibit KLF5 expression and thus colorectal cancer proliferation, we developed a reporter assay using colorectal cancer cell line (DLD-1) that stably expressed a luciferase reporter gene directed by 1,959 bp of the human KLF5 promoter upstream of the ATG start codon and performed a cell-based high-throughput screen with the Library of Pharmacologically Active Compounds that contains 1,280 biologically active compounds.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19240162"}, {"offsetInBeginSection": 1440, "offsetInEndSection": 1628, "text": "Our results show the principle of using high-throughput screening to identify small-molecule compounds that modulate KLF5 activity and consequently inhibit colorectal cancer proliferation.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19240162"}, {"offsetInBeginSection": 704, "offsetInEndSection": 856, "text": "Furthermore, the Cys528 mutation of CRM1 prevented the ability of S109 to block nuclear export and inhibit the proliferation of colorectal cancer cells.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25996664"}, {"offsetInBeginSection": 641, "offsetInEndSection": 973, "text": "Higher levels of TUC338 were found both in HCC tissues and cell lines, knockdown of TUC338 was accompanied with increased expression of RASAL1 in HCC cell line with increased proliferation and invasion ability, knockdown of TUC338 could activate the RASAL1 pathway and inhibit tumor growth genes by directly targeting RASAL1 3'-UTR.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27878301"}, {"offsetInBeginSection": 702, "offsetInEndSection": 846, "text": "Transfection with small interfering RNA (siRNA) markedly inhibited cell migration and invasion in SW480 and HCT116 colorectal cancer cell lines.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27914101"}, {"offsetInBeginSection": 0, "offsetInEndSection": 161, "text": "Identification of novel small-molecule compounds that inhibit the proproliferative Kruppel-like factor 5 in colorectal cancer cells by high-throughput screening.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19240162"}, {"offsetInBeginSection": 459, "offsetInEndSection": 570, "text": "Our data demonstrate that S109 inhibits proliferation and induces cell cycle arrest in colorectal cancer cells.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25996664"}, {"offsetInBeginSection": 0, "offsetInEndSection": 113, "text": "MiR-20b, -21, and -130b inhibit PTEN expression resulting in B7-H1 over-expression in advanced colorectal cancer.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24468585"}, {"offsetInBeginSection": 849, "offsetInEndSection": 1038, "text": "Taken together, these results showed that knockdown of CUL4B inhibit proliferation and promotes apoptosis of colorectal cancer cells through suppressing the Wnt/\u03b2-catenin signaling pathway.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26617747"}]}, {"id": "5a76122383b0d9ea6600001c", "body": "What is oclacitinib?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/24495176", "http://www.ncbi.nlm.nih.gov/pubmed/25940959", "http://www.ncbi.nlm.nih.gov/pubmed/23829933", "http://www.ncbi.nlm.nih.gov/pubmed/28513001", "http://www.ncbi.nlm.nih.gov/pubmed/25496303", "http://www.ncbi.nlm.nih.gov/pubmed/27847179", "http://www.ncbi.nlm.nih.gov/pubmed/25688708", "http://www.ncbi.nlm.nih.gov/pubmed/24581322", "http://www.ncbi.nlm.nih.gov/pubmed/25109820", "http://www.ncbi.nlm.nih.gov/pubmed/28920784"], "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 111, "text": "Oclacitinib (APOQUEL(\u00ae)) is a novel Janus kinase inhibitor with activity against cytokines involved in allergy.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24495176"}, {"offsetInBeginSection": 1129, "offsetInEndSection": 1434, "text": "These results demonstrate that oclacitinib is a targeted therapy that selectively inhibits JAK1-dependent cytokines involved in allergy, inflammation, and pruritus and suggests these are the mechanisms by which oclacitinib effectively controls clinical signs associated with allergic skin disease in dogs.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24495176"}, {"offsetInBeginSection": 0, "offsetInEndSection": 138, "text": "BACKGROUND: Oclacitinib is a selective Janus kinase inhibitor for the treatment of canine allergic pruritus and atopic dermatitis in dogs.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28513001"}, {"offsetInBeginSection": 0, "offsetInEndSection": 200, "text": "BACKGROUND: Oclacitinib is safe and effective for treating dogs with pruritus associated with allergic and atopic dermatitis, based on randomized clinical trials of up to 4\u00a0months duration.HYPOTHESIS/", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25688708"}, {"offsetInBeginSection": 1707, "offsetInEndSection": 1857, "text": "ABAS is usually an intractable condition, and, to our knowledge, oclacitinib is the first treatment shown to result in sustained clinical improvement.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28920784"}, {"offsetInBeginSection": 0, "offsetInEndSection": 105, "text": "BACKGROUND: Oclacitinib is a Janus kinase inhibitor that decreases pruritus and lesions in allergic dogs.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25940959"}, {"offsetInBeginSection": 133, "offsetInEndSection": 240, "text": "Placebo-controlled studies suggest that oclacitinib is a safe and effective alternative therapy.HYPOTHESIS/", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25496303"}, {"offsetInBeginSection": 0, "offsetInEndSection": 126, "text": "The janus kinase-inhibitor oclacitinib is licensed for the control of pruritus associated with allergic skin diseases in dogs.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27847179"}, {"offsetInBeginSection": 1288, "offsetInEndSection": 1445, "text": "On day 14, the percentage reduction from baseline CADESI-02 was significantly greater in the oclacitinib group (58.7%) than in the ciclosporin group (43.0%).", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25496303"}, {"offsetInBeginSection": 995, "offsetInEndSection": 1352, "text": "RESULTS: Both treatments produced a rapid onset of efficacy within 4\u00a0h. The mean reductions in pruritus and dermatitis scores were not significantly different between the treatments except on day\u00a014, when reductions were more pronounced for oclacitinib than prednisolone (P\u00a0=\u00a00.0193 for owner pruritus scores; P\u00a0=\u00a00.0252 for veterinarian dermatitis scores).", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25109820"}]}, {"id": "5a882b5761bb38fb24000013", "body": "List the four most important interferonopathies", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/27325888", "http://www.ncbi.nlm.nih.gov/pubmed/29093484", "http://www.ncbi.nlm.nih.gov/pubmed/26744186", "http://www.ncbi.nlm.nih.gov/pubmed/25998914", "http://www.ncbi.nlm.nih.gov/pubmed/26052098", "http://www.ncbi.nlm.nih.gov/pubmed/27821552", "http://www.ncbi.nlm.nih.gov/pubmed/26397019", "http://www.ncbi.nlm.nih.gov/pubmed/26363997", "http://www.ncbi.nlm.nih.gov/pubmed/25463593", "http://www.ncbi.nlm.nih.gov/pubmed/27260006"], "snippets": [{"offsetInBeginSection": 516, "offsetInEndSection": 661, "text": "However, recent findings suggest that even baseline levels of constitutive IFN expression and secretion are important for homeostasis of the CNS.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26397019"}, {"offsetInBeginSection": 360, "offsetInEndSection": 515, "text": "Increased type I IFN production and signaling in microglia are critically important to limit viral infection and disease progression in multiple sclerosis.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26397019"}, {"offsetInBeginSection": 0, "offsetInEndSection": 93, "text": "Type I interferons (IFNs) play a central role in the immune defense against viral infections.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25998914"}, {"offsetInBeginSection": 407, "offsetInEndSection": 499, "text": "Ubiquitin-specific peptidase 18 (USP18) is a key negative regulator of type I IFN signaling.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27325888"}, {"offsetInBeginSection": 327, "offsetInEndSection": 683, "text": "Considering the complexity of the interferon response, the identification of further monogenic diseases belonging to this disease grouping seems likely, with the recognition of type I interferonopathies becoming of increasing clinical importance as treatment options are developed based on an understanding of disease pathology and innate immune signaling.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27821552"}, {"offsetInBeginSection": 658, "offsetInEndSection": 989, "text": "Although the mechanisms underlying various disease phenotypes associated with inappropriate type I IFN activation have yet to be fully elucidated, our current understanding of the molecular pathogenesis of type I interferonopathies has provided a set of candidate molecules that can be interrogated in search of targeted therapies.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25998914"}, {"offsetInBeginSection": 0, "offsetInEndSection": 184, "text": "Dissection of the genetic basis of Aicardi-Gouti\u00e8res syndrome has highlighted a fundamental link between nucleic acid metabolism, innate immune sensors and type I interferon induction.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26052098"}, {"offsetInBeginSection": 757, "offsetInEndSection": 903, "text": "Advances in understanding the disease mechanisms underlying type I interferonopathies have pinpointed novel targets for therapeutic interventions.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26744186"}, {"offsetInBeginSection": 145, "offsetInEndSection": 346, "text": "To date, interferonopathies include Aicardi-Gouti\u00e8res syndrome, familial chilblain lupus, spondyenchondromatosis, PRoteasome-associated auto-inflammatory syndrome (PRAAS) and Singleton-Merten syndrome.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26363997"}, {"offsetInBeginSection": 885, "offsetInEndSection": 1000, "text": "These findings add USP18 deficiency to the list of genetic disorders collectively termed type I interferonopathies.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27325888"}]}, {"id": "5a6f8baeb750ff4455000057", "body": "What is the purpose of the FRAX scale?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/22492479", "http://www.ncbi.nlm.nih.gov/pubmed/22630782", "http://www.ncbi.nlm.nih.gov/pubmed/21198706", "http://www.ncbi.nlm.nih.gov/pubmed/25771422", "http://www.ncbi.nlm.nih.gov/pubmed/27163858", "http://www.ncbi.nlm.nih.gov/pubmed/28013446", "http://www.ncbi.nlm.nih.gov/pubmed/3953643", "http://www.ncbi.nlm.nih.gov/pubmed/20959961", "http://www.ncbi.nlm.nih.gov/pubmed/8825884", "http://www.ncbi.nlm.nih.gov/pubmed/7942998"], "snippets": [{"offsetInBeginSection": 952, "offsetInEndSection": 1066, "text": "The mean mental age of the fra(X) syndrome group was 5.3 yr (range 3.5-7.5 yr; Stanford-Binet Intelligence Scale).", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/8825884"}, {"offsetInBeginSection": 196, "offsetInEndSection": 414, "text": "The FRAX score, developed by the WHO, is a free web-based clinical scale assessing the 10-year fracture risk and need for lifestyle advice/reassurance, dual X-ray absorptiometry (DEXA) scanning or preventive treatment.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21198706"}, {"offsetInBeginSection": 172, "offsetInEndSection": 413, "text": "Wechsler Intelligence Scale for Children-Revised (WISC-R) subtest scores obtained on 8 fra(X) school age girls were compared with similar scores obtained on 8 \"learning-disabled\" non fra(X) girls matched on the basis of Full Scale IQ (FSIQ).", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/3953643"}, {"offsetInBeginSection": 139, "offsetInEndSection": 280, "text": "Clodronate and bazedoxifene reduced nonvertebral and clinical fracture more effectively on a relative scale in women with higher FRAX scores.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22492479"}, {"offsetInBeginSection": 1905, "offsetInEndSection": 2006, "text": "These results suggest that the effect of alendronate on a relative scale does not vary by FRAX score.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22492479"}, {"offsetInBeginSection": 379, "offsetInEndSection": 662, "text": "PURPOSE: The purpose of this study is to evaluate the validity of the updated IOF (International Osteoporosis Foundation) One Minute Osteoporosis Risk Assessment Test, FRAX, SCORE as well as age alone to detect the risk of developing osteoporosis in postmenopausal Palestinian women.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28013446"}, {"offsetInBeginSection": 518, "offsetInEndSection": 673, "text": "The purpose of this study is to develop a procedure for adjusting FRAX probability based upon the T-score difference between the LS and FN (termed offset).", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20959961"}, {"offsetInBeginSection": 0, "offsetInEndSection": 118, "text": "The combination of FRAX and Ageing Male Symptoms scale better identifies treated HIV males at risk for major fracture.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22630782"}, {"offsetInBeginSection": 1001, "offsetInEndSection": 1387, "text": "The clinical FRAX score alone, when compared with the FRAX score including the BMD result, had a sensitivity of 100% (95% CI: 70-100%), specificity of 40% (95% CI: 31-50%), positive predictive value of 16% (95% CI: 9-27%) and negative predictive value of 100% (95% CI: 90-100%) in identifying those patients needing BMD measurement (intermediate risk) or preventive therapy (high risk).", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21198706"}, {"offsetInBeginSection": 1143, "offsetInEndSection": 1303, "text": "CONCLUSIONS: There is a weak positive correlation between FRAX and falls risk score, that is likely explained by the inclusion of age and sex in the FRAX model.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25771422"}]}, {"id": "58ee217feda5a57672000015", "body": "How are topologically associating domains (TAD) associated with replication timing?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/25409831", "http://www.ncbi.nlm.nih.gov/pubmed/28348222", "http://www.ncbi.nlm.nih.gov/pubmed/25995270", "http://www.ncbi.nlm.nih.gov/pubmed/28977529", "http://www.ncbi.nlm.nih.gov/pubmed/23832846", "http://www.ncbi.nlm.nih.gov/pubmed/26590169", "http://www.ncbi.nlm.nih.gov/pubmed/27669308", "http://www.ncbi.nlm.nih.gov/pubmed/27312344", "http://www.ncbi.nlm.nih.gov/pubmed/26150425", "http://www.ncbi.nlm.nih.gov/pubmed/26558551"], "snippets": [{"offsetInBeginSection": 977, "offsetInEndSection": 1254, "text": "Genome-wide studies of replication timing (RT) have now merged these two disciplines by identifying individual units of replication regulation (replication domains; RDs) that correspond to TADs and are arranged in 3D to form spatiotemporally segregated subnuclear compartments.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26590169"}, {"offsetInBeginSection": 384, "offsetInEndSection": 531, "text": "TADs can be further classified based on expression activity, replication timing, or the histone marks or non-histone proteins associated with them.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27312344"}, {"offsetInBeginSection": 94, "offsetInEndSection": 443, "text": "In mammals, replication timing is cell-type-specific with at least half the genome switching replication timing during development, primarily in units of 400-800 kilobases ('replication domains'), whose positions are preserved in different cell types, conserved between species, and appear to confine long-range effects of chromosome rearrangements.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25409831"}, {"offsetInBeginSection": 720, "offsetInEndSection": 956, "text": "Recent Hi-C mapping has unveiled substructure within chromatin compartments called topologically associating domains (TADs) that are largely conserved in their positions between cell types and are similar in size to replication domains.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25409831"}, {"offsetInBeginSection": 217, "offsetInEndSection": 396, "text": "Genome-wide chromatin conformation capture (Hi-C) has revealed sub-megabase topologically associating domains (TADs), which are the structural counterparts of replication domains.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25995270"}, {"offsetInBeginSection": 674, "offsetInEndSection": 770, "text": "Lamina-associated domains (LADs) correlate with low gene expression and late replication timing.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27312344"}, {"offsetInBeginSection": 1700, "offsetInEndSection": 2063, "text": "Moreover, cell-type-specific replication timing of TADs partitions the genome into two large-scale sub-nuclear compartments revealing that replication-timing transitions are indistinguishable from late-replicating regions in chromatin composition and lamina association and accounting for the reduced correlation of replication timing to LADs and heterochromatin.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25409831"}, {"offsetInBeginSection": 0, "offsetInEndSection": 177, "text": "The genome of metazoan cells is organized into topologically associating domains (TADs) that have similar histone modifications, transcription level, and DNA replication timing.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28348222"}, {"offsetInBeginSection": 799, "offsetInEndSection": 1001, "text": "To investigate the molecular basis of TAD formation, we performed Hi-C experiments on cells depleted for the Forkhead transcription factors, Fkh1 and Fkh2, previously associated with replication timing.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28348222"}, {"offsetInBeginSection": 198, "offsetInEndSection": 364, "text": "Functional topologically associating domains (TADs) that constitute the building blocks of genomic organization are disrupted and reconstructed during the cell cycle.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27669308"}]}, {"id": "5a6e2b1bb750ff445500003e", "body": "Which R/Bioconductor package has been developed for the analysis of psychiatric disease genes?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/28961763", "http://www.ncbi.nlm.nih.gov/pubmed/27239475", "http://www.ncbi.nlm.nih.gov/pubmed/24222209", "http://www.ncbi.nlm.nih.gov/pubmed/25677125", "http://www.ncbi.nlm.nih.gov/pubmed/28088185", "http://www.ncbi.nlm.nih.gov/pubmed/26374744", "http://www.ncbi.nlm.nih.gov/pubmed/28134831", "http://www.ncbi.nlm.nih.gov/pubmed/26576536", "http://www.ncbi.nlm.nih.gov/pubmed/23297033", "http://www.ncbi.nlm.nih.gov/pubmed/24979058"], "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 83, "text": "psygenet2r: a R/Bioconductor package for the analysis of psychiatric disease genes.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28961763"}, {"offsetInBeginSection": 1, "offsetInEndSection": 96, "text": "APKL: R/ Bioconductor package for detecting gene exemplars and revealing their characteristics.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26374744"}, {"offsetInBeginSection": 0, "offsetInEndSection": 78, "text": "SpidermiR: An R/Bioconductor Package for Integrative Analysis with miRNA Data.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28134831"}, {"offsetInBeginSection": 983, "offsetInEndSection": 1298, "text": "We therein provide here a detailed and easy-to-use protocol of using exomePeak R/Bioconductor package along with other software programs for analysis of MeRIP-Seq data, which covers raw reads alignment, RNA methylation site detection, motif discovery, differential RNA methylation analysis, and functional analysis.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24979058"}, {"offsetInBeginSection": 953, "offsetInEndSection": 1540, "text": "The mAPKL package is accompanied with extra functionalities including (i) solid data import; (ii) data sampling following a user-defined proportion; (iii) preprocessing through several normalization and transformation alternatives; (iv) classification with the aid of SVM and performance evaluation; (v) network analysis of the significant genes (exemplars), including degree of centrality, closeness, betweeness, clustering coefficient as well as the construction of an edge list table; (vi) gene annotation analysis, (vii) pathway analysis and (viii) auto-generated analysis reporting.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26374744"}, {"offsetInBeginSection": 407, "offsetInEndSection": 640, "text": "We developed an R/Bioconductor package, namely SpidermiR, which offers an easy access to both GRNs and miRNAs to the end user, and integrates this information with differentially expressed genes obtained from The Cancer Genome Atlas.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28134831"}, {"offsetInBeginSection": 221, "offsetInEndSection": 514, "text": "PsyGeNET is a knowledge resource on psychiatric diseases and their genes, developed by text mining and curated by domain experts.Results: We present psygenet2r, an R package that contains a variety of functions for leveraging PsyGeNET database and facilitating its analysis and interpretation.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28961763"}, {"offsetInBeginSection": 1471, "offsetInEndSection": 1617, "text": "The exomePeak R/Bioconductor package is freely available from Bioconductor: http://www.bioconductor.org/packages/release/bioc/html/exomePeak.html.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24979058"}, {"offsetInBeginSection": 0, "offsetInEndSection": 109, "text": "GenomicInteractions: An R/Bioconductor package for manipulating and investigating chromatin interaction data.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26576536"}, {"offsetInBeginSection": 0, "offsetInEndSection": 73, "text": "RamiGO: an R/Bioconductor package providing an AmiGO visualize interface.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23297033"}]}, {"id": "5a7626989e632bc066000001", "body": "Has ruxolitinib received FDA approval?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/23985569", "http://www.ncbi.nlm.nih.gov/pubmed/24766055", "http://www.ncbi.nlm.nih.gov/pubmed/22544377", "http://www.ncbi.nlm.nih.gov/pubmed/28277287", "http://www.ncbi.nlm.nih.gov/pubmed/26056473", "http://www.ncbi.nlm.nih.gov/pubmed/27069082", "http://www.ncbi.nlm.nih.gov/pubmed/23977767", "http://www.ncbi.nlm.nih.gov/pubmed/24083419", "http://www.ncbi.nlm.nih.gov/pubmed/18077994", "http://www.ncbi.nlm.nih.gov/pubmed/28869184"], "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 366, "text": "On November 16, 2011, the U.S. Food and Drug Administration (FDA) granted full approval to ruxolitinib, (Jakafi; Incyte Corp.), an inhibitor of the Janus kinases 1 and 2, for the treatment of patients with intermediate- or high-risk myelofibrosis, including primary myelofibrosis, postpolycythemia vera myelofibrosis, and postessential thrombocythemia myelofibrosis.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22544377"}, {"offsetInBeginSection": 833, "offsetInEndSection": 1135, "text": "Ruxolitinib (Jakafi) is the first-in-class and only JAK inhibitor currently approved by the US Food and Drug Administration (FDA) for the treatment of patients with MF; approval was based on the results of the COMFORT (COntrolled MyeloFibrosis study with ORal JAK inhibitor Treatment) I and II studies.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23977767"}, {"offsetInBeginSection": 1140, "offsetInEndSection": 1359, "text": "CONCLUSIONS: Liposomal doxorubicin received FDA approval for use in combination with bortezomib in patients with multiple myeloma who have not previously received bortezomib and have received at least one prior therapy.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/18077994"}, {"offsetInBeginSection": 653, "offsetInEndSection": 988, "text": "Drugs approved by the FDA OHOP during this period were selected for further review, focusing on brand and generic name; approval date; applicant; indication; PRO labeling describing treatment benefit, measures, end point status, and significant results; FDA reviewer feedback on PRO end points; and study design of registration trials.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27069082"}, {"offsetInBeginSection": 356, "offsetInEndSection": 484, "text": "With such results, ruxolitinib quickly obtained the Food and Drug Administration (FDA) approval in the United States of America.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23985569"}, {"offsetInBeginSection": 0, "offsetInEndSection": 486, "text": "PURPOSE: To review the use of patient-reported outcome (PRO) data in medical product labeling granted by the US Food and Drug Administration (FDA) for new molecular entities and biologic license applications by the FDA Office of Hematology and Oncology Products (OHOP) between January 2010 and December 2014, to elucidate challenges faced by OHOP for approving PRO labeling, and to understand challenges faced by drug manufacturers to include PRO end points in oncology clinical trials.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27069082"}, {"offsetInBeginSection": 258, "offsetInEndSection": 434, "text": "The discovery of a JAK2 point mutation (JAK2 V617F) as the main cause of polycythemia vera lead to the development and FDA approval of a JAK1/2 inhibitor, ruxolitinib, in 2011.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28277287"}, {"offsetInBeginSection": 226, "offsetInEndSection": 310, "text": "Only one JAK1/JAK2 inhibitor has gained FDA approval for treatment of myelofibrosis.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24766055"}, {"offsetInBeginSection": 486, "offsetInEndSection": 652, "text": "METHODS: FDA Drug Approval Reports by Month were reviewed to obtain the number of new molecular entities and biologic license applications approved from 2010 to 2014.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27069082"}, {"offsetInBeginSection": 1008, "offsetInEndSection": 1141, "text": "Resultant research in targeting the JAK/STAT pathway led to the approval of ruxolitinib, a JAK1/JAK2 inhibitor with activity in MPNs.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24766055"}]}, {"id": "5a88370c61bb38fb24000014", "body": "What is the function of the gene MDA5?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/21185857", "http://www.ncbi.nlm.nih.gov/pubmed/29069650", "http://www.ncbi.nlm.nih.gov/pubmed/26260315", "http://www.ncbi.nlm.nih.gov/pubmed/17977974", "http://www.ncbi.nlm.nih.gov/pubmed/19324880", "http://www.ncbi.nlm.nih.gov/pubmed/21881126", "http://www.ncbi.nlm.nih.gov/pubmed/25008915", "http://www.ncbi.nlm.nih.gov/pubmed/22797917", "http://www.ncbi.nlm.nih.gov/pubmed/24939427", "http://www.ncbi.nlm.nih.gov/pubmed/16116171"], "snippets": [{"offsetInBeginSection": 889, "offsetInEndSection": 1207, "text": "Furthermore, using fluorescent imaging we present the first report of the visualisation of dsRNA and MDA5, which provides unique evidence of the relationship between viral dsRNA and MDA5 and proves without a doubt that MDA5 is the key sensor for the dsRNA replicative intermediate form of positive sense ssRNA viruses.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22797917"}, {"offsetInBeginSection": 208, "offsetInEndSection": 435, "text": "In this study, we constructed six mutants of Ctenopharyngodon idella MDA5 (CiMAD5) overexpression plasmids and generated stable transfected C. idella kidney (CIK) cell lines to study the function of different domains of CiMAD5.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26260315"}, {"offsetInBeginSection": 1948, "offsetInEndSection": 2141, "text": "In this study, we show that expression of the gene tripartite motif 13 (Trim13) is upregulated in response to inducers of type I IFN and that TRIM13 interacts with both MDA5 and RIG-I in vitro.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25008915"}, {"offsetInBeginSection": 855, "offsetInEndSection": 1083, "text": "We generated Trim13(-/-) mice and show that upon lethal challenge with encephalomyocarditis virus (EMCV), which is sensed by MDA5, Trim13(-/-) mice produce increased amounts of type I IFNs and survive longer than wild-type mice.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25008915"}, {"offsetInBeginSection": 103, "offsetInEndSection": 448, "text": "We have examined expression and function of cytosolic RNA sensors, retinoic acid inducible gene I (RIG-I), and melanoma differentiation-associated protein 5 (MDA5), in vivo in the brain of our consistent, accelerated SIV-macaque model and in vitro in SIV-infected macaque macrophages to identify the pathway of type I interferon (IFN) induction.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21881126"}, {"offsetInBeginSection": 0, "offsetInEndSection": 193, "text": "Melanoma differentiation-associated gene 5 (MDA5) is a pattern recognition receptor that recognizes cytoplasmic viral double-stranded RNA (dsRNA) and initiates rapid innate antiviral responses.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/29069650"}, {"offsetInBeginSection": 323, "offsetInEndSection": 442, "text": "The full-length MDA5 gene in Japanese flounder, Paralichthys olivaceus was cloned and found to have 11,251 nucleotides.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21185857"}, {"offsetInBeginSection": 0, "offsetInEndSection": 207, "text": "Melanoma differentiation-associated gene 5 (MDA5) is a member of retinoic acid-inducible gene I (RIG-I)-like receptor (RLR) family which can initiate type I IFN expression in response to RNA virus infection.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26260315"}, {"offsetInBeginSection": 0, "offsetInEndSection": 168, "text": "Melanoma differentiation-associated gene 5 (MDA5) is an important intracellular receptor that recognizes long molecules of viral double-stranded RNA in innate immunity.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24939427"}, {"offsetInBeginSection": 1160, "offsetInEndSection": 1289, "text": "The disruption of endogenous DNAJB1 increased MDA5- and MAVS-mediated IFN promoter activation and rendered cells virus resistant.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/29069650"}]}, {"id": "5a70de5199e2c3af26000005", "body": "Is scuba diving safe during pregnancy?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/17000494", "http://www.ncbi.nlm.nih.gov/pubmed/11777528", "http://www.ncbi.nlm.nih.gov/pubmed/12808399", "http://www.ncbi.nlm.nih.gov/pubmed/12053898", "http://www.ncbi.nlm.nih.gov/pubmed/7423656", "http://www.ncbi.nlm.nih.gov/pubmed/20086738", "http://www.ncbi.nlm.nih.gov/pubmed/8888455", "http://www.ncbi.nlm.nih.gov/pubmed/7789850", "http://www.ncbi.nlm.nih.gov/pubmed/1624782", "http://www.ncbi.nlm.nih.gov/pubmed/10416137"], "snippets": [{"offsetInBeginSection": 262, "offsetInEndSection": 530, "text": "Generally, participation in a wide range of recreational activities appears to be safe during pregnancy; however, each sport should be reviewed individually for its potential risk, and activities with a high risk of abdominal trauma should be avoided during pregnancy.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/11777528"}, {"offsetInBeginSection": 262, "offsetInEndSection": 567, "text": "Generally, participation in a wide range of recreational activities appears to be safe during pregnancy; however, each sport should be reviewed individually for its potential risk, and activities with a high risk of falling or those with a high risk of abdominal trauma should be avoided during pregnancy.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/12808399"}, {"offsetInBeginSection": 262, "offsetInEndSection": 530, "text": "Generally, participation in a wide range of recreational activities appears to be safe during pregnancy; however, each sport should be reviewed individually for its potential risk, and activities with a high risk of abdominal trauma should be avoided during pregnancy.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/12053898"}, {"offsetInBeginSection": 978, "offsetInEndSection": 1227, "text": "However, should a woman have completed a dive during early pregnancy because she was unaware she was pregnant, the present evidence is not to recommend an abortion, because several normal pregnancies have been documented even if diving is continued.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/8888455"}, {"offsetInBeginSection": 0, "offsetInEndSection": 28, "text": "[Scuba diving and pregnancy.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/7789850"}, {"offsetInBeginSection": 863, "offsetInEndSection": 977, "text": "It is prudent to advise pregnant patients of the increased risk of diving problems for the fetus during pregnancy.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/8888455"}, {"offsetInBeginSection": 309, "offsetInEndSection": 543, "text": "The different international federations and the Undersea and Hyperbaric Medical Society advise against scuba diving for pregnant women or those planning a pregnancy, but no randomized trials or trials provide a solid scientific basis.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/10416137"}, {"offsetInBeginSection": 1228, "offsetInEndSection": 1349, "text": "Snorkeling can still be practiced during pregnancy, but scuba diving should be discontinued until after the birth period.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/8888455"}, {"offsetInBeginSection": 0, "offsetInEndSection": 148, "text": "Scuba diving during pregnancy has increased in incidence as a result of substantial growth in the number of young females attracted to sport diving.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/8888455"}, {"offsetInBeginSection": 0, "offsetInEndSection": 56, "text": "Exercise during pregnancy: safe and beneficial for most.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20086738"}]}, {"id": "58ee2515eda5a57672000016", "body": "Which individuals show preferential colonization of the Prevotellaceae bacteria in their guts?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/23692388", "http://www.ncbi.nlm.nih.gov/pubmed/26637604", "http://www.ncbi.nlm.nih.gov/pubmed/28553195", "http://www.ncbi.nlm.nih.gov/pubmed/25284151", "http://www.ncbi.nlm.nih.gov/pubmed/28625783", "http://www.ncbi.nlm.nih.gov/pubmed/18836026", "http://www.ncbi.nlm.nih.gov/pubmed/28628661", "http://www.ncbi.nlm.nih.gov/pubmed/17233730", "http://www.ncbi.nlm.nih.gov/pubmed/7620812", "http://www.ncbi.nlm.nih.gov/pubmed/16233108"], "snippets": [{"offsetInBeginSection": 566, "offsetInEndSection": 859, "text": "In this study, a biologically relevant infection model in which M. ulcerans-infected mosquito larvae were fed to a species of predaceous hemiptera (African Belostomatidae) was used to demonstrate the persistent colonization of M. ulcerans and subsequent transmission of bacteria to na\u00efve prey.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/18836026"}, {"offsetInBeginSection": 652, "offsetInEndSection": 1036, "text": "In diassociated cockroaches, the facultatively anaerobic strain EbSL (a new species of Enterobacteriaceae) always outnumbered the obligately anaerobic strain FuSL (a close relative of Fusobacterium varium), irrespective of the sequence of inoculation, which showed that precolonization by facultatively anaerobic bacteria does not necessarily favor colonization by obligate anaerobes.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26637604"}, {"offsetInBeginSection": 114, "offsetInEndSection": 232, "text": "The gut cuticle of intermoult specimens of Ligidium hypnorum and Porcellio scaber was densely colonized with bacteria.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/7620812"}, {"offsetInBeginSection": 394, "offsetInEndSection": 501, "text": "In a previous study, inducible expression of truncated yncE gene (yncE*) was found lethal to host bacteria.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28628661"}, {"offsetInBeginSection": 1057, "offsetInEndSection": 1171, "text": "Even when food was supplemented for 7 d, the recombinant strains, particularly Ae10, were still found in the guts.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16233108"}, {"offsetInBeginSection": 371, "offsetInEndSection": 555, "text": "We established the cockroach Shelfordella lateralis as a gnotobiotic model and inoculated germfree nymphs with two bacterial strains isolated from the guts of conventional cockroaches.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26637604"}, {"offsetInBeginSection": 323, "offsetInEndSection": 420, "text": "In all investigated specimens of Hyloniscus riparius the guts were completely free of microflora.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/7620812"}, {"offsetInBeginSection": 674, "offsetInEndSection": 891, "text": "The cell numbers of Bacillus cereus strains Ae10 and Cx5 in the guts were consistent throughout a 7-d period without food supplementation, suggesting that these strains were able to colonize in the guts of the larvae.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16233108"}, {"offsetInBeginSection": 1361, "offsetInEndSection": 1503, "text": "Prior colonization with other bacteria reduced the chances of subsequent colonization, thus increasing the stability of higher-diversity guts.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28625783"}, {"offsetInBeginSection": 426, "offsetInEndSection": 655, "text": "Cohousing mice harboring these xenomicrobiota or a mouse cecal microbiota, along with germ-free \"bystanders,\" revealed the success of particular bacterial taxa in invading guts with established communities and empty gut habitats.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25284151"}]}, {"id": "5a6e3299b750ff4455000040", "body": "What is the main focus of the CVE R/Bioconductor package?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/28545463", "http://www.ncbi.nlm.nih.gov/pubmed/21937664", "http://www.ncbi.nlm.nih.gov/pubmed/15824474", "http://www.ncbi.nlm.nih.gov/pubmed/25246429", "http://www.ncbi.nlm.nih.gov/pubmed/26803161", "http://www.ncbi.nlm.nih.gov/pubmed/24979058", "http://www.ncbi.nlm.nih.gov/pubmed/28575171", "http://www.ncbi.nlm.nih.gov/pubmed/27646783", "http://www.ncbi.nlm.nih.gov/pubmed/24700319", "http://www.ncbi.nlm.nih.gov/pubmed/23709494"], "snippets": [{"offsetInBeginSection": 100, "offsetInEndSection": 424, "text": "For the visualization of genomic data there lacks a tool to create customizable non-circular plots of whole genomes from any species.Results: We have developed karyoploteR, an R/Bioconductor package to create linear chromosomal representations of any genome with genomic annotations and experimental data plotted along them.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28575171"}, {"offsetInBeginSection": 0, "offsetInEndSection": 102, "text": "inSilicoDb: an R/Bioconductor package for accessing human Affymetrix expert-curated datasets from GEO.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21937664"}, {"offsetInBeginSection": 0, "offsetInEndSection": 68, "text": "rTANDEM, an R/Bioconductor package for MS/MS protein identification.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24700319"}, {"offsetInBeginSection": 0, "offsetInEndSection": 94, "text": "karyoploteR: an R/Bioconductor package to plot customizable genomes displaying arbitrary data.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28575171"}, {"offsetInBeginSection": 1471, "offsetInEndSection": 1617, "text": "The exomePeak R/Bioconductor package is freely available from Bioconductor: http://www.bioconductor.org/packages/release/bioc/html/exomePeak.html.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24979058"}, {"offsetInBeginSection": 0, "offsetInEndSection": 107, "text": "Rcpi: R/Bioconductor package to generate various descriptors of proteins, compounds and their interactions.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25246429"}, {"offsetInBeginSection": 340, "offsetInEndSection": 568, "text": "The inSilicoDb R/Bioconductor package is a command-line front-end to the InSilico DB, a web-based database currently containing 86 104 expert-curated human Affymetrix expression profiles compiled from 1937 GEO repository series.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21937664"}, {"offsetInBeginSection": 282, "offsetInEndSection": 561, "text": "To solve this problem, we developed a freely available R/Bioconductor package, called Compound-Protein Interaction with R (Rcpi), for complex molecular representation from drugs, proteins and more complex interactions, including protein-protein and compound-protein interactions.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25246429"}, {"offsetInBeginSection": 983, "offsetInEndSection": 1298, "text": "We therein provide here a detailed and easy-to-use protocol of using exomePeak R/Bioconductor package along with other software programs for analysis of MeRIP-Seq data, which covers raw reads alignment, RNA methylation site detection, motif discovery, differential RNA methylation analysis, and functional analysis.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24979058"}, {"offsetInBeginSection": 488, "offsetInEndSection": 733, "text": "We have previously developed an R/Bioconductor package 'exomePeak' for detecting RNA methylation sites under a specific experimental condition or the identifying the differential RNA methylation sites in a case control study from MeRIP-Seq data.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24979058"}]}, {"id": "5a7726989e632bc06600000c", "body": "Does deflazacort have more side effects than prednisone?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/16244521", "http://www.ncbi.nlm.nih.gov/pubmed/10951436", "http://www.ncbi.nlm.nih.gov/pubmed/8329416", "http://www.ncbi.nlm.nih.gov/pubmed/8882570", "http://www.ncbi.nlm.nih.gov/pubmed/8241229", "http://www.ncbi.nlm.nih.gov/pubmed/8356936", "http://www.ncbi.nlm.nih.gov/pubmed/19488064", "http://www.ncbi.nlm.nih.gov/pubmed/7194867", "http://www.ncbi.nlm.nih.gov/pubmed/22115006", "http://www.ncbi.nlm.nih.gov/pubmed/11038071"], "snippets": [{"offsetInBeginSection": 751, "offsetInEndSection": 1088, "text": "All of them were treated with antithymocyte globulin, 10 mg/kg/day for 3 days after transplantation, azathioprine, and cyclosporine; patients were randomly assigned groups: 15 patients to receive deflazacort therapy, 1.5 mg/kg/day, and 16 patients to receive prednisone therapy, 1 mg/kg/day, starting the first day after transplantation.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/8241229"}, {"offsetInBeginSection": 144, "offsetInEndSection": 224, "text": "Deflazacort (DFC) is supposed to have fewer side effects than prednisone (PRED).", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/8882570"}, {"offsetInBeginSection": 225, "offsetInEndSection": 379, "text": "An ongoing double blind multicenter study is comparing the effects and side effects of deflazacort (0.9 mg/kg/day) and prednisone (0.75 mg/kg/day) in DMD.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/8882570"}, {"offsetInBeginSection": 0, "offsetInEndSection": 108, "text": "Deflazacort slows the progress of Duchenne muscular dystrophy (DMD) with fewer side effects than prednisone.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/11038071"}, {"offsetInBeginSection": 1535, "offsetInEndSection": 1774, "text": "Incidence of acute rejection was similar between prednisone and deflazacort groups; 33% of patients receiving prednisone therapy and 42% of patients receiving deflazacort therapy had one episode of 3A or higher rejection (not significant).", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/8241229"}, {"offsetInBeginSection": 882, "offsetInEndSection": 991, "text": "CONCLUSIONS: Prednisone and deflazacort have a significant beneficial effect on slowing the disease progress.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16244521"}, {"offsetInBeginSection": 97, "offsetInEndSection": 324, "text": "Deflazacort, an oral synthetic steroid with fewer side effects, has been successfully used in patients after heart transplantation, but a prospective study comparing deflazacort and prednisone in transplant patients is lacking.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/8241229"}, {"offsetInBeginSection": 0, "offsetInEndSection": 148, "text": "Though Deflazacort and prednisone improve clinical endpoints in Duchenne muscular dystrophy (DMD) patients, Deflazacort produces fewer side effects.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19488064"}, {"offsetInBeginSection": 0, "offsetInEndSection": 266, "text": "We randomized 18 Duchenne muscular dystrophy (DMD) boys whose age ranged from 5.2 to 14.6 years (mean, 7.3 years) for treatment with either deflazacort (0.9 mg/kg/day) or prednisone (0.75 mg/kg/day) on the basis of age and functional score at the onset of treatment.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/10951436"}, {"offsetInBeginSection": 0, "offsetInEndSection": 252, "text": "Since corticosteroids represent a fundamental tool in the treatment of uveitis, we evaluate the clinical efficacy and possible appearance of side effects of deflazacort, a new corticosteroid of third generation, versus prednisone at equiactive dosages.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/8356936"}]}, {"id": "5a885daa61bb38fb24000018", "body": "Which is the conserved motif of DEAD box proteins?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/7689221", "http://www.ncbi.nlm.nih.gov/pubmed/23523990", "http://www.ncbi.nlm.nih.gov/pubmed/9371600", "http://www.ncbi.nlm.nih.gov/pubmed/8253085", "http://www.ncbi.nlm.nih.gov/pubmed/1900936", "http://www.ncbi.nlm.nih.gov/pubmed/10727850", "http://www.ncbi.nlm.nih.gov/pubmed/8144024", "http://www.ncbi.nlm.nih.gov/pubmed/8948440", "http://www.ncbi.nlm.nih.gov/pubmed/26709771", "http://www.ncbi.nlm.nih.gov/pubmed/28559293"], "snippets": [{"offsetInBeginSection": 701, "offsetInEndSection": 976, "text": "It is not possible to classify HuDBP-RB as a member of any of the DEAD box protein subgroups identified to date since the regions of amino acid similarity between HuDBP-RB and other DEAD box proteins are restricted to the conserved motifs found in all members of this family.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/7689221"}, {"offsetInBeginSection": 580, "offsetInEndSection": 754, "text": "mDEAD2 and mDEAD3 (mouse DEAD box proteins) are > 95% identical to mouse PL10 but exhibit differential tissue-specific expression patterns; mDEAD2 and mDEAD3 are also approx.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/8144024"}, {"offsetInBeginSection": 351, "offsetInEndSection": 543, "text": "Sequence analysis of the cDNA revealed that RHELP contained DEAD sequence motif and other conserved motifs of the DEAD box protein family, indicating that RHELP is a new member of this family.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/10727850"}, {"offsetInBeginSection": 463, "offsetInEndSection": 700, "text": "Here, we report that the mRNA encoding a DEAD box protein, designated HuDBP-RB, is present at elevated levels in two of six retinoblastoma (RB) cell lines tested and is preferentially expressed in fetal tissues of neuroectodermal origin.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/7689221"}, {"offsetInBeginSection": 0, "offsetInEndSection": 60, "text": "DbpA: a DEAD box protein specifically activated by 23s rRNA.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/8253085"}, {"offsetInBeginSection": 0, "offsetInEndSection": 124, "text": "Recently, a family of proteins containing the conserved motif Asp-Glu-Ala-Asp, the \"DEAD box\" proteins, has been identified.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/1900936"}, {"offsetInBeginSection": 1008, "offsetInEndSection": 1217, "text": "mDEAD5 belongs to a second class related to translation initiation factors from yeast (TIF1/TIF2) and mammals (eIF-4A); this class contains a novel conserved peptide motif not found in other DEAD box proteins.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/8144024"}, {"offsetInBeginSection": 438, "offsetInEndSection": 721, "text": "DEAD box proteins generally act as components of large multi-protein complexes and it is thought that interactions, via their divergent N- and C-terminal extensions, with other factors in the complexes may be responsible for the many different functions attributed to these proteins.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23523990"}, {"offsetInBeginSection": 252, "offsetInEndSection": 437, "text": "Apart from unwinding RNA duplexes, which established these proteins as RNA helicases, DEAD box proteins have been shown to also catalyse RNA annealing and to displace proteins from RNA.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23523990"}, {"offsetInBeginSection": 191, "offsetInEndSection": 283, "text": "In addition, the NS3 protein contains four amino acid motifs conserved in DEAD box proteins.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/9371600"}]}, {"id": "5a7237672dc08e987e000008", "body": "Which drug can be reversed with idarucizumab?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/27224445", "http://www.ncbi.nlm.nih.gov/pubmed/28479184", "http://www.ncbi.nlm.nih.gov/pubmed/27575900", "http://www.ncbi.nlm.nih.gov/pubmed/25567155", "http://www.ncbi.nlm.nih.gov/pubmed/25899749", "http://www.ncbi.nlm.nih.gov/pubmed/27568285", "http://www.ncbi.nlm.nih.gov/pubmed/27697436", "http://www.ncbi.nlm.nih.gov/pubmed/28416406", "http://www.ncbi.nlm.nih.gov/pubmed/28695019", "http://www.ncbi.nlm.nih.gov/pubmed/27920714"], "snippets": [{"offsetInBeginSection": 194, "offsetInEndSection": 328, "text": "The lack of an antidote is a concern in patients who overdose on dabigatran, even though the drug can be eliminated with hemodialysis.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27224445"}, {"offsetInBeginSection": 952, "offsetInEndSection": 1076, "text": "Idarucizumab neutralised plasma concentrations of dabigatran, and reversed the effects of the drug on coagulation variables.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25567155"}, {"offsetInBeginSection": 967, "offsetInEndSection": 1055, "text": "Dabigatran etexilate is an oral thrombin inhibitor that can be reversed by idarucizumab.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28479184"}, {"offsetInBeginSection": 0, "offsetInEndSection": 56, "text": "Can the anticoagulant effects of dabigatran be reversed?", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27575900"}, {"offsetInBeginSection": 114, "offsetInEndSection": 264, "text": "This drug can be used for patients who need emergency surgery or invasive procedures, as well as those with life-threatening or uncontrolled bleeding.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27575900"}, {"offsetInBeginSection": 1015, "offsetInEndSection": 1182, "text": "After controlling blood pressure, dabigatran was reversed with idarucizumab, and IV-tPA was administrated beginning 197\u2009minutes after he was last seen at his baseline.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28416406"}, {"offsetInBeginSection": 775, "offsetInEndSection": 1053, "text": "In an interim analysis of the first 90 participants, idarucizumab rapidly and completely reversed the anticoagulant activity of dabigatran in 88%-98% of participants, and there were no safety concerns, with no deaths or serious adverse events being attributable to idarucizumab.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27568285"}, {"offsetInBeginSection": 775, "offsetInEndSection": 1053, "text": "In an interim analysis of the first 90 participants, idarucizumab rapidly and completely reversed the anticoagulant activity of dabigatran in 88%-98% of participants, and there were no safety concerns, with no deaths or serious adverse events being attributable to idarucizumab.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27697436"}, {"offsetInBeginSection": 807, "offsetInEndSection": 951, "text": "Both three- and four-factor PCCs mostly or completely reversed the effects of dabigatran on thromboelastometry variables and PT but not on aPTT.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25567155"}, {"offsetInBeginSection": 1734, "offsetInEndSection": 1868, "text": "Idarucizumab also reversed the effects of dabigatran and, unlike PCCs, was not associated with over-correction of thrombin generation.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25567155"}]}, {"id": "58f89eb270f9fc6f0f00001a", "body": "What is the genetic basis of Ohdo syndrome?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/7519949", "http://www.ncbi.nlm.nih.gov/pubmed/18798845", "http://www.ncbi.nlm.nih.gov/pubmed/26338144", "http://www.ncbi.nlm.nih.gov/pubmed/23395478", "http://www.ncbi.nlm.nih.gov/pubmed/12868473", "http://www.ncbi.nlm.nih.gov/pubmed/9605288", "http://www.ncbi.nlm.nih.gov/pubmed/9546834", "http://www.ncbi.nlm.nih.gov/pubmed/15127758", "http://www.ncbi.nlm.nih.gov/pubmed/9184251", "http://www.ncbi.nlm.nih.gov/pubmed/16700052"], "snippets": [{"offsetInBeginSection": 1083, "offsetInEndSection": 1312, "text": "Together with the recently described KAT6B mutations resulting in Ohdo syndrome Say/Barber/Biesecker/Young/Simpson type, our findings point to aberrant chromatin modification as being central to the pathogenesis of Ohdo syndrome.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23395478"}, {"offsetInBeginSection": 861, "offsetInEndSection": 1082, "text": "The occurrence of three different hemizygous missense mutations in three unrelated families affected by Ohdo syndrome MKB type shows that mutations in MED12 are the underlying cause of this X-linked form of Ohdo syndrome.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23395478"}, {"offsetInBeginSection": 115, "offsetInEndSection": 305, "text": "Using current nosology, five sporadic patients have Ohdo syndrome, associated with congenital hypothyroidism in two of them (thus also compatible with a diagnosis of Young-Simpson syndrome).", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16700052"}, {"offsetInBeginSection": 0, "offsetInEndSection": 198, "text": "Ohdo blepharophimosis syndrome (OBS) is a multiple congenital anomalies-mental retardation syndrome composed of blepharophimosis, ptosis, dental hypoplasia, partial deafness, and mental retardation.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/9605288"}, {"offsetInBeginSection": 0, "offsetInEndSection": 60, "text": "Vertical transmission of the Ohdo blepharophimosis syndrome.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/9605288"}, {"offsetInBeginSection": 0, "offsetInEndSection": 102, "text": "The Ohdo syndrome is characterized by blepharophimosis, ptosis, abnormal ears, and mental retardation.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/7519949"}, {"offsetInBeginSection": 0, "offsetInEndSection": 93, "text": "A clinical and genetic study of the Say/Barber/Biesecker/Young-Simpson type of Ohdo syndrome.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/18798845"}, {"offsetInBeginSection": 0, "offsetInEndSection": 144, "text": "A mentally retarded girl with congenital blepharophimosis, ptosis, hypoplastic teeth and other traits consistent with Ohdo syndrome is reported.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/9546834"}, {"offsetInBeginSection": 0, "offsetInEndSection": 96, "text": "Congenital ptosis and blepharophimosis in a mentally retarded girl: a new case of Ohdo syndrome?", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/9546834"}, {"offsetInBeginSection": 0, "offsetInEndSection": 172, "text": "Ohdo syndrome (MIM 249620) is a multiple malformation syndrome characterized by blepharophimosis, ptosis, dental hypoplasia, hearing impairment and intellectual disability.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/12868473"}]}, {"id": "5a6e472ab750ff4455000048", "body": "What is the function of the TMEM132 genes?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/29088312", "http://www.ncbi.nlm.nih.gov/pubmed/20795330", "http://www.ncbi.nlm.nih.gov/pubmed/12569411", "http://www.ncbi.nlm.nih.gov/pubmed/19947983", "http://www.ncbi.nlm.nih.gov/pubmed/15965245", "http://www.ncbi.nlm.nih.gov/pubmed/26661787", "http://www.ncbi.nlm.nih.gov/pubmed/8173323", "http://www.ncbi.nlm.nih.gov/pubmed/17888165", "http://www.ncbi.nlm.nih.gov/pubmed/16500932", "http://www.ncbi.nlm.nih.gov/pubmed/7579525"], "snippets": [{"offsetInBeginSection": 566, "offsetInEndSection": 727, "text": "The above examples of Hox3/zen (see Schmitt-Ott's chapter, this book) and Hox6/ftz show that the homeotic function may be not so tightly linked to the Hox genes.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20795330"}, {"offsetInBeginSection": 1378, "offsetInEndSection": 1537, "text": "The biological analysis of one of these genes (At1g16850) is presented here, where it is shown to be necessary for the normal response to temperature and NaCl.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17888165"}, {"offsetInBeginSection": 803, "offsetInEndSection": 933, "text": "To the best of our knowledge, PyMut is the first tool that aims to solve the \"off-target\" problem regarding the overlapping genes.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26661787"}, {"offsetInBeginSection": 82, "offsetInEndSection": 292, "text": "Indeed, the answer seems so obvious that several authors have spoken of 'the Hox function' about some of the Hox genes, namely Hox3/zen and Hox6/ftz that seem to have lost it during the evolution of Arthropods.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20795330"}, {"offsetInBeginSection": 0, "offsetInEndSection": 192, "text": "Summary: The molecular functions of TMEM132 genes remain poorly understood and under-investigated despite their mutations associated with non-syndromic hearing loss, panic disorder and cancer.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/29088312"}, {"offsetInBeginSection": 734, "offsetInEndSection": 1033, "text": "Second, while keeping the clustering results from the first step for the genes with known functions, the expression-based distance metric is used to cluster the remaining genes of unknown function, assigning each of them to either one of the clusters obtained in the first step or some new clusters.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16500932"}, {"offsetInBeginSection": 135, "offsetInEndSection": 397, "text": "Efficient RNA interference (RNAi) revealed the function of a cembratriene-ol (CBT-ol) cyclase gene responsible for conversion of geranylgeranyl pyrophosphate to CBT-ols, and verified the function of a P450 gene responsible for conversion of CBT-ols to CBT-diols.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/12569411"}, {"offsetInBeginSection": 929, "offsetInEndSection": 1176, "text": "Did the evolution of animal form involve a proliferation of new homeodomain proteins, new modes of regulation of existing gene types, or new relationships with target genes, or is evolutionary change largely the province of other classes of genes?", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/7579525"}, {"offsetInBeginSection": 0, "offsetInEndSection": 72, "text": "PyMut: a web tool for overlapping gene loss-of-function mutation design.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26661787"}, {"offsetInBeginSection": 76, "offsetInEndSection": 539, "text": "However, currently most of such studies have ignored an important problem (in this paper, we call it \"off-target\" problem), that is, if the target gene is an overlapping gene (A gene whose expressible nucleotides overlaps with that of another one), loss-of-function muta-tion by deleting the complete open reading frame (ORF) may also cause the gene it overlaps lose function, resulting a phenotype which may be rather different from that of single gene deletion.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26661787"}]}, {"id": "5a774240faa1ab7d2e000003", "body": "What is the relationship of fyn kinase and tau?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/27193083", "http://www.ncbi.nlm.nih.gov/pubmed/11826099", "http://www.ncbi.nlm.nih.gov/pubmed/23805846", "http://www.ncbi.nlm.nih.gov/pubmed/19115405", "http://www.ncbi.nlm.nih.gov/pubmed/16115884", "http://www.ncbi.nlm.nih.gov/pubmed/21741124", "http://www.ncbi.nlm.nih.gov/pubmed/9930729", "http://www.ncbi.nlm.nih.gov/pubmed/21269457", "http://www.ncbi.nlm.nih.gov/pubmed/21228179", "http://www.ncbi.nlm.nih.gov/pubmed/15708437"], "snippets": [{"offsetInBeginSection": 271, "offsetInEndSection": 570, "text": "To determine the effect of Fyn on both A\u03b2 and tau pathologies, we crossed homozygous Alzheimer's disease triple transgenic (3\u00d7Tg) mice harboring mutations in amyloid precursor protein, presenilin-1, and tau with wild-type or Fyn knockout mice to generate Fyn(+/+)3\u00d7Tg(+/-) or Fyn(+/-)3\u00d7Tg(+/-) mice.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21741124"}, {"offsetInBeginSection": 1151, "offsetInEndSection": 1266, "text": "In agreement with results already published, we found that in OLGcs, Fyn kinase is associated with Tau and tubulin.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19115405"}, {"offsetInBeginSection": 1000, "offsetInEndSection": 1181, "text": "This effect is likely to be caused by interference with the Fyn-Tau-microtubuli cascade rather than inactivation of the kinase, because Fyn bound to the mutant Tau retains activity.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/11826099"}, {"offsetInBeginSection": 1035, "offsetInEndSection": 1248, "text": "CONCLUSIONS: Fyn and Lck have subtle differences in their properties as tau kinases, and the phosphorylation of tau is one mechanism by which the genetic risk associated with Lck might be expressed pathogenically.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21269457"}, {"offsetInBeginSection": 180, "offsetInEndSection": 342, "text": "We have recently shown that tau interacts with the SH3 domain of Fyn, an Src family non-receptor tyrosine kinase, and is tyrosine-phosphorylated by Fyn on Tyr-18.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16115884"}, {"offsetInBeginSection": 1390, "offsetInEndSection": 1660, "text": "Because ligation of the cell adhesion molecule F3 on oligodendrocytes leads to activation of Fyn kinase localized in rafts, these findings suggest that recruitment of Tau and Tubulin to activated Fyn kinase in rafts is an important step in the initiation of myelination.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/11826099"}, {"offsetInBeginSection": 0, "offsetInEndSection": 94, "text": "Fyn kinase phosphorylates tau and exacerbates amyloid beta (A\u03b2)-mediated synaptic dysfunction.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21741124"}, {"offsetInBeginSection": 1053, "offsetInEndSection": 1240, "text": "Treatment with Fyn pathway inhibitors, Fyn kinase inhibitor PP2 and MEK inhibitor U0126, reversed the PrP(C)-induced tau reduction and A\u03b2 oligomer treatment modulated Fyn kinase activity.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23805846"}, {"offsetInBeginSection": 524, "offsetInEndSection": 688, "text": "In vitro, comparison of Lck and Fyn showed that while both kinases phosphorylated Tyr18 preferentially, Lck phosphorylated other tyrosines somewhat better than Fyn.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21269457"}, {"offsetInBeginSection": 0, "offsetInEndSection": 70, "text": "Tyrosine phosphorylation of tau by the SRC family kinases lck and fyn.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21269457"}]}, {"id": "5a8866958cb19eca6b000003", "body": "Are neurexins localized at pre-synapses?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/27664583", "http://www.ncbi.nlm.nih.gov/pubmed/17360903", "http://www.ncbi.nlm.nih.gov/pubmed/22262843", "http://www.ncbi.nlm.nih.gov/pubmed/26785044", "http://www.ncbi.nlm.nih.gov/pubmed/15620359", "http://www.ncbi.nlm.nih.gov/pubmed/12796785", "http://www.ncbi.nlm.nih.gov/pubmed/1621094", "http://www.ncbi.nlm.nih.gov/pubmed/28220838", "http://www.ncbi.nlm.nih.gov/pubmed/20471353", "http://www.ncbi.nlm.nih.gov/pubmed/23576952"], "snippets": [{"offsetInBeginSection": 320, "offsetInEndSection": 565, "text": "However, isoform-specific knockouts of either all \u03b1- or all \u03b2-neurexins show defects in synaptic transmission but an unaltered density of glutamatergic synapses, a finding that argues against an essential function of neurexins in synaptogenesis.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28220838"}, {"offsetInBeginSection": 0, "offsetInEndSection": 139, "text": "Neurexins and neuroligins are two distinct families of single-pass transmembrane proteins localized at pre- and postsynapses, respectively.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27664583"}, {"offsetInBeginSection": 0, "offsetInEndSection": 357, "text": "The G-protein-coupled receptor CIRL1/latrophilin-1 (CL1) and the type-1 membrane proteins neurexins represent distinct neuronal cell adhesion molecules that exhibit no similarities except for one common function: both proteins are receptors for \u03b1-latrotoxin, a component of black widow spider venom that induces massive neurotransmitter release at synapses.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22262843"}, {"offsetInBeginSection": 1168, "offsetInEndSection": 1359, "text": "These experiments suggest that neurexins are dispensable for the formation of initial synaptic contacts, but play an essential role in the stabilization and functional maturation of synapses.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28220838"}, {"offsetInBeginSection": 677, "offsetInEndSection": 836, "text": "Using immunoelectron microscopy, we found that endogenous neurexins and epitope-tagged neurexin-1beta are localized to axons and presynaptic terminals in vivo.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17360903"}, {"offsetInBeginSection": 480, "offsetInEndSection": 600, "text": "In this protein complex, postsynaptic neuroligins are thought to interact trans-synaptically with presynaptic neurexins.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17360903"}, {"offsetInBeginSection": 0, "offsetInEndSection": 115, "text": "Neurexins are presynaptic cell-adhesion molecules that form trans-synaptic complexes with postsynaptic neuroligins.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20471353"}, {"offsetInBeginSection": 0, "offsetInEndSection": 146, "text": "Neurexins (Nrxs) have emerged as potential determinants of synaptic specificity, but little is known about their localization at central synapses.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23576952"}, {"offsetInBeginSection": 322, "offsetInEndSection": 486, "text": "Here we report that neurexins are concentrated at synapses and that purified neuroligin is sufficient to cluster neurexin and to induce presynaptic differentiation.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/12796785"}, {"offsetInBeginSection": 175, "offsetInEndSection": 255, "text": "beta-neurexins and neuroligins form a trans-synaptic link at glutamate synapses.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15620359"}]}, {"id": "5a7238d32dc08e987e000009", "body": "Which two cotransporters are inhibited by sotagliflozin?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/28899222", "http://www.ncbi.nlm.nih.gov/pubmed/26049551", "http://www.ncbi.nlm.nih.gov/pubmed/28811850", "http://www.ncbi.nlm.nih.gov/pubmed/25759591", "http://www.ncbi.nlm.nih.gov/pubmed/28387957", "http://www.ncbi.nlm.nih.gov/pubmed/28872070", "http://www.ncbi.nlm.nih.gov/pubmed/26548423", "http://www.ncbi.nlm.nih.gov/pubmed/25690134", "http://www.ncbi.nlm.nih.gov/pubmed/26484403", "http://www.ncbi.nlm.nih.gov/pubmed/16446421"], "snippets": [{"offsetInBeginSection": 196, "offsetInEndSection": 542, "text": "This gene family has two major branches with different physiological functions and inverse regulation: K-Cl cotransporters (KCC1-KCC4) mediate cellular Cl- efflux, are inhibited by phosphorylation, and are activated by dephosphorylation; Na-(K)-Cl cotransporters (NCC and NKCC1/2) mediate cellular Cl- influx and are activated by phosphorylation.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16446421"}, {"offsetInBeginSection": 1375, "offsetInEndSection": 1769, "text": "Wild-type WNK3 activates Na-(K)-Cl cotransporters by increasing their phosphorylation, and catalytically inactive kinase inhibits Na-(K)-Cl cotransporters by decreasing their phosphorylation, such that our data suggest that WNK3 is a crucial component of the kinase/phosphatase signaling pathway that coordinately regulates the Cl- influx and efflux branches of the SLC12A cotransporter family.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16446421"}, {"offsetInBeginSection": 0, "offsetInEndSection": 195, "text": "SLC12A cation/Cl- cotransporters are mutated in human disease, are targets of diuretics, and are collectively involved in the regulation of cell volume, neuronal excitability, and blood pressure.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16446421"}, {"offsetInBeginSection": 713, "offsetInEndSection": 908, "text": "We previously demonstrated that WNK3, a paralog of serine-threonine kinases mutated in hereditary hypertension, is coexpressed with several cation/Cl- cotransporters and regulates their activity.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16446421"}, {"offsetInBeginSection": 0, "offsetInEndSection": 199, "text": "OBJECTIVE: To assess the safety and efficacy of dual sodium-glucose cotransporter (SGLT) 1 and SGLT2 inhibition with sotagliflozin as adjunct therapy to insulin in type 1 diabetes.RESEARCH DESIGN AND", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26049551"}, {"offsetInBeginSection": 120, "offsetInEndSection": 306, "text": "We evaluated the safety and efficacy of sotagliflozin, an oral inhibitor of sodium-glucose cotransporters 1 and 2, in combination with insulin treatment in patients with type 1 diabetes.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28899222"}, {"offsetInBeginSection": 1023, "offsetInEndSection": 1241, "text": "In contrast, catalytically inactive WNK3 abolishes the cell shrinkage-induced inhibition of KCC1-KCC4, resulting in a >100-fold stimulation of K-Cl cotransport during conditions in which transport is normally inactive.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16446421"}, {"offsetInBeginSection": 279, "offsetInEndSection": 573, "text": "PubMed databases and abstracts from recent diabetes meetings were searched using the term \"type 1 diabetes\" and the available and investigational sodium-glucose cotransporter (SGLT) inhibitors, glucagon-like peptide 1 (GLP-1) receptor agonists, dipeptidyl peptidase 4 inhibitors, and metformin.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26484403"}, {"offsetInBeginSection": 0, "offsetInEndSection": 159, "text": "Effect of Sodium Glucose Cotransporter 2 Inhibitors With Low SGLT2/SGLT1 Selectivity on Circulating Glucagon-Like Peptide 1 Levels in Type 2 Diabetes Mellitus.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28811850"}, {"offsetInBeginSection": 0, "offsetInEndSection": 194, "text": "Sodium glucose cotransporter 2 (SGLT2) inhibitors are a new class of antidiabetic drugs that improve glycemic control by inhibiting reabsorption of glucose filtered through the renal glomerulus.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28811850"}]}, {"id": "58f8a08370f9fc6f0f00001b", "body": "Which are the main manifestations of Ohdo syndrome?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/15127758", "http://www.ncbi.nlm.nih.gov/pubmed/8279489", "http://www.ncbi.nlm.nih.gov/pubmed/23395478", "http://www.ncbi.nlm.nih.gov/pubmed/12868473", "http://www.ncbi.nlm.nih.gov/pubmed/7519949", "http://www.ncbi.nlm.nih.gov/pubmed/9546834", "http://www.ncbi.nlm.nih.gov/pubmed/18798845", "http://www.ncbi.nlm.nih.gov/pubmed/9184251", "http://www.ncbi.nlm.nih.gov/pubmed/16700052", "http://www.ncbi.nlm.nih.gov/pubmed/10631927"], "snippets": [{"offsetInBeginSection": 861, "offsetInEndSection": 1082, "text": "The occurrence of three different hemizygous missense mutations in three unrelated families affected by Ohdo syndrome MKB type shows that mutations in MED12 are the underlying cause of this X-linked form of Ohdo syndrome.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23395478"}, {"offsetInBeginSection": 1083, "offsetInEndSection": 1312, "text": "Together with the recently described KAT6B mutations resulting in Ohdo syndrome Say/Barber/Biesecker/Young/Simpson type, our findings point to aberrant chromatin modification as being central to the pathogenesis of Ohdo syndrome.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23395478"}, {"offsetInBeginSection": 115, "offsetInEndSection": 305, "text": "Using current nosology, five sporadic patients have Ohdo syndrome, associated with congenital hypothyroidism in two of them (thus also compatible with a diagnosis of Young-Simpson syndrome).", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16700052"}, {"offsetInBeginSection": 0, "offsetInEndSection": 59, "text": "Two additional cases of the Ohdo blepharophimosis syndrome.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/8279489"}, {"offsetInBeginSection": 0, "offsetInEndSection": 124, "text": "Two additional cases of the Ohdo blepharophimosis syndrome are described and compared to the 5 patients previously reported.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/8279489"}, {"offsetInBeginSection": 0, "offsetInEndSection": 96, "text": "Congenital blepharophimosis and ptosis in a mentally retarded girl: a new case of Ohdo syndrome?", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/10631927"}, {"offsetInBeginSection": 122, "offsetInEndSection": 296, "text": "A review of the skeletal manifestations reported in the literature on Ohdo syndrome reveals that joint laxity and skeletal deformities are important aspects of the phenotype.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15127758"}, {"offsetInBeginSection": 0, "offsetInEndSection": 96, "text": "Congenital ptosis and blepharophimosis in a mentally retarded girl: a new case of Ohdo syndrome?", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/9546834"}, {"offsetInBeginSection": 0, "offsetInEndSection": 86, "text": "Blepharophimosis, ptosis and mental retardation: further delineation of Ohdo syndrome.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/7519949"}, {"offsetInBeginSection": 0, "offsetInEndSection": 85, "text": "Skeletal manifestations in Ohdo syndrome: a case with bilateral patella dislocations.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15127758"}]}, {"id": "5a6e5df6b750ff445500004e", "body": "Describe GARLIC (GWAS-based Prediction Toolkit for Connecting Diseases and Cell Types)", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/28007912", "http://www.ncbi.nlm.nih.gov/pubmed/28302177", "http://www.ncbi.nlm.nih.gov/pubmed/26158728", "http://www.ncbi.nlm.nih.gov/pubmed/21382596", "http://www.ncbi.nlm.nih.gov/pubmed/24799394", "http://www.ncbi.nlm.nih.gov/pubmed/28240269", "http://www.ncbi.nlm.nih.gov/pubmed/19508241", "http://www.ncbi.nlm.nih.gov/pubmed/28036406", "http://www.ncbi.nlm.nih.gov/pubmed/28598966", "http://www.ncbi.nlm.nih.gov/pubmed/21536720"], "snippets": [{"offsetInBeginSection": 522, "offsetInEndSection": 959, "text": "Based on emerging evidences suggesting that disease-associated SNPs are frequently found within cell type-specific regulatory sequences, here we present GARLIC (GWAS-based Prediction Toolkit for Connecting Diseases and Cell Types), a user-friendly, multi-purpose software with an associated database and online viewer that, using global maps of cis-regulatory elements, can aetiologically connect human diseases with relevant cell types.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28007912"}, {"offsetInBeginSection": 0, "offsetInEndSection": 110, "text": "GARLIC: a bioinformatic toolkit for aetiologically connecting diseases and cell type-specific regulatory maps.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28007912"}, {"offsetInBeginSection": 233, "offsetInEndSection": 594, "text": "Despite the identification of thousands of disease-associated genetic variants through genome-wide association studies (GWAS) in the past decade, accuracy of genetic risk prediction remains moderate for most diseases, which is largely due to the challenges in both identifying all the functionally relevant variants and accurately estimating their effect sizes.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28598966"}, {"offsetInBeginSection": 758, "offsetInEndSection": 1021, "text": "PleioPred uses GWAS summary statistics as its input, and jointly models multiple genetically correlated diseases and a variety of external information including linkage disequilibrium and diverse functional annotations to increase the accuracy of risk prediction.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28598966"}, {"offsetInBeginSection": 1691, "offsetInEndSection": 1842, "text": "Bioinformatic integration of transcriptomic data with recent GWAS data identified specific candidate genes and cell types for inflammatory pathologies.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24799394"}, {"offsetInBeginSection": 1142, "offsetInEndSection": 1379, "text": "Intestinal-specific T cell transcripts were enriched in GWAS risk loci for Crohn's disease, ulcerative colitis and coeliac disease, but also specific extraintestinal immune-mediated diseases, allowing prediction of novel candidate genes.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24799394"}, {"offsetInBeginSection": 1428, "offsetInEndSection": 1637, "text": "More generally, we demonstrate that a functional network of human genes provides a valuable statistical framework for prioritizing candidate disease genes, both for candidate gene-based and GWAS-based studies.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21536720"}, {"offsetInBeginSection": 0, "offsetInEndSection": 137, "text": "It remains challenging to predict regulatory variants in particular tissues or cell types due to highly context-specific gene regulation.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28302177"}, {"offsetInBeginSection": 0, "offsetInEndSection": 228, "text": "OBJECTIVE: Genome-wide association studies (GWAS) have identified genetic variants within multiple risk loci as predisposing to intestinal inflammatory diseases, including Crohn's disease, ulcerative colitis and coeliac disease.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24799394"}, {"offsetInBeginSection": 741, "offsetInEndSection": 814, "text": "We applied our methods to GWAS summary-level data of 14 complex diseases.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28036406"}]}, {"id": "5a7d4721faa1ab7d2e000012", "body": "What does davunetide do to microtubules?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/21902667", "http://www.ncbi.nlm.nih.gov/pubmed/23971871", "http://www.ncbi.nlm.nih.gov/pubmed/24210139", "http://www.ncbi.nlm.nih.gov/pubmed/21050875", "http://www.ncbi.nlm.nih.gov/pubmed/24873720", "http://www.ncbi.nlm.nih.gov/pubmed/22347799", "http://www.ncbi.nlm.nih.gov/pubmed/20417241", "http://www.ncbi.nlm.nih.gov/pubmed/24533805", "http://www.ncbi.nlm.nih.gov/pubmed/21524250", "http://www.ncbi.nlm.nih.gov/pubmed/25955282"], "snippets": [{"offsetInBeginSection": 700, "offsetInEndSection": 851, "text": "Davunetide is a novel neuroprotective peptide that is thought to impact neuronal integrity and cell survival through the stabilization of microtubules.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22347799"}, {"offsetInBeginSection": 708, "offsetInEndSection": 949, "text": "NAP (davunetide) interacted with microtubules, protected against microtubule toxicity associated with zinc, nocodazole and oxidative stress in vitro and against tau pathology and MAP6 (stable tubuleonly polypeptide - STOP) pathology in vivo.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21902667"}, {"offsetInBeginSection": 321, "offsetInEndSection": 626, "text": "Potential clinical uses of davunetide include neurodegenerative disorders such as Alzheimer's disease (AD), progressive supranuclear palsy (PSP), frontotemporal dementia (FTD) or cognitive impairment in other diseases such as schizophrenia where microtubule structure and function is known to be impaired.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23971871"}, {"offsetInBeginSection": 945, "offsetInEndSection": 1209, "text": "Thus, it has been hypothesized that the presence of tau on axonal microtubules renders them notably less sensitive to the microtubule-severing protein katanin, and NAP was shown to protect microtubules from katanin disruption in the face of reduced tau expression.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21524250"}, {"offsetInBeginSection": 1320, "offsetInEndSection": 1569, "text": "The davunetide and placebo groups did not differ in the change from baseline in PSPRS (median 11\u00b78 [95% CI 10\u00b75 to 13\u00b70] vs 11\u00b78 [10\u00b75 to 13\u00b70], respectively, p=0\u00b741) or SEADL (-0\u00b720 [-0\u00b720 to -0\u00b717] vs -0\u00b720 [-0\u00b722 to -0\u00b717], respectively, p=0\u00b792).", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24873720"}, {"offsetInBeginSection": 0, "offsetInEndSection": 71, "text": "Microtubules (tau) as an emerging therapeutic target: NAP (davunetide).", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21902667"}, {"offsetInBeginSection": 0, "offsetInEndSection": 204, "text": "This review focuses on the discovery of activity-dependent neuroprotective protein (ADNP) and the ensuing discovery of NAP (davunetide) toward clinical development with emphasis on microtubule protection.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21902667"}, {"offsetInBeginSection": 0, "offsetInEndSection": 124, "text": "NAP (davunetide) enhances cognitive behavior in the STOP heterozygous mouse--a microtubule-deficient model of schizophrenia.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20417241"}, {"offsetInBeginSection": 1139, "offsetInEndSection": 1306, "text": "NAP (davunetide) protection against neurodegeneration has recently been shown to extend to katanin-related microtubule disruption under conditions of tau deficiencies.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21902667"}, {"offsetInBeginSection": 398, "offsetInEndSection": 557, "text": "Possible mechanisms of NAP actions include anti-inflammatory effect, antioxidant activity, inhibition of protein aggregation and interaction with microtubules.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24533805"}]}, {"id": "5a886da58cb19eca6b000004", "body": "Has Cas9 gene editing the potential to correct inhereted hearing loss?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/25987504", "http://www.ncbi.nlm.nih.gov/pubmed/26829318", "http://www.ncbi.nlm.nih.gov/pubmed/28195574", "http://www.ncbi.nlm.nih.gov/pubmed/27500183", "http://www.ncbi.nlm.nih.gov/pubmed/26817415", "http://www.ncbi.nlm.nih.gov/pubmed/28706995", "http://www.ncbi.nlm.nih.gov/pubmed/28758991", "http://www.ncbi.nlm.nih.gov/pubmed/28527117", "http://www.ncbi.nlm.nih.gov/pubmed/27494557", "http://www.ncbi.nlm.nih.gov/pubmed/27498021"], "snippets": [{"offsetInBeginSection": 844, "offsetInEndSection": 1025, "text": "For genetic hearing loss, CRISPR/Cas9 has potential to repair gene mutations by homology-directed-repair (HDR) or to disrupt dominant mutations by NHEJ, which could restore hearing.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25987504"}, {"offsetInBeginSection": 0, "offsetInEndSection": 69, "text": "CRISPR-Cas9 gene editing: Delivery aspects and therapeutic potential.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27498021"}, {"offsetInBeginSection": 1153, "offsetInEndSection": 1361, "text": "Thus, application of CRISPR/Cas9 in hearing research will open up new avenues for understanding the pathology of genetic hearing loss and provide new routes in the development of treatment to restore hearing.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25987504"}, {"offsetInBeginSection": 0, "offsetInEndSection": 268, "text": "Targeted genome editing mediated by clustered, regularly interspaced, short palindromic repeat (CRISPR)/CRISPR-associated nuclease 9 (Cas9) technology has emerged as one of the most powerful tools to study gene functions, and with potential to treat genetic disorders.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25987504"}, {"offsetInBeginSection": 1445, "offsetInEndSection": 1646, "text": "We will highlight applications of these technologies in studies of genetic disorders and discuss issues pertaining to applications of CRISPR/Cas9 in auditory systems implicated in genetic hearing loss.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25987504"}, {"offsetInBeginSection": 393, "offsetInEndSection": 525, "text": "Here, we employed non-inheritable maternal Cas9 (maCas9) protein derived from Tg mice with systemic Cas9 overexpression (Cas9 mice).", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26817415"}, {"offsetInBeginSection": 118, "offsetInEndSection": 389, "text": "Since the introduction of CRISPR-Cas9, genome editing has become widely used in transformable plants for characterizing gene function and improving traits, mainly by inducing mutations through non-homologous end joining of double-stranded breaks generated by CRISPR-Cas9.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28758991"}, {"offsetInBeginSection": 95, "offsetInEndSection": 392, "text": "The preexisting method is largely based on the co-injection of Cas9 DNA (or mRNA) and guide RNAs (gRNAs); however, it is unclear how many genes can be simultaneously edited by this method, and a reliable means to generate transgenic (Tg) animals with multiple gene editing has yet to be developed.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26817415"}, {"offsetInBeginSection": 1084, "offsetInEndSection": 1243, "text": "Timed delivery of AcrIIA4 into human cells as either protein or expression plasmid allows on-target Cas9-mediated gene editing while reducing off-target edits.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28706995"}, {"offsetInBeginSection": 218, "offsetInEndSection": 360, "text": "CRISPR-Cas9 also holds enormous therapeutic potential for the treatment of genetic disorders by directly correcting disease-causing mutations.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27494557"}]}, {"id": "5a7345792dc08e987e000019", "body": "Describe mechanism of action of Napabucasin.", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/28573435", "http://www.ncbi.nlm.nih.gov/pubmed/26899963", "http://www.ncbi.nlm.nih.gov/pubmed/11916069", "http://www.ncbi.nlm.nih.gov/pubmed/11563078", "http://www.ncbi.nlm.nih.gov/pubmed/6217819", "http://www.ncbi.nlm.nih.gov/pubmed/22174430", "http://www.ncbi.nlm.nih.gov/pubmed/22664071", "http://www.ncbi.nlm.nih.gov/pubmed/28683005", "http://www.ncbi.nlm.nih.gov/pubmed/2464658", "http://www.ncbi.nlm.nih.gov/pubmed/23821284"], "snippets": [{"offsetInBeginSection": 861, "offsetInEndSection": 1206, "text": "The results demonstrate the ability of this model to identify the dual mechanism of action of a glucokinase activator and describe and predict its effects: Estimating a stimulating drug effect on insulin secretion and an inhibiting effect on glucose output resulted in a significantly better model fit than any other combination of effect sites.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22174430"}, {"offsetInBeginSection": 0, "offsetInEndSection": 110, "text": "1-(3-C-ethynyl-beta-D-ribo-pentofuranosyl)cytosine (ECyd, TAS-106)1: antitumor effect and mechanism of action.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/11563078"}, {"offsetInBeginSection": 0, "offsetInEndSection": 176, "text": "The antitumor activity, cellular metabolism and mechanism of action of the antitumor nucleoside analog, 1-(3-C-ethynyl-beta-D-ribo-pentofuranosyl)cytosine (ECyd) are described.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/11563078"}, {"offsetInBeginSection": 1207, "offsetInEndSection": 1354, "text": "The model may be used for dose finding in early clinical drug development and for gaining more insight into a drug candidate's mechanism of action.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22174430"}, {"offsetInBeginSection": 137, "offsetInEndSection": 358, "text": "A glucokinase activator was used as a test compound to evaluate the model's ability to identify a drug's mechanism of action and estimate its effects on glucose and insulin profiles following oral glucose tolerance tests.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22174430"}, {"offsetInBeginSection": 162, "offsetInEndSection": 412, "text": "A well-characterized mechanism of action is useful in evaluating potential off-target toxicities (e.g., a viral polymerase inhibitor may be assessed for inhibition of host polymerase) and in designing studies to monitor the development of resistance.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23821284"}, {"offsetInBeginSection": 420, "offsetInEndSection": 533, "text": "This review will describe what is known about the mechanism of action of angiostatin from the current literature.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/11916069"}, {"offsetInBeginSection": 303, "offsetInEndSection": 429, "text": "From this mechanism of action far-reaching perspectives concerning the clinical application of neocarzinostatin are discussed.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/6217819"}, {"offsetInBeginSection": 0, "offsetInEndSection": 70, "text": "Methods to determine mechanism of action of anti-influenza inhibitors.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23821284"}, {"offsetInBeginSection": 0, "offsetInEndSection": 76, "text": "The mechanism of action of angiostatin: can you teach an old dog new tricks?", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/11916069"}]}, {"id": "590af75d70f9fc6f0f00001c", "body": "Which algorithm is used by the UCSC Genome Browser?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/25348212", "http://www.ncbi.nlm.nih.gov/pubmed/22080555", "http://www.ncbi.nlm.nih.gov/pubmed/19957273", "http://www.ncbi.nlm.nih.gov/pubmed/18428780", "http://www.ncbi.nlm.nih.gov/pubmed/21975940", "http://www.ncbi.nlm.nih.gov/pubmed/23255150", "http://www.ncbi.nlm.nih.gov/pubmed/25766521", "http://www.ncbi.nlm.nih.gov/pubmed/19920125", "http://www.ncbi.nlm.nih.gov/pubmed/12519945", "http://www.ncbi.nlm.nih.gov/pubmed/17993665"], "snippets": [{"offsetInBeginSection": 145, "offsetInEndSection": 500, "text": "The University of California Santa Cruz (UCSC) Genome Bioinformatics group has developed several tools and methodologies in its study of comparative genomics, many of which have been incorporated into the UCSC Genome Browser (http://genome.ucsc.edu), an easy-to-use online tool for browsing genomic data and aligned annotation \"tracks\" in a single window.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17993665"}, {"offsetInBeginSection": 0, "offsetInEndSection": 137, "text": "RNASeqBrowser: a genome browser for simultaneous visualization of raw strand specific RNAseq reads and UCSC genome browser custom tracks.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25766521"}, {"offsetInBeginSection": 1296, "offsetInEndSection": 1429, "text": "CONCLUSIONS: The features of RNASeqBrowser: (1) RNASeqBrowser integrates UCSC genome browser and NGS visualization tools such as IGV.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25766521"}, {"offsetInBeginSection": 630, "offsetInEndSection": 864, "text": "The Genome Browser Database, browsing tools and downloadable data files can all be found on the UCSC Genome Bioinformatics website (http://genome.ucsc.edu), which also contains links to documentation and related technical information.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/12519945"}, {"offsetInBeginSection": 0, "offsetInEndSection": 232, "text": "The University of California Santa Cruz (UCSC) Genome Browser (genome.ucsc.edu) is a popular Web-based tool for quickly displaying a requested portion of a genome at any scale, accompanied by a series of aligned annotation \"tracks\".", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/18428780"}, {"offsetInBeginSection": 381, "offsetInEndSection": 566, "text": "These results are captured in the UCSC Genome Bioinformatics database and download server for visualization and data mining via the UCSC Genome Browser and companion tools (Rhead et al.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19920125"}, {"offsetInBeginSection": 497, "offsetInEndSection": 640, "text": "RESULTS: This paper introduces a visualization tool (RNASeqBrowser) that incorporates and extends the functionality of the UCSC genome browser.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25766521"}, {"offsetInBeginSection": 1430, "offsetInEndSection": 1587, "text": "It extends the functionality of the UCSC genome browser by adding several new types of tracks to show NGS data such as individual raw reads, SNPs and InDels.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25766521"}, {"offsetInBeginSection": 0, "offsetInEndSection": 198, "text": "UNLABELLED: Genome Browser in a Box (GBiB) is a small virtual machine version of the popular University of California Santa Cruz (UCSC) Genome Browser that can be run on a researcher's own computer.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25348212"}, {"offsetInBeginSection": 630, "offsetInEndSection": 795, "text": "The ENCODE web portal at UCSC (http://encodeproject.org or http://genome.ucsc.edu/ENCODE) provides information about the ENCODE data and convenient links for access.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19920125"}]}, {"id": "5a76056983b0d9ea66000012", "body": "Does DDX54 play a role in DNA damage response?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/28596291", "http://www.ncbi.nlm.nih.gov/pubmed/23239230", "http://www.ncbi.nlm.nih.gov/pubmed/27022404", "http://www.ncbi.nlm.nih.gov/pubmed/27074761", "http://www.ncbi.nlm.nih.gov/pubmed/19759019", "http://www.ncbi.nlm.nih.gov/pubmed/28525740", "http://www.ncbi.nlm.nih.gov/pubmed/22361354", "http://www.ncbi.nlm.nih.gov/pubmed/26884483", "http://www.ncbi.nlm.nih.gov/pubmed/16410768", "http://www.ncbi.nlm.nih.gov/pubmed/24795278"], "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 179, "text": "The deubiquitylation enzyme USP7/HAUSP plays a major role in regulating genome stability and cancer prevention by controlling the key proteins involved in the DNA damage response.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22361354"}, {"offsetInBeginSection": 1341, "offsetInEndSection": 1549, "text": "Together, the data presented here demonstrate that AtPDCD5 plays an important role during DNA damage responses induced by UV-B radiation in Arabidopsis and also participates in programmed cell death programs.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26884483"}, {"offsetInBeginSection": 687, "offsetInEndSection": 868, "text": "Depletion of ATAXIA-TELANGIECTASIA MUTATED (ATM) in mms21-1 enhances its root growth defect phenotype, indicating that ATM and AtMMS21 may play additive roles in DNA damage pathway.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24795278"}, {"offsetInBeginSection": 303, "offsetInEndSection": 395, "text": "Here, we report that USP7 regulation plays a central role in DNA damage signal transmission.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22361354"}, {"offsetInBeginSection": 891, "offsetInEndSection": 1094, "text": "Thus, our study highlights the importance of linkage-specific ubiquitination at DNA damage sites, and it reveals that Lys11-linkage ubiquitin modification plays a crucial role in the DNA damage response.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28525740"}, {"offsetInBeginSection": 0, "offsetInEndSection": 89, "text": "AtMMS21 regulates DNA damage response and homologous recombination repair in Arabidopsis.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24795278"}, {"offsetInBeginSection": 140, "offsetInEndSection": 274, "text": "Since most BRCT-containing proteins are involved in DNA damage response and/or DNA repair, we tested whether Ect2 plays similar roles.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27074761"}, {"offsetInBeginSection": 997, "offsetInEndSection": 1119, "text": "Conclusively, we provided evidence that AtMMS21 plays an important role in homologous recombination for DNA damage repair.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24795278"}, {"offsetInBeginSection": 616, "offsetInEndSection": 890, "text": "We show that RNF8- and Ube2S-dependent Lys11-linkage ubiquitin conjugation plays an important role in regulating DNA damage-induced transcriptional silencing, distinct from the role of Lys63-linkage ubiquitin in the recruitment of DNA damage repair proteins 53BP1 and BRCA1.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28525740"}, {"offsetInBeginSection": 235, "offsetInEndSection": 505, "text": "In this work, we investigated the role of an Arabidopsis (Arabidopsis thaliana) protein, AtPDCD5, which is highly similar to the human PDCD5 protein; it is induced by ultraviolet (UV)-B radiation and participates in programmed cell death in the UV-B DNA damage response.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26884483"}]}, {"id": "5a7d5033faa1ab7d2e000015", "body": "Is davunetide being considered for the treatment of progressive supranuclear palsy?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/22347799", "http://www.ncbi.nlm.nih.gov/pubmed/24873720", "http://www.ncbi.nlm.nih.gov/pubmed/23971871", "http://www.ncbi.nlm.nih.gov/pubmed/26459661", "http://www.ncbi.nlm.nih.gov/pubmed/21902667", "http://www.ncbi.nlm.nih.gov/pubmed/26227071", "http://www.ncbi.nlm.nih.gov/pubmed/26421389", "http://www.ncbi.nlm.nih.gov/pubmed/20678069", "http://www.ncbi.nlm.nih.gov/pubmed/26948290", "http://www.ncbi.nlm.nih.gov/pubmed/28436538"], "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 296, "text": "BACKGROUND: Two recent, randomized, placebo-controlled phase II/III trials (clinicaltrials.gov: NCT01110720, NCT01049399) of davunetide and tideglusib in progressive supranuclear palsy (PSP) generated prospective, 1-year longitudinal datasets of high-resolution T1-weighted three-dimensional MRI.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28436538"}, {"offsetInBeginSection": 1515, "offsetInEndSection": 1707, "text": "Based on these extensive preclinical results, davunetide (NAP) is now being evaluated in a Phase II/III study of the tauopathy, progressive supranuclear palsy (PSP); (Allon Therapeutics Inc.).", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21902667"}, {"offsetInBeginSection": 111, "offsetInEndSection": 224, "text": "Because progressive supranuclear palsy (PSP) is linked to tau pathology, davunetide could be a treatment for PSP.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24873720"}, {"offsetInBeginSection": 0, "offsetInEndSection": 96, "text": "Critical appraisal of the role of davunetide in the treatment of progressive supranuclear palsy.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22347799"}, {"offsetInBeginSection": 321, "offsetInEndSection": 626, "text": "Potential clinical uses of davunetide include neurodegenerative disorders such as Alzheimer's disease (AD), progressive supranuclear palsy (PSP), frontotemporal dementia (FTD) or cognitive impairment in other diseases such as schizophrenia where microtubule structure and function is known to be impaired.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23971871"}, {"offsetInBeginSection": 1229, "offsetInEndSection": 1583, "text": "It is hoped that davunetide, a most advanced drug in clinical development will rapidly advance as a first effective treatment for a number of brain disorders broadly categorized as frontotemporal dementia (FTD) and serve as a prototype for future therapeutic development toward modification and remedy of currently intractable neurodegenerative diseases.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20678069"}, {"offsetInBeginSection": 0, "offsetInEndSection": 123, "text": "Davunetide in patients with progressive supranuclear palsy: a randomised, double-blind, placebo-controlled phase 2/3 trial.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24873720"}, {"offsetInBeginSection": 384, "offsetInEndSection": 603, "text": "An abundance of tau inclusions, in the absence of \u03b2-amyloid deposits, defines Pick's disease (frontotemporal lobar degeneration), progressive supranuclear palsy (PSP), corticobasal degeneration (CBD) and other diseases.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20678069"}, {"offsetInBeginSection": 165, "offsetInEndSection": 318, "text": "Multiple system atrophy (MSA), progressive supranuclear palsy (PSP) and corticobasal degeneration (CBD) are commonly summarized under this umbrella term.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26421389"}, {"offsetInBeginSection": 0, "offsetInEndSection": 83, "text": "Therapeutic advances in multiple system atrophy and progressive supranuclear palsy.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26227071"}]}, {"id": "5a8941c5bc7bade53a000002", "body": "Which aminoacid position in the human CREB protein is phosphorylated?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/7554179", "http://www.ncbi.nlm.nih.gov/pubmed/1532242", "http://www.ncbi.nlm.nih.gov/pubmed/8065935", "http://www.ncbi.nlm.nih.gov/pubmed/2136830", "http://www.ncbi.nlm.nih.gov/pubmed/8627701", "http://www.ncbi.nlm.nih.gov/pubmed/8125987", "http://www.ncbi.nlm.nih.gov/pubmed/27816995", "http://www.ncbi.nlm.nih.gov/pubmed/8754745", "http://www.ncbi.nlm.nih.gov/pubmed/23143030", "http://www.ncbi.nlm.nih.gov/pubmed/7854055"], "snippets": [{"offsetInBeginSection": 1091, "offsetInEndSection": 1487, "text": "In contrast, immunocytochemistry and Western protein blotting using an antipeptide antibody specific to CREB phosphorylated at serine 133 (P-CREB), which is the activated from of the CREB protein, revealed a dramatic increase in the phosphorylated form of CREB within 20 min of gonadotropin treatment of granulosa cells that was transient and was decreased by 60 min after gonadotropin treatment.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/8754745"}, {"offsetInBeginSection": 1102, "offsetInEndSection": 1338, "text": "CONCLUSIONS: We conclude that in the failing and nonfailing human heart, CREB is expressed on the protein and mRNA levels and that CREB is phosphorylated and able to bind to CREs, indicating a functional role of CREB in the human heart.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/7554179"}, {"offsetInBeginSection": 0, "offsetInEndSection": 162, "text": "Recombinant cyclic AMP response element binding protein (CREB) phosphorylated on Ser-133 is transcriptionally active upon its introduction into fibroblast nuclei.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/8125987"}, {"offsetInBeginSection": 872, "offsetInEndSection": 1088, "text": "The activity of phosphorylated CREB, nonphosphorylated CREB, and a mutant form of CREB, containing Ala substituted for Ser at position 133, was found to be nearly identical in cell-free in vitro transcription assays.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/8125987"}, {"offsetInBeginSection": 1221, "offsetInEndSection": 1454, "text": "Finally, transfection of CREB protein and protein kinase A expression vectors were found to activate Zp in Jurkat cells, suggesting that phosphorylated form of CREB protein can play a determining role in the EBV reactivation process.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/8627701"}, {"offsetInBeginSection": 1045, "offsetInEndSection": 1245, "text": "First, the upregulation of CREB expression that allows sufficient level of activated and phosphorylated protein is the primordial event that promotes the induction of genes of the DNA Damage Response.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27816995"}, {"offsetInBeginSection": 157, "offsetInEndSection": 298, "text": "Using a model of human neuronal cells we demonstrate herein, that CREB is phosphorylated after oxidative stress induced by hydrogen peroxide.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27816995"}, {"offsetInBeginSection": 512, "offsetInEndSection": 641, "text": "Many dental pulp stromal cells and periodontal ligament fibroblasts expressed CREB and showed phosphorylation of CREB at Ser-133.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23143030"}, {"offsetInBeginSection": 0, "offsetInEndSection": 138, "text": "The transcription factor CREB is not phosphorylated at serine 133 in axotomized neurons: implications for the expression of AP-1 proteins.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/7854055"}, {"offsetInBeginSection": 889, "offsetInEndSection": 1094, "text": "One of the phosphorylated proteins co-migrates with immuno-affinity-purified CREB protein--also phosphorylated in vitro--and competes with the peptide antigen, which proves the specificity of the reaction.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/1532242"}]}, {"id": "5a737b483b9d13c70800000b", "body": "Which drugs were tested in the KEYNOTE-006 study?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/28987768", "http://www.ncbi.nlm.nih.gov/pubmed/28822576", "http://www.ncbi.nlm.nih.gov/pubmed/26846323", "http://www.ncbi.nlm.nih.gov/pubmed/28125365", "http://www.ncbi.nlm.nih.gov/pubmed/27896938", "http://www.ncbi.nlm.nih.gov/pubmed/28964438", "http://www.ncbi.nlm.nih.gov/pubmed/28837405", "http://www.ncbi.nlm.nih.gov/pubmed/12942788", "http://www.ncbi.nlm.nih.gov/pubmed/6594234", "http://www.ncbi.nlm.nih.gov/pubmed/26034052"], "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 230, "text": "OBJECTIVE: Report results of patient-reported health-related quality of life (HRQoL) and symptoms from phase III KEYNOTE-006 study of pembrolizumab versus ipilimumab in patients with ipilimumab-naive advanced melanoma.PATIENTS AND", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28987768"}, {"offsetInBeginSection": 720, "offsetInEndSection": 1197, "text": "In the trials with active comparator arms, pembrolizumab regimens significantly improved progression-free survival (PFS), overall survival (OS) and overall response rates (ORR) relative to ipilimumab in ipilimumab-na\u00efve patients (KEYNOTE 006), and significantly improved PFS and ORR, but not OS (although OS data are immature), relative to chemotherapy in ipilimumab-refractory patients, who had also received BRAF/MEK inhibitor therapy if BRAF-mutation positive (KEYNOTE 002).", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26846323"}, {"offsetInBeginSection": 0, "offsetInEndSection": 158, "text": "Safety and Antitumor Activity of Pembrolizumab in Patients With Programmed Death-Ligand 1-Positive Nasopharyngeal Carcinoma: Results of the KEYNOTE-028 Study.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28837405"}, {"offsetInBeginSection": 0, "offsetInEndSection": 186, "text": "BACKGROUND: Interim analyses of the phase 3 KEYNOTE-006 study showed superior overall and progression-free survival of pembrolizumab versus ipilimumab in patients with advanced melanoma.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28822576"}, {"offsetInBeginSection": 700, "offsetInEndSection": 884, "text": "The model used Kaplan-Meier estimates of progression-free survival and overall survival from a recent randomized phase 3 study (KEYNOTE-006) that compared pembrolizumab and ipilimumab.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28125365"}, {"offsetInBeginSection": 0, "offsetInEndSection": 155, "text": "Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006).", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28822576"}, {"offsetInBeginSection": 209, "offsetInEndSection": 472, "text": "This intravenous drug is indicated for the treatment of advanced (unresectable or metastatic) melanoma, on the basis of its clinical benefit in this setting in the phase I KEYNOTE 001 trial (expansion cohorts) and the phase II and III trials, KEYNOTE 002 and 006.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26846323"}, {"offsetInBeginSection": 178, "offsetInEndSection": 298, "text": "The MICs of levofloxacin (LVFX) and other oral antimicrobial drugs were determined and evaluated by the NCCLS guideline.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/12942788"}, {"offsetInBeginSection": 0, "offsetInEndSection": 131, "text": "Patient-reported outcomes in KEYNOTE-006, a randomised study of pembrolizumab versus ipilimumab in patients with advanced melanoma.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28987768"}, {"offsetInBeginSection": 300, "offsetInEndSection": 556, "text": "The most active of the penicillins tested were ampicillin (MIC = 0.06-8 mg/l) and temocilin (MIC = 0.125 - 16 mg/l); the most active cephalosporins were ceftazidime (MIC = 0.03 - 0.5 mg/l), HR 810 (MIC = 0.06 - 1 mg/l) and cefoxitin (MIC = 0.125 - 2 mg/l).", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/6594234"}]}, {"id": "590c740d70f9fc6f0f00001d", "body": "Which proteins are controlling sterol metabolism in S. cerevisiae?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/28830344", "http://www.ncbi.nlm.nih.gov/pubmed/8474436", "http://www.ncbi.nlm.nih.gov/pubmed/20870767", "http://www.ncbi.nlm.nih.gov/pubmed/12006573", "http://www.ncbi.nlm.nih.gov/pubmed/7729765", "http://www.ncbi.nlm.nih.gov/pubmed/10929718", "http://www.ncbi.nlm.nih.gov/pubmed/7896706", "http://www.ncbi.nlm.nih.gov/pubmed/8067730", "http://www.ncbi.nlm.nih.gov/pubmed/8743048", "http://www.ncbi.nlm.nih.gov/pubmed/9090292"], "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 293, "text": "We had previously isolated the temperature-sensitive erg26-1 mutant and characterized the sterol defects in erg26-1 cells (Baudry, K., Swain, E., Rahier, A., Germann, M., Batta, A., Rondet, S., Mandala, S., Henry, K., Tint, G. S., Edlind, T., Kurtz, M., and Nickels, J. T., Jr. (2001) J. Biol.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/12006573"}, {"offsetInBeginSection": 306, "offsetInEndSection": 654, "text": "To assess the role of Tum1 in cell metabolism and the putative functional connection between lipid metabolism and tRNA modification, we analysed evolutionary conservation of the rhodanese protein superfamily, investigated the role of Tum1 in lipid metabolism, and examined the phenotype of yeast strains expressing the mouse homologue of Tum1, TST.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28830344"}, {"offsetInBeginSection": 1389, "offsetInEndSection": 1566, "text": "Heterologous expression of CBU1206 rescued S. cerevisiae erg4 sensitivity to growth in the presence of brefeldin A and cycloheximide and resulted in new synthesis of ergosterol.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20870767"}, {"offsetInBeginSection": 0, "offsetInEndSection": 80, "text": "Tum1 is involved in the metabolism of sterol esters in Saccharomyces cerevisiae.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28830344"}, {"offsetInBeginSection": 1274, "offsetInEndSection": 1545, "text": "Inhibition of sterol synthesis in S. cerevisiae and S. pombe cells or in cultured human fibroblasts by treatment with the 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor lovastatin resulted in elevated levels of squalene synthetase mRNA in all three cell types.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/8474436"}, {"offsetInBeginSection": 0, "offsetInEndSection": 133, "text": "BACKGROUND: The only hitherto known biological role of yeast Saccharomyces cerevisiae Tum1 protein is in the tRNA thiolation pathway.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28830344"}, {"offsetInBeginSection": 1011, "offsetInEndSection": 1273, "text": "Expression of cDNA clones encoding S. pombe or hybrid human-S. cerevisiae squalene synthetases reversed the ergosterol requirement of S. cerevisiae cells bearing ERG9 gene disruptions, showing that these enzymes can functionally replace the S. cerevisiae enzyme.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/8474436"}, {"offsetInBeginSection": 1226, "offsetInEndSection": 1379, "text": "We further showed that the tRNA thiolation pathway is not involved in the regulation of sterol ester content in S. cerevisiae, as overexpression of the t", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28830344"}, {"offsetInBeginSection": 374, "offsetInEndSection": 518, "text": "The amino acid sequences of the human and S. pombe proteins deduced from cloned cDNAs were compared to those of the known S. cerevisiae protein.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/8474436"}, {"offsetInBeginSection": 498, "offsetInEndSection": 591, "text": "The sporulating S. cerevisiae cells contained 3.5% sterols and 1.5% ergosterol of dry matter.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/7729765"}]}, {"id": "5a7607f683b0d9ea66000014", "body": "Is Drk essential for anesthesia-resistant memory (ARM) in Drosophila?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/28973902", "http://www.ncbi.nlm.nih.gov/pubmed/28416593", "http://www.ncbi.nlm.nih.gov/pubmed/21808003", "http://www.ncbi.nlm.nih.gov/pubmed/24239122", "http://www.ncbi.nlm.nih.gov/pubmed/14972677", "http://www.ncbi.nlm.nih.gov/pubmed/15143285", "http://www.ncbi.nlm.nih.gov/pubmed/27195782", "http://www.ncbi.nlm.nih.gov/pubmed/21530256", "http://www.ncbi.nlm.nih.gov/pubmed/10073459", "http://www.ncbi.nlm.nih.gov/pubmed/27466338"], "snippets": [{"offsetInBeginSection": 745, "offsetInEndSection": 1106, "text": "When interpreted in the context of a four-phase model of memory consolidation, the results suggest that 1) cold anesthesia disrupts both short-term memory (STM) and anesthesia-resistant memory (ARM), 2) hypoxia disrupts ARM specifically, 3) both of them leave long-term memory (LTM) intact, and 4) LTM may be independent of availability of STM and ARM in flies.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/10073459"}, {"offsetInBeginSection": 199, "offsetInEndSection": 386, "text": "In Drosophila, anesthesia-resistant memory (ARM) and long-term memory (LTM) are genetically distinct forms of long-lasting memory that exist in parallel for at least a day after training.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/14972677"}, {"offsetInBeginSection": 0, "offsetInEndSection": 180, "text": "BACKGROUND: Drosophila olfactory aversive conditioning produces two components of intermediate-term memory: anesthesia-sensitive memory (ASM) and anesthesia-resistant memory (ARM).", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24239122"}, {"offsetInBeginSection": 0, "offsetInEndSection": 163, "text": "Two types of consolidated memory have been described in Drosophila, anesthesia-resistant memory (ARM), a shorter-lived form, and stabilized long-term memory (LTM).", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15143285"}, {"offsetInBeginSection": 601, "offsetInEndSection": 1154, "text": "Three supporting lines of evidence indicate that ARM formation requires 5HT released from only two dorsal paired medial (DPM) neurons onto the mushroom bodies (MBs), the olfactory learning and memory center in Drosophila: (i) DPM neurons were 5HT-antibody immunopositive; (ii) temporal inhibition of 5HT synthesis or release from DPM neurons, but not from other serotonergic neurons, impaired ARM formation; (iii) knocking down the expression of d5HT1A serotonin receptors in \u03b1/\u03b2 MB neurons, which are innervated by DPM neurons, inhibited ARM formation.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21808003"}, {"offsetInBeginSection": 270, "offsetInEndSection": 491, "text": "Whereas D1 receptors are known to contribute to Drosophila aversive odor learning per se, we here show that D2 receptors are specific for support of a consolidated form of odor memory known as anesthesia-resistant memory.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27466338"}, {"offsetInBeginSection": 0, "offsetInEndSection": 100, "text": "Circuit Analysis of a Drosophila Dopamine Type 2 Receptor That Supports Anesthesia-Resistant Memory.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27466338"}, {"offsetInBeginSection": 0, "offsetInEndSection": 155, "text": "Associative olfactory memory in Drosophila has two components called labile anesthesia-sensitive memory and consolidated anesthesia-resistant memory (ARM).", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27195782"}, {"offsetInBeginSection": 0, "offsetInEndSection": 247, "text": "Pavlovian olfactory learning in Drosophila produces two genetically distinct forms of intermediate-term memories: anesthesia-sensitive memory, which requires the amnesiac gene, and anesthesia-resistant memory (ARM), which requires the radish gene.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21808003"}, {"offsetInBeginSection": 0, "offsetInEndSection": 102, "text": "Serotonin-mushroom body circuit modulating the formation of anesthesia-resistant memory in Drosophila.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21808003"}]}, {"id": "5a7d50d0faa1ab7d2e000016", "body": "Is ACI-35 a passive vaccine?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/27485083", "http://www.ncbi.nlm.nih.gov/pubmed/6272472", "http://www.ncbi.nlm.nih.gov/pubmed/8041130", "http://www.ncbi.nlm.nih.gov/pubmed/26985884", "http://www.ncbi.nlm.nih.gov/pubmed/27079929", "http://www.ncbi.nlm.nih.gov/pubmed/12600748", "http://www.ncbi.nlm.nih.gov/pubmed/8613399", "http://www.ncbi.nlm.nih.gov/pubmed/20920572", "http://www.ncbi.nlm.nih.gov/pubmed/10431138", "http://www.ncbi.nlm.nih.gov/pubmed/6262995"], "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 234, "text": "Passive transfer models were developed to evaluate the ability of antibodies generated in cynomolgus macaques and humans vaccinated with a recombinant plague vaccine (rF1V) to protect na\u00efve Swiss Webster mice against pneumonic plague.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20920572"}, {"offsetInBeginSection": 235, "offsetInEndSection": 357, "text": "Development of the passive transfer model is intended to support clinical and nonclinical development of the rF1V vaccine.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20920572"}, {"offsetInBeginSection": 544, "offsetInEndSection": 744, "text": "This report describes the first step in elucidating the mechanism of passive immunization of offspring through actively immunizing the female parent through an orally delivered, plant-derived vaccine.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/12600748"}, {"offsetInBeginSection": 1353, "offsetInEndSection": 1566, "text": "Passive vaccination with formalin-sterilized IgY against multiple antigens extracted from one commercial egg may be a cost-effective and advantageous complementary or alternative to attenuated vaccines in poultry.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27079929"}, {"offsetInBeginSection": 599, "offsetInEndSection": 885, "text": "Results of these studies demonstrated that passive immunization protected mice from challenge or extended mean survival time and that the passive transfer assay can be used to evaluate the functional role of antibodies induced by rF1V vaccination in protection against aerosol exposure.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20920572"}, {"offsetInBeginSection": 0, "offsetInEndSection": 97, "text": "Passive immunization of mice pups through oral immunization of dams with a plant-derived vaccine.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/12600748"}, {"offsetInBeginSection": 0, "offsetInEndSection": 100, "text": "Practical aspects in the use of passive immunization as an alternative to attenuated viral vaccines.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27079929"}, {"offsetInBeginSection": 142, "offsetInEndSection": 397, "text": "Although many reports have shown active immunization of animals and human through the use of plant-derived vaccines, only one report has given evidence of passive immunization of offspring through oral immunization of parents using plant-derived vaccines.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/12600748"}, {"offsetInBeginSection": 0, "offsetInEndSection": 87, "text": "Prevention strategies for respiratory syncytial virus: passive and active immunization.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/10431138"}, {"offsetInBeginSection": 532, "offsetInEndSection": 772, "text": "It was proved that the pigs who had a passive immunity and were vaccinated with one dose of vaccine, did not build up a stable and active immunity after their vaccination, due to the neutralization of the vaccinal virus by passive immunity.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/6262995"}]}, {"id": "5a894f6abc7bade53a000004", "body": "Which are the effects of ALDH2 deficiency?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/25831092", "http://www.ncbi.nlm.nih.gov/pubmed/23689279", "http://www.ncbi.nlm.nih.gov/pubmed/12905081", "http://www.ncbi.nlm.nih.gov/pubmed/27186430", "http://www.ncbi.nlm.nih.gov/pubmed/26173414", "http://www.ncbi.nlm.nih.gov/pubmed/20515806", "http://www.ncbi.nlm.nih.gov/pubmed/17127431", "http://www.ncbi.nlm.nih.gov/pubmed/26734919", "http://www.ncbi.nlm.nih.gov/pubmed/27488451", "http://www.ncbi.nlm.nih.gov/pubmed/8290656"], "snippets": [{"offsetInBeginSection": 725, "offsetInEndSection": 1005, "text": "It was reported that Mongoloids such as Japanese and Chinese people carry the enzymatically active (ALDH2*1) subunit and/or the inactive (ALDH2*2) one, and that a low proportion of ALDH2 deficiency (ALDH2*2 allele frequency) was found in alcoholics compared with healthy controls.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26734919"}, {"offsetInBeginSection": 938, "offsetInEndSection": 1077, "text": "This is the first example for studying pathological effects of Aldh2 deficiency using Aldh -/- mice exposed to a low level of acetaldehyde.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17127431"}, {"offsetInBeginSection": 346, "offsetInEndSection": 770, "text": "To assess the effects of inactive ALDH2 subunits, encoded by the mutant ALDH2(2) allele, on the catalytic activity of tetrameric enzyme molecules, we have phenotyped ALDH2 from 30 gastroendoscopic biopsies by using agarose isoelectric focusing and determined the genotypes from leukocytes of the same individuals by using polymerase-chain-reaction amplification and hybridization with allele-specific oligonucleotide probes.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/8290656"}, {"offsetInBeginSection": 644, "offsetInEndSection": 865, "text": "N2-ethylidene-dG levels in livers of Aldh2-/- mice were always lower than those of Aldh2+/+ mice, suggesting that Aldh2 deficiency might cause the induction of acetaldehyde metabolizing enzymes in the liver such as P450s.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20515806"}, {"offsetInBeginSection": 1899, "offsetInEndSection": 2158, "text": "Defining autophagymediated cytoprotection against alcohol-induced genotoxicity in the context of Aldh2 deficiency, our study provides mechanistic insights into the tumor suppressor functions of ALDH2 and autophagy in alcohol-related esophageal carcinogenesis.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27186430"}, {"offsetInBeginSection": 286, "offsetInEndSection": 464, "text": "We evaluated the effect of ALDH2 deficiency on EtOH-induced disruption of intestinal epithelial tight junctions and adherens junctions, gut barrier dysfunction, and liver injury.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26173414"}, {"offsetInBeginSection": 242, "offsetInEndSection": 488, "text": "In recent studies involving DNA analysis, it was found that a deficiency of the ALDH2 isozyme (ALDH2*2) was responsible for the flushing symptoms as well as other vasomotor symptoms caused by a higher acetaldehyde level after alcohol consumption.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26734919"}, {"offsetInBeginSection": 358, "offsetInEndSection": 498, "text": "In this study, wild type (Aldh2+/+) and Aldh2KO (Aldh2-/-) mice were exposed to the air containing 0, 125, 500 ppm acetaldehyde for 2 weeks.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20515806"}, {"offsetInBeginSection": 489, "offsetInEndSection": 724, "text": "Deficiency of ALDH2 activity has been found prevalently only among people of Mongoloid origin, and the deficiency of ALDH2 prevents them from developing alcohol dependence due to the unpleasant physical effects of the flushing symptom.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26734919"}, {"offsetInBeginSection": 1898, "offsetInEndSection": 2031, "text": "ALDH2 deficiency potentiates oxidative stress and AMPK phosphorylation induced by diabetes via post-translational regulation of LKB1.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27488451"}]}, {"id": "5a7604de83b0d9ea66000011", "body": "What is mechanism of action of galunisertib?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/28691737", "http://www.ncbi.nlm.nih.gov/pubmed/27756784", "http://www.ncbi.nlm.nih.gov/pubmed/26057634", "http://www.ncbi.nlm.nih.gov/pubmed/28436712", "http://www.ncbi.nlm.nih.gov/pubmed/26902851", "http://www.ncbi.nlm.nih.gov/pubmed/26309397", "http://www.ncbi.nlm.nih.gov/pubmed/27509307", "http://www.ncbi.nlm.nih.gov/pubmed/25573078", "http://www.ncbi.nlm.nih.gov/pubmed/28481241", "http://www.ncbi.nlm.nih.gov/pubmed/26976322"], "snippets": [{"offsetInBeginSection": 1452, "offsetInEndSection": 1530, "text": "Inhibition of SMAD2 phosphorylation is probably a central mechanism of action.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28691737"}, {"offsetInBeginSection": 1531, "offsetInEndSection": 1683, "text": "In addition, blocking the production and maturation of collagens and promoting their degradation are related to the antifibrotic action of galunisertib.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28691737"}, {"offsetInBeginSection": 15, "offsetInEndSection": 140, "text": "PURPOSE: Liver fibrosis is a major cause of liver-related mortality and, so far, no effective antifibrotic drug is available.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28691737"}, {"offsetInBeginSection": 0, "offsetInEndSection": 130, "text": "PURPOSE: The transforming growth factor-beta (TGF-\u03b2) signaling pathway is known to play a critical role in promoting tumor growth.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25573078"}, {"offsetInBeginSection": 0, "offsetInEndSection": 181, "text": "Galunisertib (LY2157299) is a selective ATP-mimetic inhibitor of TGF-\u03b2 receptor (T\u03b2R)-I activation currently under clinical investigation in hepatocellular carcinoma (HCC) patients.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26057634"}, {"offsetInBeginSection": 479, "offsetInEndSection": 692, "text": "Galunisertib (LY2157299 monohydrate) is an oral small molecule inhibitor of the TGF-\u03b2 receptor I kinase that specifically downregulates the phosphorylation of SMAD2, abrogating activation of the canonical pathway.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26309397"}, {"offsetInBeginSection": 1599, "offsetInEndSection": 1809, "text": "CONCLUSIONS: Galunisertib suppresses activation of SMAD2 in neuroblastomas and aNK cells, restores NK cytotoxic mechanisms, and increases the efficacy of dinutuximab with aNK cells against neuroblastoma tumors.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27756784"}, {"offsetInBeginSection": 0, "offsetInEndSection": 133, "text": "Galunisertib (LY2157299), a selective ATP-mimetic inhibitor of TGF-\u03b2 receptor I (TGF-\u03b2RI), is the only known TGF-\u03b2 pathway inhibitor.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27509307"}, {"offsetInBeginSection": 207, "offsetInEndSection": 447, "text": "In order to achieve an optimal anti-tumor effect, however, it remains to be established whether blocking the TGF-\u03b2 signaling pathway alone is sufficient, or whether the tumor microenvironment plays an additional, possibly synergistic, role.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25573078"}, {"offsetInBeginSection": 141, "offsetInEndSection": 258, "text": "Galunisertib, a TGF-\u03b2 receptor type I kinase inhibitor, is a potential candidate for the treatment of liver fibrosis.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28691737"}]}, {"id": "590c74d170f9fc6f0f00001e", "body": "Which gene is the paralog of yeast UPC2?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/28986257", "http://www.ncbi.nlm.nih.gov/pubmed/24163365", "http://www.ncbi.nlm.nih.gov/pubmed/24453983", "http://www.ncbi.nlm.nih.gov/pubmed/11208779", "http://www.ncbi.nlm.nih.gov/pubmed/1885560", "http://www.ncbi.nlm.nih.gov/pubmed/26448198", "http://www.ncbi.nlm.nih.gov/pubmed/18487346", "http://www.ncbi.nlm.nih.gov/pubmed/17174052", "http://www.ncbi.nlm.nih.gov/pubmed/25385116", "http://www.ncbi.nlm.nih.gov/pubmed/9696767"], "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 101, "text": "Ecm22 and Upc2 regulate yeast mating through control of expression of the mating genes PRM1 and PRM4.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28986257"}, {"offsetInBeginSection": 720, "offsetInEndSection": 866, "text": "Yarrowia lipolytica, a deep-branching species, is the only genome known to contain intact and full-length orthologs of both SREBP (Sre1) and Upc2.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24453983"}, {"offsetInBeginSection": 185, "offsetInEndSection": 305, "text": "Here, we examine the role of the related transcription factors Ecm22 and Upc2 in Saccharomyces cerevisiae filamentation.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26448198"}, {"offsetInBeginSection": 792, "offsetInEndSection": 926, "text": "Using resistance to Ca2+ as a screening vehicle, we cloned UPC2 and showed that it is YDR213W, an open reading frame on chromosome IV.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/9696767"}, {"offsetInBeginSection": 1221, "offsetInEndSection": 1340, "text": "Our results indicate that Upc2 must occupy UPC2 AR1b elements in order for ERG gene expression induction to take place.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24163365"}, {"offsetInBeginSection": 274, "offsetInEndSection": 375, "text": "Another predicted transcriptional activator, the YLR228c gene product, is highly homologous to Upc2p.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/11208779"}, {"offsetInBeginSection": 366, "offsetInEndSection": 482, "text": "These genes are strongly induced in response to mating pheromone, which is also largely dependent on ECM22 and UPC2.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28986257"}, {"offsetInBeginSection": 193, "offsetInEndSection": 363, "text": "The constitutive upregulation of these genes is usually caused by gain-of-function mutations in the zinc cluster transcription factors Upc2, Mrr1, and Tac1, respectively.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25385116"}, {"offsetInBeginSection": 761, "offsetInEndSection": 898, "text": "The AR1b elements are absolutely required for auto-induction of UPC2 gene expression and protein and require Upc2 and Ecm22 for function.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24163365"}, {"offsetInBeginSection": 505, "offsetInEndSection": 728, "text": "Deletion of the SSU RPS6B paralog, but not of the RPS6A paralog increased replicative life span robustly by 45%, while deletion of both the SSU RPS18A, and RPS18B paralogs increased RLS moderately, but significantly by 15%.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17174052"}]}, {"id": "5a760c8483b0d9ea66000017", "body": "What is the FIRE (Functional Inference of Regulators of Expression) tool?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/28961785", "http://www.ncbi.nlm.nih.gov/pubmed/28066488", "http://www.ncbi.nlm.nih.gov/pubmed/19442636", "http://www.ncbi.nlm.nih.gov/pubmed/24564496", "http://www.ncbi.nlm.nih.gov/pubmed/20418949", "http://www.ncbi.nlm.nih.gov/pubmed/18314574", "http://www.ncbi.nlm.nih.gov/pubmed/27794550", "http://www.ncbi.nlm.nih.gov/pubmed/22759573", "http://www.ncbi.nlm.nih.gov/pubmed/25910697", "http://www.ncbi.nlm.nih.gov/pubmed/17493254"], "snippets": [{"offsetInBeginSection": 281, "offsetInEndSection": 678, "text": "Methods to predict whether or not individual SNVs are likely to regulate gene expression would aid interpretation of variants of unknown significance identified in whole-genome sequencing studies.Results: We developed FIRE (Functional Inference of Regulators of Expression), a tool to score both noncoding and coding SNVs based on their potential to regulate the expression levels of nearby genes.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28961785"}, {"offsetInBeginSection": 1517, "offsetInEndSection": 1879, "text": "Additionally, we show that the location of the regulators in the LeMoNe regulation programs and their conditional entropy may be used to prioritize regulators for functional validation, and that the combination of the bottom-up clustering strategy with the conditional entropy-based assignment of regulators improves the handling of missing or hidden regulators.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17493254"}, {"offsetInBeginSection": 0, "offsetInEndSection": 77, "text": "FIRE: functional inference of genetic variants that regulate gene expression.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28961785"}, {"offsetInBeginSection": 169, "offsetInEndSection": 514, "text": "A computational method is demonstrated herein to assess gene function from gene expression measured in deletion mutants using Bayesian decomposition, a matrix factorization technique that permits the extraction of patterns and functional units from the data, i.e., sets of genes belonging to the same pathways shared by sets of knockout mutants.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/18314574"}, {"offsetInBeginSection": 1157, "offsetInEndSection": 1473, "text": "FIRE scores are also predictive of cis -eQTL SNVs across a variety of tissue types.Availability: FIRE scores for genome-wide SNVs in hg19/GRCh37 are available for download at https://sites.google.com/site/fireregulatoryvariation/ .Supplementary information: Supplementary data are available at Bioinformatics online.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28961785"}, {"offsetInBeginSection": 860, "offsetInEndSection": 1376, "text": "We demonstrate 1) the steps to discretize the expression data for the computation of conditional probabilities in a Bayesian network, 2) the procedure to construct a Bayesian network using the structure of a known pathway and the transcription factors and microRNAs predicted to target genes in that pathway, and 3) the inference results as potential regulators of three signaling pathways using microarray expression profiles of microRNA and mRNA in estrogen receptor positive and estrogen receptor negative tumors.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22759573"}, {"offsetInBeginSection": 0, "offsetInEndSection": 168, "text": "Expression data from knockout mutants is a powerful tool for gene function inference, permitting observation of the phenotype of a deleted gene on the organismal scale.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/18314574"}, {"offsetInBeginSection": 457, "offsetInEndSection": 623, "text": "A recursive model of gene expression allowing for identification of active gene expression control networks with up to two regulators of one target gene is presented.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19442636"}, {"offsetInBeginSection": 838, "offsetInEndSection": 1139, "text": "Also, their use remains unnecessarily restricted to computational biologists, as accurate inference of modules and their regulators requires integration of diverse tools and heterogeneous data sources, which in turn requires scripting skills, data infrastructure and powerful computational facilities.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24564496"}, {"offsetInBeginSection": 679, "offsetInEndSection": 858, "text": "FIRE consists of 23 random forests trained to recognize SNVs in cis -expression quantitative trait loci ( cis -eQTLs) using a set of 92 genomic annotations as predictive features.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28961785"}]}, {"id": "5a7d51dafaa1ab7d2e000017", "body": "What is the administration route of IVIG in Alzheimer's disease patients?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/23735288", "http://www.ncbi.nlm.nih.gov/pubmed/25476011", "http://www.ncbi.nlm.nih.gov/pubmed/21138577", "http://www.ncbi.nlm.nih.gov/pubmed/20577707", "http://www.ncbi.nlm.nih.gov/pubmed/25392130", "http://www.ncbi.nlm.nih.gov/pubmed/24517534", "http://www.ncbi.nlm.nih.gov/pubmed/19620605", "http://www.ncbi.nlm.nih.gov/pubmed/16998751", "http://www.ncbi.nlm.nih.gov/pubmed/26330100", "http://www.ncbi.nlm.nih.gov/pubmed/18294736"], "snippets": [{"offsetInBeginSection": 131, "offsetInEndSection": 386, "text": "Pilot studies with the IVIG preparations Octagam and Gammagard in individuals with mild-to-moderate Alzheimer's disease (AD) suggested stabilization of cognitive functioning in these patients, and a phase II trial with Gammagard reported similar findings.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23735288"}, {"offsetInBeginSection": 212, "offsetInEndSection": 386, "text": "IVIG contains naturally occurring auto-antibodies, including antibodies (Abs) against \u03b2-amyloid (A\u03b2) peptides accumulating in the brains of Alzheimer's disease (AD) patients.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21138577"}, {"offsetInBeginSection": 0, "offsetInEndSection": 129, "text": "The therapeutic effects of intravenous immunoglobulin (IVIG) products were recently studied in Alzheimer's disease (AD) patients.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26330100"}, {"offsetInBeginSection": 0, "offsetInEndSection": 259, "text": "Recent phase II and III studies with intravenous immunoglobulin (IVIG) in patients with Alzheimer's disease (AD) did not find evidence for the slowing of AD progression compared to placebo-treated patients, in contrast to encouraging results in pilot studies.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25476011"}, {"offsetInBeginSection": 0, "offsetInEndSection": 123, "text": "The effects of intravenous immunoglobulin (IVIG) products were recently examined in patients with Alzheimer's disease (AD).", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25392130"}, {"offsetInBeginSection": 2194, "offsetInEndSection": 2415, "text": "Emerging data suggest that IVIg, by suppressing proinflammatory cytokines, may exert a beneficial effect in patients with Alzheimer's disease, postpolio syndrome, chronic pain syndromes, fibrotic disorders and narcolepsy.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16998751"}, {"offsetInBeginSection": 0, "offsetInEndSection": 201, "text": "OBJECTIVE: To compare the incidence of Alzheimer disease and related disorders (ADRD) in patients treated with IV immunoglobulin (IVIg) for non-Alzheimer disease (AD) indications vs untreated controls.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19620605"}, {"offsetInBeginSection": 1259, "offsetInEndSection": 1425, "text": "The mechanisms of action and transport across the blood-brain barrier (BBB) for an Alzheimer's disease therapeutic, intravenous immunoglobulin (IVIG), remain unknown.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24517534"}, {"offsetInBeginSection": 0, "offsetInEndSection": 186, "text": "Intravenous immunoglobulin (IVIG) contains anti-amyloid-\u03b2 antibodies as well as antibodies providing immunomodulatory effects that may modify chronic inflammation in Alzheimer's disease.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24517534"}, {"offsetInBeginSection": 1357, "offsetInEndSection": 1671, "text": "Because administration of antibodies to phosphorylated tau has been found to reduce tau-associated pathology in transgenic mouse models of tauopathy, increasing the levels of anti-pTau antibodies, together with other selected antibodies such as anti-A\u03b2, in IVIG might increase its ability to slow AD's progression.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26330100"}]}, {"id": "5a89800efcd1d6a10c00000c", "body": "Where is the enzyme PM20D1 localized?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/27374330", "http://www.ncbi.nlm.nih.gov/pubmed/27378359", "http://www.ncbi.nlm.nih.gov/pubmed/24166889", "http://www.ncbi.nlm.nih.gov/pubmed/26999364", "http://www.ncbi.nlm.nih.gov/pubmed/25431941", "http://www.ncbi.nlm.nih.gov/pubmed/29143709", "http://www.ncbi.nlm.nih.gov/pubmed/25855069", "http://www.ncbi.nlm.nih.gov/pubmed/24618023", "http://www.ncbi.nlm.nih.gov/pubmed/7117251", "http://www.ncbi.nlm.nih.gov/pubmed/9307964"], "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 85, "text": "The Secreted Enzyme PM20D1 Regulates Lipidated Amino Acid Uncouplers of Mitochondria.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27374330"}, {"offsetInBeginSection": 569, "offsetInEndSection": 707, "text": "A secreted enzyme, PM20D1, enriched in UCP1+ adipocytes, exhibits catalytic and hydrolytic activity to reversibly form N-acyl amino acids.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27378359"}, {"offsetInBeginSection": 209, "offsetInEndSection": 344, "text": "Here, we identify a secreted enzyme, peptidase M20 domain containing 1 (PM20D1), that is enriched in UCP1(+) versus UCP1(-) adipocytes.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27374330"}, {"offsetInBeginSection": 154, "offsetInEndSection": 285, "text": "We explored whether glycolytic enzymes are localized in Drosophila flight muscle and whether localization is required for function.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/9307964"}, {"offsetInBeginSection": 286, "offsetInEndSection": 377, "text": "We find that glycerol-3-phosphate dehydrogenase (GPDH) is localized at Z-discs and M-lines.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/9307964"}, {"offsetInBeginSection": 345, "offsetInEndSection": 544, "text": "We\u00a0demonstrate that PM20D1 is a bidirectional enzyme in\u00a0vitro, catalyzing both the condensation of fatty acids and amino acids to generate N-acyl amino acids and also the reverse hydrolytic reaction.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27374330"}, {"offsetInBeginSection": 244, "offsetInEndSection": 568, "text": "The four cycle enzymes were constitutively localized in mitochondria, with the exception of the dual localization of the fourth enzyme, 2-methylisocitrate lyase, in mitochondria and cytoplasm, where the lyase may function to supply pyruvate (the end-product of the catabolism of the propionate residue) to various reactions.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/7117251"}, {"offsetInBeginSection": 378, "offsetInEndSection": 583, "text": "The glycolytic enzymes aldolase and glyceraldehyde-3-phosphate dehydrogenase (GAPDH) are also localized along the sarcomere with a periodic pattern that is indistinguishable from that of GPDH localization.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/9307964"}, {"offsetInBeginSection": 754, "offsetInEndSection": 1015, "text": "We find evidence for an association with PD for rs1775143 as well as a haplotype located around the 5' region of RAB7L1, implicating variants which are not in high linkage disequilibrium with the strongest signal from a recent large meta-analysis in Caucasians.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25855069"}, {"offsetInBeginSection": 584, "offsetInEndSection": 792, "text": "Furthermore, localization of aldolase and GAPDH requires simultaneous localization of GPDH, because aldolase and GAPDH are not localized along the sarcomere in muscles of strains that carry Gpdh null alleles.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/9307964"}]}, {"id": "5a760ed883b0d9ea66000019", "body": "Is dasatinib effective for treatment of glioblastoma?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/19190119", "http://www.ncbi.nlm.nih.gov/pubmed/22891038", "http://www.ncbi.nlm.nih.gov/pubmed/21153679", "http://www.ncbi.nlm.nih.gov/pubmed/26517812", "http://www.ncbi.nlm.nih.gov/pubmed/23090987", "http://www.ncbi.nlm.nih.gov/pubmed/20664932", "http://www.ncbi.nlm.nih.gov/pubmed/20165690", "http://www.ncbi.nlm.nih.gov/pubmed/21226671", "http://www.ncbi.nlm.nih.gov/pubmed/19098899", "http://www.ncbi.nlm.nih.gov/pubmed/25758746"], "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 147, "text": "Co-administration of NVP-AEW541 and dasatinib induces mitochondrial-mediated apoptosis through Bax activation in malignant human glioma cell lines.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20664932"}, {"offsetInBeginSection": 1605, "offsetInEndSection": 1779, "text": "These results strongly support the clinical use of dasatinib in the treatment of glioblastoma and provide a rationale for combination therapy with dasatinib and temozolomide.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19190119"}, {"offsetInBeginSection": 255, "offsetInEndSection": 651, "text": "Several early- and late-phase clinical trials for chronic myelogeneous leukaemia (CML) have demonstrated the direct inhibition of BCR-ABL fusion protein and SFKs, which led to dasatinib approval by the Food and Drug Administration (FDA) and the European Union for the treatment of imatinib-resistant or -intolerant CML, and Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL).", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21226671"}, {"offsetInBeginSection": 0, "offsetInEndSection": 95, "text": "Phase 2 trial of dasatinib in target-selected patients with recurrent glioblastoma (RTOG 0627).", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25758746"}, {"offsetInBeginSection": 0, "offsetInEndSection": 115, "text": "A combination of tyrosine kinase inhibitors, crizotinib and dasatinib for the treatment of glioblastoma multiforme.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26517812"}, {"offsetInBeginSection": 1115, "offsetInEndSection": 1406, "text": "Ongoing clinical trials evaluate dasatinib in the treatment of several solid tumours, including gastrointestinal stromal tumours (GIST), prostate cancer, malignant pleural mesothelioma, sarcomas, NSCLC, colorectal cancer, glioblastoma and other haematologic malignancies as multiple myeloma.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21226671"}, {"offsetInBeginSection": 0, "offsetInEndSection": 107, "text": "EORTC 26083 phase I/II trial of dasatinib in combination with CCNU in patients with recurrent glioblastoma.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23090987"}, {"offsetInBeginSection": 436, "offsetInEndSection": 731, "text": "Follow-up experiments on the finding that SRC is frequently phosphorylated in glioblastoma cell lines showed that SRC is also activated in primary glioblastoma patient samples and that the SRC inhibitor dasatinib (Sprycel) inhibits viability and cell migration in vitro and tumor growth in vivo.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19098899"}, {"offsetInBeginSection": 1186, "offsetInEndSection": 1372, "text": "In this phase I study of recurrent glioblastoma patients, the combination of CCNU and dasatinib showed significant hematological toxicities and led to suboptimal exposure to both agents.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23090987"}, {"offsetInBeginSection": 0, "offsetInEndSection": 83, "text": "Dasatinib-induced autophagy is enhanced in combination with temozolomide in glioma.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19190119"}]}, {"id": "5916f14070f9fc6f0f00001f", "body": "What is the role of the positive effector of transcription (pet) in the hepatitis B virus?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/8107218", "http://www.ncbi.nlm.nih.gov/pubmed/9311882", "http://www.ncbi.nlm.nih.gov/pubmed/26983541", "http://www.ncbi.nlm.nih.gov/pubmed/18448976", "http://www.ncbi.nlm.nih.gov/pubmed/24769044", "http://www.ncbi.nlm.nih.gov/pubmed/8138254", "http://www.ncbi.nlm.nih.gov/pubmed/9013081", "http://www.ncbi.nlm.nih.gov/pubmed/9126788", "http://www.ncbi.nlm.nih.gov/pubmed/23422505", "http://www.ncbi.nlm.nih.gov/pubmed/8978357"], "snippets": [{"offsetInBeginSection": 291, "offsetInEndSection": 690, "text": "Of these 32 patients, 14 (44%) were hepatitis B virus carriers with hepatitis D virus superinfection (1 with hepatitis C virus infection), 3 others had coexisting hepatitis B virus and hepatitis C virus infections, 6 had reactivation of underlying chronic hepatitis B, 4 had acute hepatitis B, 2 had acute hepatitis C and 1 had acute hepatitis E. Pathogenesis in the remaining two cases was unclear.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/8138254"}, {"offsetInBeginSection": 1382, "offsetInEndSection": 1821, "text": "CONCLUSIONS: The present Southern blot analysis demonstrates that clonally integrated HBV DNA sequences were identified even in hepatitis C virus-infected hepatocellular carcinoma patients at a high rate (10/18, 55.6%), and suggests that integrated hepatitis B virus, whose major component is the X gene, may play an important role in hepatocarcinogenesis in hepatitis B virus-integrated cases with and without hepatitis C virus infection.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/9126788"}, {"offsetInBeginSection": 267, "offsetInEndSection": 597, "text": "We assessed the possible contributions of hepatitis B virus integration to the occurrence of hepatocellular carcinoma in hepatitis C virus-infected as well as in hepatitis B virus-infected patients by identifying the integrated HBV DNA sequence, and the X and preS2/S regions were further investigated in HBV DNA-integrated cases.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/9126788"}, {"offsetInBeginSection": 549, "offsetInEndSection": 842, "text": "This inhibitory effect was HBx-independent and mediated by the transcriptional regulation of viral genome via the activation of exogenous signal-regulated kinase 1/2 and the reduced expression of hepatocyte nuclear factor 4\u03b1, a transcription factor essential for hepatitis B virus replication.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24769044"}, {"offsetInBeginSection": 933, "offsetInEndSection": 1165, "text": "APOBEC3B inhibits hepatitis-B-virus gene transcription, and APOBEC3B and APOBEC3G preferentially mutate the hepatitis-B-virus x gene leading to the truncated hepatitis-B-virus x variants in hepatitis-B-virus-associated liver cancer.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/18448976"}, {"offsetInBeginSection": 1165, "offsetInEndSection": 1389, "text": "SUMMARY: The interferon-inducible APOBEC3G and the other APOBEC3s restrict hepatitis B virus by cytidine deamination in hepatitis-B-virus minus-strand cDNA and by direct inhibition of hepatitis-B-virus reverse transcriptase.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/18448976"}, {"offsetInBeginSection": 0, "offsetInEndSection": 290, "text": "We tested serum samples from 25 fulminant hepatitis and 7 subfulminant hepatitis patients for hepatitis A, B, C, D and E viral markers and nucleic acids by means of polymerase chain reaction to determine the role of each virus on such catastrophic events in an area endemic for hepatitis B.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/8138254"}, {"offsetInBeginSection": 588, "offsetInEndSection": 713, "text": "APOBEC3B, APOBEC3F and APOBEC3G directly inhibit hepatitis-B-virus reverse transcription independently of deaminase activity.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/18448976"}, {"offsetInBeginSection": 350, "offsetInEndSection": 587, "text": "FINDINGS: The cytidine deaminases APOBEC3B, APOBEC3C, APOBEC3F and APOBEC3G deaminate cytidine residues in hepatitis-B-virus minus-strand cDNA, resulting in G to A hypermutated genomes in the serum of hepatitis-B-virus-infected patients.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/18448976"}, {"offsetInBeginSection": 0, "offsetInEndSection": 219, "text": "We have found that transcription of the pregenome of an avian hepadnavirus, duck hepatitis B virus (DHBV), is dependent on the presence of a small element in the 5' transcribed region of the pregenome-encoding sequence.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/8107218"}]}, {"id": "5a774ce1faa1ab7d2e000006", "body": "Is there increased recombination rate in human regulatory domains?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/29058599", "http://www.ncbi.nlm.nih.gov/pubmed/27503290", "http://www.ncbi.nlm.nih.gov/pubmed/20395511", "http://www.ncbi.nlm.nih.gov/pubmed/1324834", "http://www.ncbi.nlm.nih.gov/pubmed/8845024", "http://www.ncbi.nlm.nih.gov/pubmed/11074256", "http://www.ncbi.nlm.nih.gov/pubmed/12821945", "http://www.ncbi.nlm.nih.gov/pubmed/24225854", "http://www.ncbi.nlm.nih.gov/pubmed/1318616", "http://www.ncbi.nlm.nih.gov/pubmed/21949720"], "snippets": [{"offsetInBeginSection": 89, "offsetInEndSection": 404, "text": "It was found that co-transfection of Oct2A together with an artificial recombination substrate increased the rate of V(D)J recombination by a factor of 3.4 in the fibroblast cell line L4 which had been stably transfected with genomic DNA containing the rag-1 and rag-2 genes and their flanking regulatory sequences.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/8845024"}, {"offsetInBeginSection": 0, "offsetInEndSection": 67, "text": "Evidence of reduced recombination rate in human regulatory domains.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/29058599"}, {"offsetInBeginSection": 1101, "offsetInEndSection": 1341, "text": "The increase in the recombination rate was probably not due to recombination events resulting in large deletions or insertions (greater than 50 bp), but rather was probably due to a combination of homologous and nonhomologous recombination.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/1318616"}, {"offsetInBeginSection": 1431, "offsetInEndSection": 1602, "text": "RevTADs manifest distinct correlation patterns between placements of human accelerated regions, human-specific transcription factor-binding sites, and recombination rates.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27503290"}, {"offsetInBeginSection": 328, "offsetInEndSection": 469, "text": "RESULTS: We study the relationship between recombination rate and gene regulatory domains, defined by a gene and its linked control elements.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/29058599"}, {"offsetInBeginSection": 473, "offsetInEndSection": 652, "text": "The effect of Oct2A depends on the presence of its transactivation domains indicating that Oct2A increase the transcription of genes that increase the rate of V(D)J recombination.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/8845024"}, {"offsetInBeginSection": 860, "offsetInEndSection": 1107, "text": "This recombination rate\u00a0valley is most pronounced for gene regulatory domains of early embryonic development genes, housekeeping genes, and constitutive regulatory elements, which are known to show increased evolutionary constraint across species.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/29058599"}, {"offsetInBeginSection": 728, "offsetInEndSection": 859, "text": "Each link type shows a \"recombination rate\u00a0valley\" of significantly reduced recombination rate compared to matched control regions.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/29058599"}, {"offsetInBeginSection": 896, "offsetInEndSection": 1155, "text": "The general pattern is similar to that observed in yeast, as well as in positive-regulatory domain zinc finger protein 9-knockout mice, suggesting that recombination initiation described here in Mimulus may reflect ancient and conserved eukaryotic mechanisms.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24225854"}, {"offsetInBeginSection": 428, "offsetInEndSection": 585, "text": "Domain recombination resulted in greater diversity in pathway response dynamics than did duplication of genes, of single domains, or of two unlinked domains.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20395511"}]}, {"id": "5a7d54adfaa1ab7d2e000019", "body": "Has IVIG been tested in clinical trials for the treatment of Alzheimer's disease?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/24760112", "http://www.ncbi.nlm.nih.gov/pubmed/20329802", "http://www.ncbi.nlm.nih.gov/pubmed/25561275", "http://www.ncbi.nlm.nih.gov/pubmed/21180569", "http://www.ncbi.nlm.nih.gov/pubmed/19883422", "http://www.ncbi.nlm.nih.gov/pubmed/28381506", "http://www.ncbi.nlm.nih.gov/pubmed/18685921", "http://www.ncbi.nlm.nih.gov/pubmed/25826319", "http://www.ncbi.nlm.nih.gov/pubmed/25115544", "http://www.ncbi.nlm.nih.gov/pubmed/17330405"], "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 175, "text": "The human polyclonal IgG antibody preparation known as Intravenous Immunoglobulin (IVIG) has been under study as a potential treatment for Alzheimer's disease (AD) since 2002.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24760112"}, {"offsetInBeginSection": 0, "offsetInEndSection": 241, "text": "Alzheimer's disease (AD) is characterized by deleterious accumulation of amyloid-\u03b2 (A\u03b2) peptide into senile plaque, neurofibrillary tangles formed from hyperphosphorylated tau protein, and loss of cholinergic synapses in the cerebral cortex.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25115544"}, {"offsetInBeginSection": 224, "offsetInEndSection": 415, "text": "These comparisons were performed to identify if an elevated fraction existed in Gammagard, which reported small putative benefits in a recent Phase III clinical trial for Alzheimer's Disease.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25826319"}, {"offsetInBeginSection": 435, "offsetInEndSection": 715, "text": "The primary cognitive outcome was change from baseline to 18 months on the 11-item cognitive subscale of the Alzheimer's Disease Assessment Scale; the primary functional outcome was 18-month change on the Alzheimer's Disease Cooperative Study-Activities of Daily Living Inventory.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28381506"}, {"offsetInBeginSection": 898, "offsetInEndSection": 1110, "text": "Studies with IVIg in patients with Alzheimer's disease have reported increased plasma anti-Abeta antibody titres associated with decreased Abeta peptide levels in the cerebrospinal fluid following IVIg treatment.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19883422"}, {"offsetInBeginSection": 609, "offsetInEndSection": 731, "text": "However, other indications are currently being explored including Alzheimer's disease, postpolio syndrome, and narcolepsy.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21180569"}, {"offsetInBeginSection": 660, "offsetInEndSection": 792, "text": "IVIg has been tested in some neurodegenerative disorders, but a controlled study in Alzheimer disease yielded disappointing results.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25561275"}, {"offsetInBeginSection": 0, "offsetInEndSection": 160, "text": "Anti-a\u03b2 oligomer IgG and surface sialic acid in intravenous immunoglobulin: measurement and correlation with clinical outcomes in Alzheimer's disease treatment.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25826319"}, {"offsetInBeginSection": 0, "offsetInEndSection": 99, "text": "Intravenous immunoglobulins as a treatment for Alzheimer's disease: rationale and current evidence.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20329802"}, {"offsetInBeginSection": 1214, "offsetInEndSection": 1442, "text": "For neurodegenerative diseases such as Alzheimer's disease, post-polio syndrome, pain, fibrosis, and autoimmune sleep disorders, some early promising results for the use of IVIg are emerging, but remain to be fully investigated.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/18685921"}]}, {"id": "5a8a9f18fcd1d6a10c00001a", "body": "Is NEMO a zinc finger protein?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/21309033", "http://www.ncbi.nlm.nih.gov/pubmed/26224629", "http://www.ncbi.nlm.nih.gov/pubmed/19033441", "http://www.ncbi.nlm.nih.gov/pubmed/18313693", "http://www.ncbi.nlm.nih.gov/pubmed/12867425", "http://www.ncbi.nlm.nih.gov/pubmed/24100029", "http://www.ncbi.nlm.nih.gov/pubmed/28814200", "http://www.ncbi.nlm.nih.gov/pubmed/28035815", "http://www.ncbi.nlm.nih.gov/pubmed/20345847", "http://www.ncbi.nlm.nih.gov/pubmed/16794254"], "snippets": [{"offsetInBeginSection": 1150, "offsetInEndSection": 1398, "text": "The deprotonated, zinc-bound configuration alone predominantly maintains its tertiary structure throughout all 5 \u03bcs and alludes rare conformations potentially important for (im)proper zinc-finger-related protein-protein or protein-DNA interactions.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28035815"}, {"offsetInBeginSection": 1251, "offsetInEndSection": 1616, "text": "Because the zinc finger domain of IKK\u03b3 is very likely involved in mediating interactions with ubiquitinated proteins, investigations that look for upstream activators or inhibitors of the IKK complex that bind to and interact with the zinc finger of IKK\u03b3 are required to gain a better insight into the exact roles of this domain and into the pathogenesis of HED-ID.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20345847"}, {"offsetInBeginSection": 138, "offsetInEndSection": 426, "text": "Although mice with either CYLD deficiency or an alteration in the zinc finger domain of NEMO (K392R) are born healthy, we found that the combination of these two gene defects in double mutant (DM) mice is early embryonic lethal but can be rescued by the absence of TNF receptor 1 (TNFR1).", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26224629"}, {"offsetInBeginSection": 1110, "offsetInEndSection": 1378, "text": "Furthermore, phosphorylation and polyubiquitination of upstream TAK1 were significantly reduced in the E391X zinc-finger deleted patients, indicating that the NEMO zinc finger may play an important role in assembling the proximal signaling complex for MAPK activation.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21309033"}, {"offsetInBeginSection": 0, "offsetInEndSection": 68, "text": "The zinc finger domain of IKK\u03b3 (NEMO) protein in health and disease.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20345847"}, {"offsetInBeginSection": 0, "offsetInEndSection": 180, "text": "An important regulatory domain of NF-[Formula: see text]B Essential Modulator (NEMO) is a ubiquitin-binding zinc finger, with a tetrahedral CYS3HIS1 zinc-coordinating binding site.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28814200"}, {"offsetInBeginSection": 845, "offsetInEndSection": 1055, "text": "Therefore, our data demonstrate an unexpected non-catalytic function for CYLD as an adapter protein between TRAF2 and the NEMO zinc finger that is important for TNF-induced NF-\u03baB signaling during embryogenesis.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26224629"}, {"offsetInBeginSection": 371, "offsetInEndSection": 531, "text": "Nevertheless, the biological function of the NEMO zinc-finger domain in the regulation of mitogen-activated protein kinase (MAPK) activity is poorly understood.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21309033"}, {"offsetInBeginSection": 604, "offsetInEndSection": 848, "text": "Mutations affecting IKK\u03b3 have been associated with X-linked hypohidrotic ectodermal dysplasia with immune deficiency (HED-ID), with the majority of these mutations affecting the C-terminal region of the protein where the zinc finger is located.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20345847"}, {"offsetInBeginSection": 136, "offsetInEndSection": 343, "text": "NEMO function is mediated by two distal ubiquitin binding domains located in the regulatory C-terminal domain of the protein: the coiled-coil 2-leucine zipper (CC2-LZ) domain and the zinc finger (ZF) domain.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24100029"}]}, {"id": "5a7612b483b0d9ea6600001d", "body": "Is enzastaurin effective treatment of glioblastoma?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/20156802", "http://www.ncbi.nlm.nih.gov/pubmed/20124186", "http://www.ncbi.nlm.nih.gov/pubmed/16103100", "http://www.ncbi.nlm.nih.gov/pubmed/25398844", "http://www.ncbi.nlm.nih.gov/pubmed/23911595", "http://www.ncbi.nlm.nih.gov/pubmed/20934407", "http://www.ncbi.nlm.nih.gov/pubmed/22291006", "http://www.ncbi.nlm.nih.gov/pubmed/20971826", "http://www.ncbi.nlm.nih.gov/pubmed/19098118", "http://www.ncbi.nlm.nih.gov/pubmed/22413865"], "snippets": [{"offsetInBeginSection": 580, "offsetInEndSection": 927, "text": "Despite promising phase II clinical trial results and patient benefit in terms of clinical improvement and longer progression-free survival, an overall survival benefit has not been demonstrated in four randomized phase III trials of bevacizumab or cilengitide in newly diagnosed glioblastoma or cediranib or enzastaurin in recurrent glioblastoma.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25398844"}, {"offsetInBeginSection": 0, "offsetInEndSection": 377, "text": "BACKGROUND: This study's primary objective was evaluation of the progression-free survival rate at 6 months (PFS-6) in patients with newly diagnosed glioblastoma without O(6)-methylguanine-DNA-methyltransferase (MGMT) promoter hypermethylation postsurgically treated with enzastaurin before and concomitantly with radiation therapy, followed by enzastaurin maintenance therapy.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23911595"}, {"offsetInBeginSection": 0, "offsetInEndSection": 324, "text": "We conducted a phase I study to determine the safety and recommended phase II dose of enzastaurin (oral inhibitor of the protein kinase C-beta [PKCbeta] and the PI3K/AKT pathways) when given in combination with radiation therapy (RT) plus temozolomide to patients with newly diagnosed glioblastoma multiforme or gliosarcoma.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20156802"}, {"offsetInBeginSection": 0, "offsetInEndSection": 211, "text": "The protein kinase Cbeta-selective inhibitor, Enzastaurin (LY317615.HCl), suppresses signaling through the AKT pathway, induces apoptosis, and suppresses growth of human colon cancer and glioblastoma xenografts.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16103100"}, {"offsetInBeginSection": 1268, "offsetInEndSection": 1465, "text": "Simultaneous and sequential treatment regimens with enzastaurin and BCNU delayed tumor growth and increased lifespan in mice bearing subcutaneous or intracranial human T98G glioblastoma multiforme.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19098118"}, {"offsetInBeginSection": 0, "offsetInEndSection": 111, "text": "Phase III study of enzastaurin compared with lomustine in the treatment of recurrent intracranial glioblastoma.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20124186"}, {"offsetInBeginSection": 0, "offsetInEndSection": 189, "text": "Enzastaurin before and concomitant with radiation therapy, followed by enzastaurin maintenance therapy, in patients with newly diagnosed glioblastoma without MGMT promoter hypermethylation.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23911595"}, {"offsetInBeginSection": 667, "offsetInEndSection": 861, "text": "Oral dosing with Enzastaurin to yield plasma concentrations similar to those achieved in clinical trials significantly suppresses the growth of human glioblastoma and colon carcinoma xenografts.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16103100"}, {"offsetInBeginSection": 1622, "offsetInEndSection": 1810, "text": "CONCLUSION: Enzastaurin was well tolerated and had a better hematologic toxicity profile but did not have superior efficacy compared with lomustine in patients with recurrent glioblastoma.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20124186"}, {"offsetInBeginSection": 0, "offsetInEndSection": 172, "text": "PURPOSE: This phase III open-label study compared the efficacy and safety of enzastaurin versus lomustine in patients with recurrent glioblastoma (WHO grade 4).PATIENTS AND", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20124186"}]}, {"id": "5925227670f9fc6f0f000020", "body": "Which enzymes are responsible for base J creation in Trypanosoma brucei?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/25064607", "http://www.ncbi.nlm.nih.gov/pubmed/18729733", "http://www.ncbi.nlm.nih.gov/pubmed/8692684", "http://www.ncbi.nlm.nih.gov/pubmed/20724435", "http://www.ncbi.nlm.nih.gov/pubmed/12235375", "http://www.ncbi.nlm.nih.gov/pubmed/12366829", "http://www.ncbi.nlm.nih.gov/pubmed/9742081", "http://www.ncbi.nlm.nih.gov/pubmed/24891501", "http://www.ncbi.nlm.nih.gov/pubmed/20215442", "http://www.ncbi.nlm.nih.gov/pubmed/17706299"], "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 124, "text": "In 1993, a new base, beta-d-glucopyranosyloxymethyluracil (base J), was identified in the nuclear DNA of Trypanosoma brucei.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/18729733"}, {"offsetInBeginSection": 491, "offsetInEndSection": 833, "text": "UDP-Glc is also the glucosyl donor for the unfolded glycoprotein glucosyltransferase (UGGT) involved in glycoprotein quality control in the endoplasmic reticulum and is the presumed donor for the synthesis of base J (\u03b2-D-glucosylhydroxymethyluracil), a rare deoxynucleotide found in telomere-proximal DNA in the bloodstream form of T. brucei.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20724435"}, {"offsetInBeginSection": 0, "offsetInEndSection": 100, "text": "Tb927.10.6900 encodes the glucosyltransferase involved in synthesis of base J in Trypanosoma brucei.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25064607"}, {"offsetInBeginSection": 0, "offsetInEndSection": 122, "text": "Expression of the human DNA glycosylase hSMUG1 in Trypanosoma brucei causes DNA damage and interferes with J biosynthesis.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/12235375"}, {"offsetInBeginSection": 0, "offsetInEndSection": 117, "text": "JBP2, a SWI2/SNF2-like protein, regulates de novo telomeric DNA glycosylation in bloodstream form Trypanosoma brucei.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17706299"}, {"offsetInBeginSection": 716, "offsetInEndSection": 899, "text": "The deletion of both alleles of JGT from the genome of Trypanosoma brucei generates a cell line that completely lacks base J. Reintroduction of JGT in the JGT KO restores J synthesis.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24891501"}, {"offsetInBeginSection": 0, "offsetInEndSection": 100, "text": "The telomeric GGGTTA repeats of Trypanosoma brucei contain the hypermodified base J in both strands.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/8692684"}, {"offsetInBeginSection": 0, "offsetInEndSection": 112, "text": "Base J is a hypermodified DNA base localized primarily to telomeric regions of the genome of Trypanosoma brucei.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20215442"}, {"offsetInBeginSection": 642, "offsetInEndSection": 797, "text": "(Nucleic Acids Res 2013;41:7635) suggested that Tb927.10.6900 encodes the glucosyltransferase (HmdUGT) responsible for converting HOMedU to J in T. brucei.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25064607"}, {"offsetInBeginSection": 1450, "offsetInEndSection": 1569, "text": "Here we discuss the regulation of hmU and base J formation in the trypanosome genome by JGT and base J-binding protein.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24891501"}]}, {"id": "5a80d6cbfaa1ab7d2e000024", "body": "What is the role of Kmt5a in liver?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/28899750", "http://www.ncbi.nlm.nih.gov/pubmed/28746875", "http://www.ncbi.nlm.nih.gov/pubmed/25554733", "http://www.ncbi.nlm.nih.gov/pubmed/23419719", "http://www.ncbi.nlm.nih.gov/pubmed/20953199", "http://www.ncbi.nlm.nih.gov/pubmed/23575530", "http://www.ncbi.nlm.nih.gov/pubmed/18581285", "http://www.ncbi.nlm.nih.gov/pubmed/17620307", "http://www.ncbi.nlm.nih.gov/pubmed/16193099", "http://www.ncbi.nlm.nih.gov/pubmed/23410872"], "snippets": [{"offsetInBeginSection": 581, "offsetInEndSection": 723, "text": "In conclusion, \u03b2-Catenin plays an important role in regulating the balance between TNF-\u03b1 and Fas-induced liver injury via its effect on NF-\u03baB.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23410872"}, {"offsetInBeginSection": 0, "offsetInEndSection": 98, "text": "\u03b2-Catenin plays many critical roles during various liver physiological and pathological processes.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23410872"}, {"offsetInBeginSection": 170, "offsetInEndSection": 387, "text": "Using hepatocyte specific \u03b2-Catenin knockout mice, we found that loss of \u03b2-Catenin in hepatocyte significantly reduced GalN/LPS-induced liver damage and hepatocyte apoptosis, but exacerbated Jo2-mediated liver injury.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23410872"}, {"offsetInBeginSection": 99, "offsetInEndSection": 169, "text": "However, the role of \u03b2-Catenin in acute liver failure remains unclear.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23410872"}, {"offsetInBeginSection": 0, "offsetInEndSection": 94, "text": "Role of \u03b2-Catenin in regulating the balance between TNF-\u03b1- and Fas-induced acute liver injury.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23410872"}, {"offsetInBeginSection": 418, "offsetInEndSection": 627, "text": "Here, we determined the role of p27 in liver tumorigenesis in C57BL/6J mice, a liver tumor resistant strain, in response to a diethylnitrosamine (DEN) and phenolbarbital (PB) two-stage carcinogenesis protocol.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17620307"}, {"offsetInBeginSection": 342, "offsetInEndSection": 407, "text": "In liver-specific Kmt5a-deficient mice, reduced levels of H4K20Me", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28746875"}, {"offsetInBeginSection": 140, "offsetInEndSection": 341, "text": "Here, we show that, in non-dividing hepatic cells, H4K20Me1 is specifically enriched in active gene bodies and dynamically regulated by the antagonistic action of Kmt5a methylase and Kdm7b demethylase.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28746875"}, {"offsetInBeginSection": 0, "offsetInEndSection": 190, "text": "Downregulation of UBE2E2 in rat liver cells after hepatocarcinogen treatment facilitates cell proliferation and slowing down of DNA damage response in GST-P-expressing preneoplastic lesions.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28899750"}, {"offsetInBeginSection": 854, "offsetInEndSection": 1190, "text": "At the 9-mo time point, p27-/- mice developed significantly enhanced liver tumor phenotypes than p27+/+ mice as demonstrated by increased numbers and sizes of liver surface nodules, increased liver-to-body weight ratios, and increased numbers of G6Pase-deficient nodules and histologically diagnosed foci and adenomas in liver sections.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17620307"}]}, {"id": "5a7d5ce0faa1ab7d2e00001b", "body": "How does increased GDF15 affect body weight?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/28846097", "http://www.ncbi.nlm.nih.gov/pubmed/26672741", "http://www.ncbi.nlm.nih.gov/pubmed/28846098", "http://www.ncbi.nlm.nih.gov/pubmed/28953886", "http://www.ncbi.nlm.nih.gov/pubmed/28846099", "http://www.ncbi.nlm.nih.gov/pubmed/29046435", "http://www.ncbi.nlm.nih.gov/pubmed/27239403", "http://www.ncbi.nlm.nih.gov/pubmed/27986797", "http://www.ncbi.nlm.nih.gov/pubmed/29144449", "http://www.ncbi.nlm.nih.gov/pubmed/28898507"], "snippets": [{"offsetInBeginSection": 280, "offsetInEndSection": 500, "text": "A connection between GDF15 and body-weight regulation was initially suggested on the basis of an observation that increasing GDF15 levels in serum correlated with weight loss in individuals with advanced prostate cancer.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28846098"}, {"offsetInBeginSection": 791, "offsetInEndSection": 1012, "text": "Gfral is expressed in neurons of the area postrema and nucleus of the solitary tract in mice and humans, and genetic deletion of the receptor abrogates the ability of GDF15 to decrease food intake and body weight in mice.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28846097"}, {"offsetInBeginSection": 491, "offsetInEndSection": 728, "text": "Adeno-associated virus-mediated overexpression of GDF15 and recombinant GDF15 treatments reduced food intake and body weight and improved metabolic profiles in various metabolic disease models in mice, rats, and obese cynomolgus monkeys.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/29046435"}, {"offsetInBeginSection": 340, "offsetInEndSection": 471, "text": "The mechanisms through which GDF15 reduces body weight remain poorly understood, because the cognate receptor for GDF15 is unknown.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28846097"}, {"offsetInBeginSection": 1021, "offsetInEndSection": 1162, "text": "GFRAL binds to GDF15 in vitro and is required for the metabolic actions of GDF15 with respect to body weight and food intake in vivo in mice.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28846098"}, {"offsetInBeginSection": 1686, "offsetInEndSection": 1839, "text": "CONCLUSION: GDF15 and other inflammatory markers are associated with weight loss, decreased aLBM and strength, and poor survival in patients with cancer.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26672741"}, {"offsetInBeginSection": 459, "offsetInEndSection": 594, "text": "We also found that GDF15-mediated reductions in food intake and body weight of mice with obesity were abolished in GFRAL-knockout mice.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28846099"}, {"offsetInBeginSection": 1434, "offsetInEndSection": 1589, "text": "GDF15 levels increase in response to tissue stress and injury, and elevated levels are associated with body weight loss in numerous chronic human diseases.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28953886"}, {"offsetInBeginSection": 166, "offsetInEndSection": 339, "text": "In humans, elevated GDF15 correlates with weight loss, and the administration of GDF15 to mice with obesity reduces body weight, at least in part, by decreasing food intake.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28846097"}, {"offsetInBeginSection": 0, "offsetInEndSection": 177, "text": "Growth differentiation factor 15 (GDF15; also known as MIC-1) is a divergent member of the TGF-\u03b2 superfamily and is associated with body-weight regulation in humans and rodents.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28846099"}]}, {"id": "5a7617b183b0d9ea66000022", "body": "What is inhibited by a drug rilotumumab?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/23454250", "http://www.ncbi.nlm.nih.gov/pubmed/19649990", "http://www.ncbi.nlm.nih.gov/pubmed/25912961", "http://www.ncbi.nlm.nih.gov/pubmed/27966237", "http://www.ncbi.nlm.nih.gov/pubmed/25185191", "http://www.ncbi.nlm.nih.gov/pubmed/25712685", "http://www.ncbi.nlm.nih.gov/pubmed/24965569", "http://www.ncbi.nlm.nih.gov/pubmed/25584489", "http://www.ncbi.nlm.nih.gov/pubmed/26750997", "http://www.ncbi.nlm.nih.gov/pubmed/28958504"], "snippets": [{"offsetInBeginSection": 2087, "offsetInEndSection": 2326, "text": "Median PFS was 5\u00b71 months (95% CI 2\u00b79-7\u00b70) in the rilotumumab 15 mg/kg group, 6\u00b78 months (4\u00b75-7\u00b75) in the rilotumumab 7\u00b75 mg/kg group, 5\u00b77 months (4\u00b75-7\u00b70) in both rilotumumab groups combined, and 4\u00b72 months (2\u00b79-4\u00b79) in the placebo group.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24965569"}, {"offsetInBeginSection": 2327, "offsetInEndSection": 2566, "text": "The hazard ratio for PFS events compared with placebo was 0\u00b769 (80% CI 0\u00b749-0\u00b797; p=0\u00b7164) for rilotumumab 15 mg/kg, 0\u00b753 (80% CI 0\u00b738-0\u00b773; p=0\u00b7009) for rilotumumab 7\u00b75 mg/kg, and 0\u00b760 (80% CI 0\u00b745-0\u00b779; p=0\u00b7016) for combined rilotumumab.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24965569"}, {"offsetInBeginSection": 118, "offsetInEndSection": 299, "text": "The aim of this study was to evaluate the potential pharmacokinetic (PK)-based drug-drug interaction (DDI) between rilotumumab and epirubicin (E), cisplatin(C) and capecitabine (X).", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27966237"}, {"offsetInBeginSection": 771, "offsetInEndSection": 1124, "text": "Data from preclinical studies and a phase Ib trial demonstrated that rilotumumab had an additive effect when combined with chemotherapeutic agents, leading to the initiation of several phase II trials that are enrolling patients with different tumor types to assess combinations of rilotumumab with chemotherapeutic regimens, as well as with other mAbs.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19649990"}, {"offsetInBeginSection": 265, "offsetInEndSection": 887, "text": "In this review, we examine the pharmacokinetic and pharmacodynamic data that have been collected in the rilotumumab programme to date, and discuss retrospectively how the knowledge acquired in this programme can be applied to a number of key issues in oncology drug development, including: (i) using preclinical data to inform first-in-human study design; (ii) the role of biomarkers in the identification of a target patient population; (iii) the potential for drug interactions between therapeutic proteins and other anticancer agents; and (iv) pharmacokinetic and pharmacodynamic considerations in phase 3 study design.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25912961"}, {"offsetInBeginSection": 915, "offsetInEndSection": 1104, "text": "Treatment with 300 and 500 \u03bcg rilotumumab inhibited (18)F-FDG accumulation with significant decreases of -37% and -40% in the percent injected dose per gram of tissue (%ID/g), respectively.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23454250"}, {"offsetInBeginSection": 703, "offsetInEndSection": 1043, "text": "Phase 1b was an open-label, dose de-escalation study to identify a safe dose of rilotumumab (initial dose 15 mg/kg intravenously on day 1) plus ECX (epirubicin 50 mg/m(2) intravenously on day 1, cisplatin 60 mg/m(2) intravenously on day 1, capecitabine 625 mg/m(2) twice a day orally on days 1-21, respectively), administered every 3 weeks.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24965569"}, {"offsetInBeginSection": 1153, "offsetInEndSection": 1452, "text": "RESULTS: Among MET-positive patients, higher rilotumumab exposure, vs placebo and low exposure, was associated with improved median PFS (80% CI: 7.0 (5.7-9.7) vs 4.4 (2.9-4.9) and 5.5 (4.2-6.8) months) and OS (13.4 (10.6-18.6) vs 5.7 (4.7-10.2) and 8.1 (6.9-11.1) months) without increased toxicity.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25584489"}, {"offsetInBeginSection": 1128, "offsetInEndSection": 1379, "text": "FINDINGS: Between Nov 7, 2012, and Nov 21, 2014, 609 patients were randomly assigned to rilotumumab plus epirubicin, cisplatin, and capecitabine (rilotumumab group; n=304) or placebo plus epirubicin, cisplatin, and capecitabine (placebo group; n=305).", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28958504"}, {"offsetInBeginSection": 793, "offsetInEndSection": 914, "text": "RESULTS: In the dose response study, rilotumumab at doses of 300 and 500 \u03bcg was similarly effective against tumor growth.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23454250"}]}, {"id": "593fe5c270f9fc6f0f000021", "body": "How many PML isoforms exist in the human genome?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/23135708", "http://www.ncbi.nlm.nih.gov/pubmed/15107834", "http://www.ncbi.nlm.nih.gov/pubmed/20664248", "http://www.ncbi.nlm.nih.gov/pubmed/21092142", "http://www.ncbi.nlm.nih.gov/pubmed/24036361", "http://www.ncbi.nlm.nih.gov/pubmed/7535592", "http://www.ncbi.nlm.nih.gov/pubmed/16778193", "http://www.ncbi.nlm.nih.gov/pubmed/20205709", "http://www.ncbi.nlm.nih.gov/pubmed/27860076", "http://www.ncbi.nlm.nih.gov/pubmed/18509536"], "snippets": [{"offsetInBeginSection": 599, "offsetInEndSection": 855, "text": "Using a yeast two-hybrid screen employing peptide sequences unique to PML isoform I (PML-I), we identified an interaction with the eukaryotic initiation factor 3 subunit K (eIF3K), and in the process identified a novel eIF3K isoform, which we term eIF3K-2.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24036361"}, {"offsetInBeginSection": 856, "offsetInEndSection": 1033, "text": "We further demonstrate that eIF3K and PML interact both in vitro via pull-down assays, as well as in vivo within human cells by co-immunoprecipitation and co-immunofluorescence.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24036361"}, {"offsetInBeginSection": 1174, "offsetInEndSection": 1574, "text": "We also demonstrate that SUMOylation of PML at Lysine positions K160 and/or K490 are required for nuclear body formation in vivo.We propose a model in which the isoform specific residence times of PML provide both, structural stability to function as a scaffold and flexibility to attract specific nuclear proteins for efficient biochemical reactions at the surface of nuclear bodies.MCS code: 92C37.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20205709"}, {"offsetInBeginSection": 1029, "offsetInEndSection": 1169, "text": "Coimmunoprecipitation assays showed that E1A-13S preferentially interacts with only one (PML-II) of at least six nuclear human PML isoforms.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23135708"}, {"offsetInBeginSection": 1894, "offsetInEndSection": 2001, "text": "In contrast, HPVs require the presence of PML protein for efficient transcription of incoming viral genome.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27860076"}, {"offsetInBeginSection": 552, "offsetInEndSection": 750, "text": "Although multiple PML splice variants exist, we demonstrate that the ratio of a subset of cytoplasmic PML isoforms lacking exons 5 & 6 is enriched in cells exposed to herpes simplex virus-1 (HSV-1).", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/18509536"}, {"offsetInBeginSection": 824, "offsetInEndSection": 1078, "text": "RESULTS: Expression of NLS mutated PML isoforms in U2OS cells revealed that PML I targets early endosomes, PML II targets the inner nuclear membrane (partially due to an extra NLS at its C-terminus), and PML III, IV and V target late endosomes/lysosomes.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21092142"}, {"offsetInBeginSection": 331, "offsetInEndSection": 499, "text": "Overexpression of only one of them, PML-IV, promotes senescence in human diploid fibroblasts, whereas PML-III was proposed to specifically interact with the centrosome.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16778193"}, {"offsetInBeginSection": 723, "offsetInEndSection": 825, "text": "We show that all six human nuclear PML isoforms are able to form nuclear bodies in PML negative cells.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20205709"}, {"offsetInBeginSection": 832, "offsetInEndSection": 969, "text": "Appearance of PML nuclear bodies in the 2-cell-stage embryo may correspond to the major transcriptional activity of the embryonic genome.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20664248"}]}, {"id": "5a80d965faa1ab7d2e000025", "body": "What is metaSPAdes?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/28298430", "http://www.ncbi.nlm.nih.gov/pubmed/28407798", "http://www.ncbi.nlm.nih.gov/pubmed/28693474", "http://www.ncbi.nlm.nih.gov/pubmed/28948103", "http://www.ncbi.nlm.nih.gov/pubmed/29036597"], "snippets": [{"offsetInBeginSection": 928, "offsetInEndSection": 1165, "text": "CONCLUSIONS: These simulations provide benchmarks for selecting analysis cut-offs and establish that an optimized sample-to-ecological-inference viromics pipeline is robust for making ecological inferences from natural viral communities.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28948103"}, {"offsetInBeginSection": 1313, "offsetInEndSection": 1771, "text": "However, on metagenomes tested, Faucet,o outputs had 14-110% higher mean NGA50 lengths compared with Minia, and 2- to 11-fold higher mean NGA50 lengths compared with LightAssembler, the only other streaming assembler available.Availability and implementation: Faucet is available at https://github.com/Shamir-Lab/Faucet.Contact: rshamir@tau.ac.il or eranhalperin@gmail.com.Supplementary information: Supplementary data are available at Bioinformatics online.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/29036597"}, {"offsetInBeginSection": 0, "offsetInEndSection": 164, "text": "BACKGROUND: Viral metagenomics (viromics) is increasingly used to obtain uncultivated viral genomes, evaluate community diversity, and assess ecological hypotheses.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28948103"}, {"offsetInBeginSection": 0, "offsetInEndSection": 131, "text": "BACKGROUND: Metagenomics is the study of the microbial genomes isolated from communities found on our bodies or in our environment.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28407798"}, {"offsetInBeginSection": 267, "offsetInEndSection": 428, "text": "However, while several platforms have been developed for this critical step, there is currently no clear framework for the assembly of metagenomic sequence data.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28693474"}, {"offsetInBeginSection": 165, "offsetInEndSection": 326, "text": "While viromic experimental methods are relatively mature and widely accepted by the research community, robust bioinformatics standards remain to be established.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28948103"}, {"offsetInBeginSection": 1528, "offsetInEndSection": 1744, "text": "MetaSPAdes excelled in diverse sets, IDBA-UD performed well all around, metaVelvet had high accuracy in high abundance organisms, and MEGAHIT was able to accurately differentiate similar organisms within a community.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28407798"}, {"offsetInBeginSection": 276, "offsetInEndSection": 578, "text": "We demonstrate this functionality by performing streaming graph assembly of publicly available data, and observe that the ratio of disk use to raw data size decreases as coverage is increased.Results: Faucet pairs the de Bruijn graph obtained from the reads with additional meta-data derived from them.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/29036597"}, {"offsetInBeginSection": 488, "offsetInEndSection": 618, "text": "Read pre-processing, such as partitioning, had virtually no impact on assembly output, but may be useful when hardware is limited.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28948103"}, {"offsetInBeginSection": 1990, "offsetInEndSection": 2181, "text": "It is important to choose the appropriate assembler, and thus clearly define the biological problem\u00a0of an experiment, as different assemblers will give different answers to the same question.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28407798"}]}, {"id": "5a7d6287faa1ab7d2e00001c", "body": "Which receptor does GDF15 bind?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/28846097", "http://www.ncbi.nlm.nih.gov/pubmed/28846099", "http://www.ncbi.nlm.nih.gov/pubmed/28846098", "http://www.ncbi.nlm.nih.gov/pubmed/21803025", "http://www.ncbi.nlm.nih.gov/pubmed/26497212", "http://www.ncbi.nlm.nih.gov/pubmed/24597762", "http://www.ncbi.nlm.nih.gov/pubmed/28953886", "http://www.ncbi.nlm.nih.gov/pubmed/28847729", "http://www.ncbi.nlm.nih.gov/pubmed/27093475", "http://www.ncbi.nlm.nih.gov/pubmed/24191265"], "snippets": [{"offsetInBeginSection": 607, "offsetInEndSection": 790, "text": "Furthermore, we find that GDF15 binds with high affinity to GDNF family receptor \u03b1-like (GFRAL), a distant relative of receptors for a distinct class of the TGF-\u03b2 superfamily ligands.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28846097"}, {"offsetInBeginSection": 229, "offsetInEndSection": 458, "text": "Here we show that GDF15 binds specifically to GDNF family receptor \u03b1-like (GFRAL) with high affinity, and that GFRAL requires association with the coreceptor RET to elicit intracellular signaling in response to GDF15 stimulation.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28846099"}, {"offsetInBeginSection": 887, "offsetInEndSection": 1020, "text": "Here we report that GDNF-family receptor \u03b1-like (GFRAL), an orphan member of the GFR-\u03b1 family, is a high-affinity receptor for GDF15.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28846098"}, {"offsetInBeginSection": 340, "offsetInEndSection": 471, "text": "The mechanisms through which GDF15 reduces body weight remain poorly understood, because the cognate receptor for GDF15 is unknown.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28846097"}, {"offsetInBeginSection": 0, "offsetInEndSection": 91, "text": "GFRAL is the receptor for GDF15 and is required for the anti-obesity effects of the ligand.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28846099"}, {"offsetInBeginSection": 178, "offsetInEndSection": 228, "text": "However, the cognate receptor of GDF15 is unknown.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28846099"}, {"offsetInBeginSection": 0, "offsetInEndSection": 98, "text": "GFRAL is the receptor for GDF15 and the ligand promotes weight loss in mice and nonhuman primates.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28846097"}, {"offsetInBeginSection": 1590, "offsetInEndSection": 1820, "text": "By isolating GFRAL as the receptor for GDF15-induced anorexia and weight loss, we identify a mechanistic basis for the non-homeostatic regulation of neural circuitry by a peripheral signal associated with tissue damage and stress.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28953886"}, {"offsetInBeginSection": 1495, "offsetInEndSection": 1648, "text": "Lastly, GDF15 protein bound to the activin receptor-like kinase 1 receptor and promoted airway epithelial senescence via activation of the Smad1 pathway.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27093475"}, {"offsetInBeginSection": 0, "offsetInEndSection": 73, "text": "The metabolic effects of GDF15 are mediated by the orphan receptor GFRAL.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28846098"}]}, {"id": "5a76196faacfb9cd4c000001", "body": "List the two most important hematological features of the Evans syndrome", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/21088621", "http://www.ncbi.nlm.nih.gov/pubmed/17179698", "http://www.ncbi.nlm.nih.gov/pubmed/2095900", "http://www.ncbi.nlm.nih.gov/pubmed/25548448", "http://www.ncbi.nlm.nih.gov/pubmed/17943645", "http://www.ncbi.nlm.nih.gov/pubmed/28055149", "http://www.ncbi.nlm.nih.gov/pubmed/27082565", "http://www.ncbi.nlm.nih.gov/pubmed/12554529", "http://www.ncbi.nlm.nih.gov/pubmed/15495242", "http://www.ncbi.nlm.nih.gov/pubmed/22796025"], "snippets": [{"offsetInBeginSection": 1213, "offsetInEndSection": 1766, "text": "Peripheral blood finding were: anemia in 83.3%, with two cases of hemolytic anemia and positive direct Coombs test, one of them associated with thrombocytopenia (Evans syndrome); leukopenia in 21%, basically due to neutropenia; thrombocytopenia in 33.3%, in one case associated with positive antiplatelet antibodies and with pure megakaryocytic aplasia in others; pancytopenia in 13.5% of cases (8 patients) associated to bone marrow cytophagocytosis in 5 cases (64.5%) and thus suggesting that this might be the major underlying pathogenetic mechanism.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/2095900"}, {"offsetInBeginSection": 0, "offsetInEndSection": 252, "text": "We present a rare case of newly diagnosed Evans syndrome associated with lung papillary adenocarcinoma in which the patient showed prompt restoration of blood cell count and long-lasting complete remission of Evans syndrome after lung cancer resection.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28055149"}, {"offsetInBeginSection": 754, "offsetInEndSection": 893, "text": "This rare case report illustrates the unique relationship between primary lung cancer and the development of paraneoplastic Evans syndrome.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28055149"}, {"offsetInBeginSection": 0, "offsetInEndSection": 136, "text": "The aim of the study was to investigate the clinical features of systemic lupus erythematous (SLE) complicated with Evans syndrome (ES).", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27082565"}, {"offsetInBeginSection": 349, "offsetInEndSection": 487, "text": "She was diagnosed as having the mixed type Evans syndrome with the clinical features of symptomatic anemia, jaundice and thrombocytopenia.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17179698"}, {"offsetInBeginSection": 548, "offsetInEndSection": 852, "text": "Rituximab appears safe and modestly effective in a variety of immune-mediated hematologic diseases, including autoimmune hemolytic anemia, chronic immune thrombocytopenia, Evans syndrome, pure red cell aplasia, mixed type II cryoglobulinemia, cold agglutinin disease, and Waldenstrom's macroglobulinemia.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15495242"}, {"offsetInBeginSection": 0, "offsetInEndSection": 128, "text": "Clinical Features of Systemic Lupus Erythematosus Patients Complicated With Evans Syndrome: A Case-Control, Single Center Study.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27082565"}, {"offsetInBeginSection": 0, "offsetInEndSection": 87, "text": "Rituximab for refractory Evans syndrome and other immune-mediated hematologic diseases.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15495242"}, {"offsetInBeginSection": 253, "offsetInEndSection": 313, "text": "Detailed investigation led to a diagnosis of Evans syndrome.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28055149"}, {"offsetInBeginSection": 0, "offsetInEndSection": 61, "text": "Mixed type Evans syndrome is a very rare hematologic disease.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17179698"}]}, {"id": "593fe7f970f9fc6f0f000022", "body": "How many of the human PML isoforms are cytosolic?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/15107834", "http://www.ncbi.nlm.nih.gov/pubmed/23135708", "http://www.ncbi.nlm.nih.gov/pubmed/7535592", "http://www.ncbi.nlm.nih.gov/pubmed/24036361", "http://www.ncbi.nlm.nih.gov/pubmed/20205709", "http://www.ncbi.nlm.nih.gov/pubmed/16778193", "http://www.ncbi.nlm.nih.gov/pubmed/19279115", "http://www.ncbi.nlm.nih.gov/pubmed/16501113", "http://www.ncbi.nlm.nih.gov/pubmed/23734343", "http://www.ncbi.nlm.nih.gov/pubmed/21115099"], "snippets": [{"offsetInBeginSection": 1174, "offsetInEndSection": 1574, "text": "We also demonstrate that SUMOylation of PML at Lysine positions K160 and/or K490 are required for nuclear body formation in vivo.We propose a model in which the isoform specific residence times of PML provide both, structural stability to function as a scaffold and flexibility to attract specific nuclear proteins for efficient biochemical reactions at the surface of nuclear bodies.MCS code: 92C37.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20205709"}, {"offsetInBeginSection": 891, "offsetInEndSection": 1017, "text": "Finally, the key players involved in the degradation of the PML isoforms in response to As2O3 or other inducers are discussed.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23734343"}, {"offsetInBeginSection": 933, "offsetInEndSection": 1122, "text": "These effects, observed with IFN\u03b3 and not IFN\u03b1, required PML localization in the nucleus as they were not observed with the cytoplasmic isoform PMLVIIb or the cytoplasmic variants of PMLIV.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21115099"}, {"offsetInBeginSection": 1029, "offsetInEndSection": 1169, "text": "Coimmunoprecipitation assays showed that E1A-13S preferentially interacts with only one (PML-II) of at least six nuclear human PML isoforms.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23135708"}, {"offsetInBeginSection": 730, "offsetInEndSection": 1005, "text": "Although two physiologically expressed PML isoforms are detectable by immunocytochemistry only or predominantly in the cytoplasm of transfected cells, the cytoplasmic localization of PML is a property also shared by the PML isoforms that predominantly localize to the nuclei.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/7535592"}, {"offsetInBeginSection": 723, "offsetInEndSection": 825, "text": "We show that all six human nuclear PML isoforms are able to form nuclear bodies in PML negative cells.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20205709"}, {"offsetInBeginSection": 0, "offsetInEndSection": 162, "text": "Nuclear domain 10 (ND10s), or promyelocytic leukemia protein (PML) nuclear bodies, are spherical nuclear structures that require PML proteins for their formation.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16501113"}, {"offsetInBeginSection": 584, "offsetInEndSection": 755, "text": "Unexpectedly, we found that PML-III, PML-IV, and PML-V are quantitatively minor isoforms compared with PML-I/II and could not confirm the centrosomal targeting of PML-III.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16778193"}, {"offsetInBeginSection": 653, "offsetInEndSection": 932, "text": "Herein, we show that overexpression of all nuclear PML isoforms (I-VI) in human cells increased IFN\u03b3-induced STAT1 phosphorylation, resulting in higher binding of STAT1 to DNA, higher activation of IFN-stimulated genes (ISGs), and an increase in the expression of their products.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21115099"}, {"offsetInBeginSection": 756, "offsetInEndSection": 1015, "text": "Stable expression of each isoform, in a pml-null background, yields distinct subcellular localization patterns, suggesting that, like in other RBCC/TRIM proteins, the COOH-terminal domains of PML are involved in interactions with specific cellular components.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16778193"}]}, {"id": "593ff22b70f9fc6f0f000023", "body": "How many Groucho-related genes (GRG) are contained in the mouse genome?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/8892234", "http://www.ncbi.nlm.nih.gov/pubmed/8369224", "http://www.ncbi.nlm.nih.gov/pubmed/8989517", "http://www.ncbi.nlm.nih.gov/pubmed/8573724", "http://www.ncbi.nlm.nih.gov/pubmed/7916324", "http://www.ncbi.nlm.nih.gov/pubmed/12666196", "http://www.ncbi.nlm.nih.gov/pubmed/8955148", "http://www.ncbi.nlm.nih.gov/pubmed/10512199", "http://www.ncbi.nlm.nih.gov/pubmed/11266540", "http://www.ncbi.nlm.nih.gov/pubmed/15923151"], "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 157, "text": "Groucho-related genes (Grgs) encode transcriptional co-repressors of Lef/Tcf and Hes proteins, which are mediators of Wnt and Notch signalling, respectively.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15923151"}, {"offsetInBeginSection": 0, "offsetInEndSection": 78, "text": "Expression of avian Groucho-related genes (Grgs) during embryonic development.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15923151"}, {"offsetInBeginSection": 0, "offsetInEndSection": 157, "text": "Transcripts of Grg4, a murine groucho-related gene, are detected in adjacent tissues to other murine neurogenic gene homologues during embryonic development.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/8892234"}, {"offsetInBeginSection": 0, "offsetInEndSection": 131, "text": "Grg3, a murine Groucho-related gene, is expressed in the developing nervous system and in mesenchyme-induced epithelial structures.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/8989517"}, {"offsetInBeginSection": 0, "offsetInEndSection": 124, "text": "We have isolated cDNAs representing multiple members of murine groucho homologues, designated Grg for groucho-related genes.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/8989517"}, {"offsetInBeginSection": 0, "offsetInEndSection": 148, "text": "Mammalian Hairy/Enhancer-of-split-like (Hes) proteins interact with transcriptional corepressors encoded by the Groucho-related genes (Grg in mice).", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/10512199"}, {"offsetInBeginSection": 323, "offsetInEndSection": 489, "text": "Here we describe the cloning and RNA expression analysis of a mouse gene, designated Grg, that is homologous to just the amino-terminal region of the groucho product.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/8369224"}, {"offsetInBeginSection": 305, "offsetInEndSection": 475, "text": "The 3' region of the Grg gene contains two functional polyadenylation sites that give rise to two transcripts that are differentially expressed among adult mouse tissues.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/7916324"}, {"offsetInBeginSection": 0, "offsetInEndSection": 179, "text": "Genomic organization, alternative polyadenylation, and chromosomal localization of Grg, a mouse gene related to the groucho transcript of the Drosophila Enhancer of split complex.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/7916324"}, {"offsetInBeginSection": 0, "offsetInEndSection": 83, "text": "The groucho-related genes (Grg) of the mouse comprise at least four family members.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/8892234"}]}, {"id": "59bf823b542ba3824b000001", "body": "Does a tonsillectomy affect the patient's voice?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/26846544", "http://www.ncbi.nlm.nih.gov/pubmed/21074280", "http://www.ncbi.nlm.nih.gov/pubmed/18468843", "http://www.ncbi.nlm.nih.gov/pubmed/20926254", "http://www.ncbi.nlm.nih.gov/pubmed/19841332", "http://www.ncbi.nlm.nih.gov/pubmed/25704470", "http://www.ncbi.nlm.nih.gov/pubmed/22803405", "http://www.ncbi.nlm.nih.gov/pubmed/16966154", "http://www.ncbi.nlm.nih.gov/pubmed/12161728", "http://www.ncbi.nlm.nih.gov/pubmed/22242470"], "snippets": [{"offsetInBeginSection": 1053, "offsetInEndSection": 1134, "text": "CONCLUSION: Upper airway oeprations can affect acoustics and perception of voice.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/12161728"}, {"offsetInBeginSection": 0, "offsetInEndSection": 81, "text": "Does Tonsillectomy Affect Voice in Early or Late Postoperative Periods in Adults?", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26846544"}, {"offsetInBeginSection": 1102, "offsetInEndSection": 1263, "text": "CONCLUSION: Tonsillectomy affects voice performance negatively in adults in short term; however, it does not affect voice performance in long term after surgery.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26846544"}, {"offsetInBeginSection": 15, "offsetInEndSection": 152, "text": "HYPOTHESIS: Anecdotal evidence suggests that tonsillectomy has no deleterious consequences on a person's voice under normal vocal demand.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20926254"}, {"offsetInBeginSection": 1163, "offsetInEndSection": 1321, "text": "CONCLUSIONS: The surgical technique, whether it is cold knife or thermal welding system, does not appear to affect voice and speech in tonsillectomy patients.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21074280"}, {"offsetInBeginSection": 0, "offsetInEndSection": 241, "text": "OBJECTIVE: To compare acoustic, aerodynamic and perceptual voice and speech parameters in thermal welding system tonsillectomy and cold knife tonsillectomy patients in order to determine the impact of operation technique on voice and speech.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21074280"}, {"offsetInBeginSection": 0, "offsetInEndSection": 79, "text": "Thermal welding vs. cold knife tonsillectomy: a comparison of voice and speech.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21074280"}, {"offsetInBeginSection": 595, "offsetInEndSection": 906, "text": "Calculated results show that a tonsillectomy causes a frequency shift of the 3rd (down by approximately 180 Hz) and 4th (down by approximately 120 Hz) formants down to the lower frequencies for the vowel /a:/ and similarly for the 2nd, 4th and 5th formants for the vowel /i:/ (all down by approximately 100 Hz).", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16966154"}, {"offsetInBeginSection": 0, "offsetInEndSection": 45, "text": "Effects of tonsillectomy on speech and voice.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/18468843"}, {"offsetInBeginSection": 153, "offsetInEndSection": 296, "text": "However, whether the enlarged dimensions of the oropharynx after tonsillectomy impair the quality of a professional voice user remains unclear.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20926254"}]}, {"id": "59d09a0cbc32f93e6d000001", "body": "What is the difference between ganglion mother cells (GMC) and intermediate neural precursor cells (INP) in Drosophila?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/23376107", "http://www.ncbi.nlm.nih.gov/pubmed/15704126", "http://www.ncbi.nlm.nih.gov/pubmed/21996673", "http://www.ncbi.nlm.nih.gov/pubmed/14973280", "http://www.ncbi.nlm.nih.gov/pubmed/29158446", "http://www.ncbi.nlm.nih.gov/pubmed/28325554", "http://www.ncbi.nlm.nih.gov/pubmed/25285448", "http://www.ncbi.nlm.nih.gov/pubmed/11688564", "http://www.ncbi.nlm.nih.gov/pubmed/8095484", "http://www.ncbi.nlm.nih.gov/pubmed/18342578"], "snippets": [{"offsetInBeginSection": 141, "offsetInEndSection": 347, "text": "Each of the approximately 25 NBs per hemisegment undergoes repeated asymmetric divisions to produce, on average, 5-10 smaller ganglion mother cells (GMCs); each GMC, in turn, divides to produce two neurons.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/8095484"}, {"offsetInBeginSection": 0, "offsetInEndSection": 195, "text": "In the Drosophila CNS, neuroblasts undergo self-renewing asymmetric divisions, whereas their progeny, ganglion mother cells (GMCs), divide asymmetrically to generate terminal postmitotic neurons.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/14973280"}, {"offsetInBeginSection": 434, "offsetInEndSection": 641, "text": "PAN neuroblasts rely on the segregating determinants Numb and Brat to generate smaller, secondary neuroblasts that in turn give rise to ganglion mother cells (GMCs) and neurons throughout larval development.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/18342578"}, {"offsetInBeginSection": 0, "offsetInEndSection": 110, "text": "Generating neuronal diversity in the Drosophila central nervous system: a view from the ganglion mother cells.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15704126"}, {"offsetInBeginSection": 168, "offsetInEndSection": 419, "text": "Type I neuroblasts produce ganglion mother cells (GMCs) that divide once to produce differentiated progeny, while type II neuroblasts produce self-renewing intermediate neural progenitors (INPs) and thus generate lineages containing many more progeny.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23376107"}, {"offsetInBeginSection": 0, "offsetInEndSection": 138, "text": "The bipotential Ganglion Mother Cells, or GMCs, in the Drosophila CNS asymmetrically divide to generate two distinct post-mitotic neurons.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/11688564"}, {"offsetInBeginSection": 0, "offsetInEndSection": 145, "text": "The Drosophila Hem/Kette/Nap1 protein regulates asymmetric division of neural precursor cells by regulating localization of Inscuteable and Numb.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21996673"}, {"offsetInBeginSection": 702, "offsetInEndSection": 1017, "text": "Our results suggest that the presence of ectopically induced dPOU28/pdm-2 protein in the progeny of GMC-1 is sufficient to cause both of these cells to adopt their parental GMC-1 cell fate, leading to duplication of the RP2 neuron (and its sister cell) on the basis of both immunological and morphological criteria.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/8095484"}, {"offsetInBeginSection": 0, "offsetInEndSection": 153, "text": "The role of a Drosophila POU homeo domain gene in the specification of neural precursor cell identity in the developing embryonic central nervous system.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/8095484"}, {"offsetInBeginSection": 0, "offsetInEndSection": 107, "text": "The Drosophila SERTAD protein Taranis determines lineage-specific neural progenitor proliferation patterns.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23376107"}]}, {"id": "5a003e0a966455904c000001", "body": "What is the function of the TFIIS transcriptional factor (Dst1) in yeast?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/17535246", "http://www.ncbi.nlm.nih.gov/pubmed/28521214", "http://www.ncbi.nlm.nih.gov/pubmed/16492753", "http://www.ncbi.nlm.nih.gov/pubmed/15082542", "http://www.ncbi.nlm.nih.gov/pubmed/18628399", "http://www.ncbi.nlm.nih.gov/pubmed/15359273", "http://www.ncbi.nlm.nih.gov/pubmed/10811649", "http://www.ncbi.nlm.nih.gov/pubmed/21761155", "http://www.ncbi.nlm.nih.gov/pubmed/20179968", "http://www.ncbi.nlm.nih.gov/pubmed/9712888"], "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 134, "text": "TFIIS, an elongation factor encoded by DST1 in Saccharomyces cerevisiae, stimulates transcript cleavage in arrested RNA polymerase II.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15359273"}, {"offsetInBeginSection": 0, "offsetInEndSection": 190, "text": "The transcriptionally active fragment of the yeast RNA polymerase II transcription elongation factor, TFIIS, comprises a three-helix bundle and a zinc ribbon motif joined by a linker region.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/9712888"}, {"offsetInBeginSection": 499, "offsetInEndSection": 1123, "text": "We showed that: (1) dst1 and rpb9 mutants have a synthetic growth defective phenotype when combined with fyv4, gim5, htz1, yal011w, ybr231c, soh1, vps71, and vps72 mutants that is exacerbated during germination or at high salt concentrations; (2) TFIIS and Rpb9 are essential when the cells are challenged with microtubule-destabilizing drugs; (3) among the SDO (synthetic with Dst one), SOH1 shows the strongest genetic interaction with DST1; (4) the presence of multiple copies of TAF14, SUA7, GAL11, RTS1, and TYS1 alleviate the growth phenotype of dst1 soh1 mutants; and (5) SRB5 and SIN4 genetically interact with DST1.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15082542"}, {"offsetInBeginSection": 1017, "offsetInEndSection": 1203, "text": "Our results also indicate that Taf14's YEATS domain is not necessary for complementing the synthetic lethality between TAF14 and the general transcription factor TFIIS (encoded by DST1).", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20179968"}, {"offsetInBeginSection": 906, "offsetInEndSection": 1102, "text": "We additionally show that Dst1, a homolog of mammalian transcription elongation factor TFIIS, interferes with NER-dependent repair of AP lesions while suppressing homologous recombination pathway.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28521214"}, {"offsetInBeginSection": 128, "offsetInEndSection": 399, "text": "In S. cerevisiae, Taf14 is a protein physically associated with many critical multisubunit complexes including the general transcription factors TFIID and TFIIF, the chromatin remodeling complexes SWI/SNF, Ino80 and RSC, Mediator and the histone modification enzyme NuA3.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20179968"}, {"offsetInBeginSection": 576, "offsetInEndSection": 817, "text": "A mild but systematic increase in RNA polymerase occupancy and a strict dependency on the transcript cleavage factor TFIIS (Dst1) also suggest a slower rate of translocation or higher probability of transcriptional stalling in this mutation.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21761155"}, {"offsetInBeginSection": 569, "offsetInEndSection": 648, "text": "We have solved the structure of domain I of yeast TFIIS using NMR spectroscopy.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/10811649"}, {"offsetInBeginSection": 758, "offsetInEndSection": 1048, "text": "Using the yeast structure as a template, we have modeled the homologous domains from elongin A and CRSP70 and identified a conserved positively charged patch on the surface of all three proteins, which may be involved in conserved functional interactions with the transcriptional machinery.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/10811649"}, {"offsetInBeginSection": 388, "offsetInEndSection": 542, "text": "However, deletion of DST1, the gene encoding the yeast homolog of TFIIS, had only a small effect on transcriptional fidelity, as determined by this assay.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16492753"}]}, {"id": "5a3566bb966455904c000003", "body": "Does TFIIS affect nucleosome positioning?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/21177855", "http://www.ncbi.nlm.nih.gov/pubmed/12765535", "http://www.ncbi.nlm.nih.gov/pubmed/19140324", "http://www.ncbi.nlm.nih.gov/pubmed/19856965", "http://www.ncbi.nlm.nih.gov/pubmed/22019336", "http://www.ncbi.nlm.nih.gov/pubmed/15808512", "http://www.ncbi.nlm.nih.gov/pubmed/23032292", "http://www.ncbi.nlm.nih.gov/pubmed/17081995", "http://www.ncbi.nlm.nih.gov/pubmed/24733939", "http://www.ncbi.nlm.nih.gov/pubmed/19527704"], "snippets": [{"offsetInBeginSection": 651, "offsetInEndSection": 783, "text": "The nucleosome positioning on the GalCyc promoter does not depend on nucleosome positioning (or its absence) on adjoining sequences.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/12765535"}, {"offsetInBeginSection": 419, "offsetInEndSection": 601, "text": "Other mutations associated with enhanced cryptic transcription activity, such as set2\u0394, alp13\u0394 and FACT complex subunit pob3\u0394, did not, or only mildly, affect nucleosome positioning.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23032292"}, {"offsetInBeginSection": 543, "offsetInEndSection": 650, "text": "Its replacement with different DNA sequences does not affect nucleosome positioning on the GalCyc promoter.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/12765535"}, {"offsetInBeginSection": 1381, "offsetInEndSection": 1482, "text": "Galactose-induced expression does not affect nucleosome positioning with coding region of NPTII gene.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19140324"}, {"offsetInBeginSection": 845, "offsetInEndSection": 1067, "text": "It was found also that nucleosomes' positioning on the NPTII gene and their mutual disposition, namely the spacing between neighboring nucleosomes (linker length) are determined by the location of positioning signals only.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/12765535"}, {"offsetInBeginSection": 375, "offsetInEndSection": 459, "text": "Nucleosome positioning within NPTII gene in repressed and active states was studied.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19140324"}, {"offsetInBeginSection": 0, "offsetInEndSection": 119, "text": "[Nucleosome positioning within neomycinphosphotransferase gene (NPTII) on yeast plasmid in repressed and active state].", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19140324"}, {"offsetInBeginSection": 89, "offsetInEndSection": 461, "text": "To understand the structural role played by histone variants H2A.Z and H3.3, both of which are implicated in transcription regulation, we conducted extensive biochemical and biophysical analysis on mononucleosomes reconstituted from either random-sequence DNA derived from native nucleosomes or a defined DNA nucleosome positioning sequence and recombinant human histones.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19856965"}, {"offsetInBeginSection": 756, "offsetInEndSection": 929, "text": "Interestingly, both H2A.Z and H3.3 affect nucleosome positioning, either creating new positions or altering the relative occupancy of the existing nucleosome position space.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19856965"}, {"offsetInBeginSection": 110, "offsetInEndSection": 236, "text": "DNA methylation can affect nucleosome positioning and so alter gene expression epigenetically (without changing DNA sequence).", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24733939"}]}, {"id": "5a37df1c966455904c000004", "body": "How does Dst1 knock-out affect transcription in yeast?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/17535246", "http://www.ncbi.nlm.nih.gov/pubmed/28521214", "http://www.ncbi.nlm.nih.gov/pubmed/18823333", "http://www.ncbi.nlm.nih.gov/pubmed/24780862", "http://www.ncbi.nlm.nih.gov/pubmed/15082542", "http://www.ncbi.nlm.nih.gov/pubmed/16492753", "http://www.ncbi.nlm.nih.gov/pubmed/14690608", "http://www.ncbi.nlm.nih.gov/pubmed/19197357", "http://www.ncbi.nlm.nih.gov/pubmed/15956671", "http://www.ncbi.nlm.nih.gov/pubmed/11296232"], "snippets": [{"offsetInBeginSection": 774, "offsetInEndSection": 1137, "text": "ELONGATOR: Intriguingly, strains lacking non-Elongator HATs (gcn5, hat1, hpa3 and sas3) or non-Elongator transcription elongation factors TFIIS (dst1) and Spt4p (spt4) cannot confer resistance towards the K.lactis zymocin, thus providing evidence that Elongator equals TOT and that Elongator plays an important role in signalling toxicity of the K.lactis zymocin.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/11296232"}, {"offsetInBeginSection": 316, "offsetInEndSection": 614, "text": "To improve our knowledge of transcription elongation and its coupling to TC-NER, we used the yeast library of non-essential knock-out mutations to screen for genes conferring resistance to the transcription-elongation inhibitor mycophenolic acid and the DNA-damaging agent 4-nitroquinoline-N-oxide.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19197357"}, {"offsetInBeginSection": 499, "offsetInEndSection": 1123, "text": "We showed that: (1) dst1 and rpb9 mutants have a synthetic growth defective phenotype when combined with fyv4, gim5, htz1, yal011w, ybr231c, soh1, vps71, and vps72 mutants that is exacerbated during germination or at high salt concentrations; (2) TFIIS and Rpb9 are essential when the cells are challenged with microtubule-destabilizing drugs; (3) among the SDO (synthetic with Dst one), SOH1 shows the strongest genetic interaction with DST1; (4) the presence of multiple copies of TAF14, SUA7, GAL11, RTS1, and TYS1 alleviate the growth phenotype of dst1 soh1 mutants; and (5) SRB5 and SIN4 genetically interact with DST1.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15082542"}, {"offsetInBeginSection": 615, "offsetInEndSection": 776, "text": "Our data provide evidence that subunits of the SAGA and Ccr4-Not complexes, Mediator, Bre1, Bur2, and Fun12 affect transcription elongation to different extents.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19197357"}, {"offsetInBeginSection": 0, "offsetInEndSection": 297, "text": "Deletions of three yeast genes, SET2, CDC73, and DST1, involved in transcriptional elongation and/or chromatin metabolism were used in conjunction with genetic array technology to screen approximately 4700 yeast deletions and identify double deletion mutants that produce synthetic growth defects.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/14690608"}, {"offsetInBeginSection": 205, "offsetInEndSection": 302, "text": "The present study reveals a novel function of Sub1 as a transcription repressor in budding yeast.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/18823333"}, {"offsetInBeginSection": 459, "offsetInEndSection": 632, "text": "Previous reports indicate that Rad26, a yeast homolog of transcription-repair coupling factor CSB, partly mediates strand-specific repair of UV-dimers as well as AP lesions.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28521214"}, {"offsetInBeginSection": 906, "offsetInEndSection": 1102, "text": "We additionally show that Dst1, a homolog of mammalian transcription elongation factor TFIIS, interferes with NER-dependent repair of AP lesions while suppressing homologous recombination pathway.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28521214"}, {"offsetInBeginSection": 0, "offsetInEndSection": 120, "text": "Stimulation of RNA polymerase II transcript cleavage activity contributes to maintain transcriptional fidelity in yeast.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17535246"}, {"offsetInBeginSection": 510, "offsetInEndSection": 652, "text": "Yet we find strong genetic interaction of rpb4\u2206 with mutants in many transcription elongation factors such as Paf1, Spt4, Dst1, Elp3 and Rpb9.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24780862"}]}, {"id": "5a39453d966455904c000006", "body": "Which method for subsampling of NGS reads requires only gene counts?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/26130573", "http://www.ncbi.nlm.nih.gov/pubmed/24708854", "http://www.ncbi.nlm.nih.gov/pubmed/26253000", "http://www.ncbi.nlm.nih.gov/pubmed/23565205", "http://www.ncbi.nlm.nih.gov/pubmed/28419628", "http://www.ncbi.nlm.nih.gov/pubmed/26558903", "http://www.ncbi.nlm.nih.gov/pubmed/25894390", "http://www.ncbi.nlm.nih.gov/pubmed/25349885", "http://www.ncbi.nlm.nih.gov/pubmed/23441149", "http://www.ncbi.nlm.nih.gov/pubmed/25183223"], "snippets": [{"offsetInBeginSection": 622, "offsetInEndSection": 1151, "text": "It consists of three separate workflows: (1) the SA_RunStats workflow generates basic statistics about an NGS dataset, including numbers of raw, cleaned, redundant and unique reads, redundancy rate, and a list of unique sequences with length and read count; (2) the SA_Run2Ref workflow estimates the breadth, depth and evenness of genome-wide coverage of the NGS dataset at a nucleotide resolution; and (3) the SA_Run2Run workflow compares two NGS datasets to determine the redundancy (overlapping rate) between the two NGS runs.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25349885"}, {"offsetInBeginSection": 263, "offsetInEndSection": 589, "text": "For clustering genomes using such NGS data, word-count based alignment-free sequence comparison is a promising approach, but for this approach, the underlying expected word counts are essential.A plausible model for this underlying distribution of word counts is given through modeling the DNA sequence as a Markov chain (MC).", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26130573"}, {"offsetInBeginSection": 410, "offsetInEndSection": 992, "text": "RESULTS: The main results of our investigations are as follows: (1) the subsampling of RNA-seq data gave biologically realistic simulations of sequencing experiments with smaller sequencing depth but not direct scaling of count matrices; (2) the saturation of results required an average sequencing depth larger than 32 million reads and an individual sequencing depth larger than 46 million reads; and (3) for an abrogated feature selection, higher moments of the distribution of all expressed genes had a higher sensitivity for signal detection than the corresponding mean values.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26253000"}, {"offsetInBeginSection": 1152, "offsetInEndSection": 1481, "text": "Statistics produced by SeqAssist or derived from SeqAssist output files are designed to inform the user: whether, what percentage, how many times and how evenly a genomic locus (i.e., gene, scaffold, chromosome or genome) is covered by sequencing reads, how redundant the sequencing reads are in a single run or between two runs.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25349885"}, {"offsetInBeginSection": 407, "offsetInEndSection": 615, "text": "The method consists of constructing an extensive dictionary of HLA alleles, precise mapping of the NGS reads, and calculating a score based on weighted read counts to select the most suitable pair of alleles.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28419628"}, {"offsetInBeginSection": 1261, "offsetInEndSection": 1524, "text": "Within this context, NGS produces binomial counts along the genome, i.e., the number of sequenced reads that matches with the SNP of the parental reference strain, which is a proxy for the number of individuals in the offspring that share the SNP with the parent.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23441149"}, {"offsetInBeginSection": 1467, "offsetInEndSection": 1610, "text": "Comparison between raw reads and processed reads also showed that subsequent analyses (genome assembly, gene prediction, gene annotation, etc.)", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23565205"}, {"offsetInBeginSection": 1018, "offsetInEndSection": 1204, "text": "Furthermore, we determined the complete genomic sequence of an HLA-A-like-pseudogene when we assembled NGS reads that had caused arguable typing, and found its identity with HLA-Y*02:01.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28419628"}, {"offsetInBeginSection": 466, "offsetInEndSection": 651, "text": "Here, we developed an in silico method of searching NGS raw sequence reads to detect this mutation, without the need to recalculate sequence alignments or to screen every sample by PCR.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26558903"}, {"offsetInBeginSection": 1049, "offsetInEndSection": 1186, "text": "RESULTS: We proposed a new method BayesTyping1 to assign HLA alleles for PacBio circular consensus sequencing reads using Bayes' theorem.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25183223"}]}, {"id": "5a3e8683966455904c000007", "body": "Which test is used to diagnose colour synesthesia?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/25734257", "http://www.ncbi.nlm.nih.gov/pubmed/22073035", "http://www.ncbi.nlm.nih.gov/pubmed/21531581", "http://www.ncbi.nlm.nih.gov/pubmed/23458658", "http://www.ncbi.nlm.nih.gov/pubmed/19739904", "http://www.ncbi.nlm.nih.gov/pubmed/16083418", "http://www.ncbi.nlm.nih.gov/pubmed/1584615", "http://www.ncbi.nlm.nih.gov/pubmed/3876538", "http://www.ncbi.nlm.nih.gov/pubmed/24367321", "http://www.ncbi.nlm.nih.gov/pubmed/23279836"], "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 130, "text": "The use of colour difference vectors in diagnosing congenital colour vision deficiencies with the Farnsworth-Munsell 100-hue test.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/1584615"}, {"offsetInBeginSection": 587, "offsetInEndSection": 840, "text": "This study aims to find the most reliable way of diagnosing grapheme-colour synaesthesia based on maximising sensitivity (i.e., ability of a test to identify true synaesthetes) and specificity (i.e., ability of a test to identify true non-synaesthetes).", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23458658"}, {"offsetInBeginSection": 696, "offsetInEndSection": 856, "text": "We recruited 2847 participants to complete The Synesthesia Battery and found the prevalence of grapheme-colour synesthesia in the general population to be 1.2%.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25734257"}, {"offsetInBeginSection": 0, "offsetInEndSection": 98, "text": "In colour-grapheme synesthesia, non-coloured graphemes are perceived as being inherently coloured.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22073035"}, {"offsetInBeginSection": 330, "offsetInEndSection": 513, "text": "In 2007 however, Eagleman and colleagues presented an online 'Synesthesia Battery' of tests aimed at identifying synesthesia by assessing consistency but within a single test session.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25734257"}, {"offsetInBeginSection": 0, "offsetInEndSection": 129, "text": "Colour difference vector analysis provides useful and meaningful information in scoring the Farnsworth-Munsell (FM) 100-hue test.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/1584615"}, {"offsetInBeginSection": 597, "offsetInEndSection": 764, "text": "METHOD: We tested six known protan heterozygotes (four whose sons have a protan colour vision deficiency and two whose fathers are protan) with the Medmont C-100 test.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16083418"}, {"offsetInBeginSection": 0, "offsetInEndSection": 76, "text": "Diagnosing protan heterozygosity using the Medmont C-100 colour vision test.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16083418"}, {"offsetInBeginSection": 152, "offsetInEndSection": 329, "text": "Testing the consistency of these sensations over long time intervals is the behavioural gold standard assessment for detecting synesthesia (e.g., Simner, Mulvenna et al., 2006).", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25734257"}, {"offsetInBeginSection": 323, "offsetInEndSection": 429, "text": "First, we used the McGurk illusion to test the strength and number of illusory perceptions in synesthesia.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23279836"}]}, {"id": "5a43a139966455904c000008", "body": "What is measured through the NOMe-Seq methodology?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/28035030", "http://www.ncbi.nlm.nih.gov/pubmed/26484155", "http://www.ncbi.nlm.nih.gov/pubmed/27899623", "http://www.ncbi.nlm.nih.gov/pubmed/22960375", "http://www.ncbi.nlm.nih.gov/pubmed/28653622", "http://www.ncbi.nlm.nih.gov/pubmed/22479200", "http://www.ncbi.nlm.nih.gov/pubmed/21835883", "http://www.ncbi.nlm.nih.gov/pubmed/28222791", "http://www.ncbi.nlm.nih.gov/pubmed/25747664", "http://www.ncbi.nlm.nih.gov/pubmed/28413449"], "snippets": [{"offsetInBeginSection": 1198, "offsetInEndSection": 1404, "text": "Finally, these scores correctly predict known transcriptional regulators as illustrated by the application to novel DNaseI-seq and NOMe-seq data for primary human hepatocytes and CD4+ T-cells, respectively.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27899623"}, {"offsetInBeginSection": 478, "offsetInEndSection": 745, "text": "In this study, we make progress toward understanding these conflicting phenomena by implementing a bioinformatics approach that combines MNase-seq and NOMe-seq data and by comprehensively profiling DNA methylation and nucleosome occupancy throughout the human genome.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28413449"}, {"offsetInBeginSection": 256, "offsetInEndSection": 559, "text": "We have developed a method (NOMe-seq) that uses a GpC methyltransferase (M.CviPI) and next generation sequencing to generate a high resolution footprint of nucleosome positioning genome-wide using less than 1 million cells while retaining endogenous DNA methylation information from the same DNA strand.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22960375"}, {"offsetInBeginSection": 497, "offsetInEndSection": 521, "text": "DNaseI-seq and NOMe-seq.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27899623"}, {"offsetInBeginSection": 608, "offsetInEndSection": 914, "text": "Therefore, there is a great demand in developing computational methods to identify chromatin accessibility from MAPit-BGS and NOMe-seq.Results: In this article, we present CAME (Chromatin Accessibility and Methylation), a seed-extension based approach that identifies chromatin accessibility from NOMe-seq.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28035030"}, {"offsetInBeginSection": 203, "offsetInEndSection": 461, "text": "We develop a statistical method, epiG, to infer and differentiate between different epi-allelic haplotypes, annotated with CpG methylation status and DNA polymorphisms, from whole-genome bisulfite sequencing data, and nucleosome occupancy from NOMe-seq data.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28222791"}, {"offsetInBeginSection": 698, "offsetInEndSection": 935, "text": "Here we describe the bioinformatic pipeline and methods that we developed for the processing and analysis of the NOMe-seq data published by (Taberlay et al., 2014 [1]) and deposited in the Gene Expression Omnibus with accession GSE57498.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26484155"}, {"offsetInBeginSection": 735, "offsetInEndSection": 1068, "text": "According to our genome-wide expression and DNA methylation profiles, we find that the complete re-activation of silenced genes requires the insertion of the histone variant H2A.Z, which facilitates the acquisition of regions fully depleted of nucleosome as demonstrated by NOMe-seq (Nucleosome Occupancy Methylome-sequencing) assay.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22479200"}, {"offsetInBeginSection": 317, "offsetInEndSection": 607, "text": "Recently, Methyltransferase Accessibility Protocol for individual templates-Bisulfite Genome Sequencing (MAPit-BGS) and nucleosome occupancy and methylome sequencing (NOMe-seq) have been developed for simultaneously profiling chromatin accessibility and DNA methylation on single molecules.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28035030"}, {"offsetInBeginSection": 1082, "offsetInEndSection": 1391, "text": "Furthermore, using NOMe-Seq and clonal analysis, we show that in RUNX3 expressing 623 melanoma cells, RUNX3 P1 has two distinct chromatin configurations: one is unmethylated with an NDR upstream of the TSS; another is methylated and nucleosome occupied, indicating that RUNX3 P1 is monoallelically methylated.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21835883"}]}, {"id": "5a43a214966455904c000009", "body": "Is DNA methylation correlated with nucleosome occupancy?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/28413449", "http://www.ncbi.nlm.nih.gov/pubmed/23839233", "http://www.ncbi.nlm.nih.gov/pubmed/23686312", "http://www.ncbi.nlm.nih.gov/pubmed/25437056", "http://www.ncbi.nlm.nih.gov/pubmed/22960375", "http://www.ncbi.nlm.nih.gov/pubmed/24733939", "http://www.ncbi.nlm.nih.gov/pubmed/26484155", "http://www.ncbi.nlm.nih.gov/pubmed/21835883", "http://www.ncbi.nlm.nih.gov/pubmed/20602769", "http://www.ncbi.nlm.nih.gov/pubmed/25578963"], "snippets": [{"offsetInBeginSection": 1392, "offsetInEndSection": 1778, "text": "Together, these results demonstrate that the epigenetic signatures comprising DNA methylation, histone marks and nucleosome occupancy of non-CpG island promoters are almost identical to CpG island promoters, suggesting that aberrant methylation patterns of non-CpG island promoters may also contribute to tumorigenesis and should therefore be included in analyses of cancer epigenetics.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21835883"}, {"offsetInBeginSection": 142, "offsetInEndSection": 270, "text": "However, the debate on whether or not DNA methylation is a reliable indicator of high nucleosome occupancy has not been settled.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28413449"}, {"offsetInBeginSection": 890, "offsetInEndSection": 1006, "text": "Importantly, DNA methylation regulated nucleosome occupancy specifically at the -1 positioned nucleosome of MAGEA11.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23839233"}, {"offsetInBeginSection": 1184, "offsetInEndSection": 1365, "text": "Thus, DNA methylation regulates nucleosome occupancy at MAGEA11, and this appears to function cooperatively with sequence-specific transcription factors to regulate gene expression.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23839233"}, {"offsetInBeginSection": 478, "offsetInEndSection": 745, "text": "In this study, we make progress toward understanding these conflicting phenomena by implementing a bioinformatics approach that combines MNase-seq and NOMe-seq data and by comprehensively profiling DNA methylation and nucleosome occupancy throughout the human genome.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28413449"}, {"offsetInBeginSection": 745, "offsetInEndSection": 919, "text": "RESULTS: The results demonstrated that increasing methylated CpG density is correlated with nucleosome occupancy in the total genome and within nearly all subgenomic regions.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28413449"}, {"offsetInBeginSection": 467, "offsetInEndSection": 697, "text": "To address this we used Nucleosome Occupancy and Methylation sequencing (NOMe-seq) to compare the genome-wide DNA methylation and nucleosome occupancy profiles between normal and cancer cell line models of the breast and prostate.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26484155"}, {"offsetInBeginSection": 1518, "offsetInEndSection": 1821, "text": "Prominent exceptions to the correlations between methylated CpG density and nucleosome occupancy include CpG islands marked by H3K27me3 and CpG-poor heterochromatin marked by H3K9me3, and these modifications, along with DNA methylation, distinguish the major silencing mechanisms of the human epigenome.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28413449"}, {"offsetInBeginSection": 256, "offsetInEndSection": 559, "text": "We have developed a method (NOMe-seq) that uses a GpC methyltransferase (M.CviPI) and next generation sequencing to generate a high resolution footprint of nucleosome positioning genome-wide using less than 1 million cells while retaining endogenous DNA methylation information from the same DNA strand.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22960375"}, {"offsetInBeginSection": 1821, "offsetInEndSection": 2015, "text": "CONCLUSIONS: Thus, the relationship between DNA methylation and nucleosome occupancy is influenced by the density of methylated CpG dinucleotides and by other epigenomic components in chromatin.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28413449"}]}, {"id": "5a43a581966455904c00000a", "body": "Which are the properties of mammalian GA-sequences?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/19043592", "http://www.ncbi.nlm.nih.gov/pubmed/19270754", "http://www.ncbi.nlm.nih.gov/pubmed/22626543", "http://www.ncbi.nlm.nih.gov/pubmed/1463824", "http://www.ncbi.nlm.nih.gov/pubmed/9545369", "http://www.ncbi.nlm.nih.gov/pubmed/19845643", "http://www.ncbi.nlm.nih.gov/pubmed/2558055", "http://www.ncbi.nlm.nih.gov/pubmed/11884146", "http://www.ncbi.nlm.nih.gov/pubmed/10037452", "http://www.ncbi.nlm.nih.gov/pubmed/6301150"], "snippets": [{"offsetInBeginSection": 703, "offsetInEndSection": 1076, "text": "We propose that mammalian TE sequences have specific nucleosome binding properties with regulatory implications for nearby genes, are involved in the phasing of nucleosomes, and recruit epigenetic modifications to function as enhancers; that epigenetic modifications at TE sequences affect the regulation of nearby genes; and that TEs serve as epigenetic boundary elements.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19845643"}, {"offsetInBeginSection": 241, "offsetInEndSection": 536, "text": "The third GA module of protein G from the group G streptococcal strain G148 (G148-GA3) and the second GA module of protein PAB from P.magnus strain ALB8 (ALB8-GA) exhibit 59% sequence identity and both fold to form three-helix bundle structures that are very stable against thermal denaturation.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/11884146"}, {"offsetInBeginSection": 537, "offsetInEndSection": 689, "text": "ALB8-GA binds human serum albumin with higher affinity than G148-GA3, but G148-GA3 shows substantially broader albumin-binding specificity than ALB8-GA.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/11884146"}, {"offsetInBeginSection": 143, "offsetInEndSection": 658, "text": "Here, we provide an overview of the neuroanatomical, neurophysiological and molecular properties of reticular neurons within the nucleus gigantocellularis (NGC) of the mammalian medulla, and propose that the properties of these neurons equip them to contribute powerfully to GA. We also explore the hypothesis that these neurons may have evolved from the Mauthner cell in the medulla of teleost fish, although NGC neurons have a wider range of action far beyond the specific escape network served by Mauthner cells.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22626543"}, {"offsetInBeginSection": 0, "offsetInEndSection": 95, "text": "Outline of a genome navigation system based on the properties of GA-sequences and their flanks.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19270754"}, {"offsetInBeginSection": 0, "offsetInEndSection": 149, "text": "The article describes DNA sequences of mammalian genomes that are longer than 50 bases, but consist exclusively of G's and A's ('pure GA-sequences').", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19043592"}, {"offsetInBeginSection": 717, "offsetInEndSection": 905, "text": "Sequence comparison with a GA responsive promoter of an alpha-amylase gene identified the conserved element GCAACGGCAACGATGG which is required intact for full expression of both promoters.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/1463824"}, {"offsetInBeginSection": 754, "offsetInEndSection": 946, "text": "The GAAACG repeats of interferon- and virus-inducible genes, and the GA-rich repeats of HSV1 IE genes confer similar functional properties when appended to the promoter of a heterologous gene.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/2558055"}, {"offsetInBeginSection": 0, "offsetInEndSection": 207, "text": "Introducing a new method to visualize large stretches of genomic DNA (see Appendix S1) the article reports that most GA-sequences [1] shared chains of tetra-GA-motifs and contained upstream poly(A)-segments.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19270754"}, {"offsetInBeginSection": 906, "offsetInEndSection": 1156, "text": "However, there was no identifiable similarity in the cathepsin-like promoter with the GA-responsive element of alpha-amylase promoters with the consensus sequence TAACAAA, suggesting that GA affects more than one mechanism of transcriptional control.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/1463824"}]}, {"id": "5a43a933966455904c00000b", "body": "How may CTCF mediate splicing?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/26711177", "http://www.ncbi.nlm.nih.gov/pubmed/21964334", "http://www.ncbi.nlm.nih.gov/pubmed/25934638", "http://www.ncbi.nlm.nih.gov/pubmed/27083996", "http://www.ncbi.nlm.nih.gov/pubmed/24657531", "http://www.ncbi.nlm.nih.gov/pubmed/28594324", "http://www.ncbi.nlm.nih.gov/pubmed/28150704", "http://www.ncbi.nlm.nih.gov/pubmed/26938874", "http://www.ncbi.nlm.nih.gov/pubmed/20020479", "http://www.ncbi.nlm.nih.gov/pubmed/26154016"], "snippets": [{"offsetInBeginSection": 1703, "offsetInEndSection": 1899, "text": "CONCLUSIONS: Our results show that a considerable number of alternative splicing events could have a chromatin-dependent regulation involving the association of HP1\u03b1 and CTCF near regulated exons.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25934638"}, {"offsetInBeginSection": 294, "offsetInEndSection": 534, "text": "In particular, the CCCTC-binding factor (CTCF), the Argonaute protein AGO1, and members of the heterochromatin protein 1 (HP1) family have been implicated in the regulation of splicing associated with chromatin and the elongation of RNAPII.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25934638"}, {"offsetInBeginSection": 565, "offsetInEndSection": 828, "text": "Here we provide the first evidence that a DNA-binding protein, CCCTC-binding factor (CTCF), can promote inclusion of weak upstream exons by mediating local RNA polymerase II pausing both in a mammalian model system for alternative splicing, CD45, and genome-wide.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21964334"}, {"offsetInBeginSection": 325, "offsetInEndSection": 514, "text": "Here, we reveal the methylcytosine dioxygenases TET1 and TET2 as active regulators of CTCF-mediated alternative splicing through conversion of 5-methylcytosine to its oxidation derivatives.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26711177"}, {"offsetInBeginSection": 931, "offsetInEndSection": 1147, "text": "We further show genomewide that reciprocal exchange of 5-hydroxymethylcytosine and 5-methylcytosine at downstream CTCF-binding sites is a general feature of alternative splicing in na\u00efve and activated CD4(+) T cells.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26711177"}, {"offsetInBeginSection": 0, "offsetInEndSection": 230, "text": "Intragenic 5-methylcytosine and CTCF mediate opposing effects on pre-mRNA splicing: CTCF promotes inclusion of weak upstream exons through RNA polymerase II pausing, whereas 5-methylcytosine evicts CTCF, leading to exon exclusion.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26711177"}, {"offsetInBeginSection": 0, "offsetInEndSection": 53, "text": "Role of CTCF in Regulating SLC45A3-ELK4 Chimeric RNA.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26938874"}, {"offsetInBeginSection": 1558, "offsetInEndSection": 1703, "text": "Additionally, we found a significant association of HP1\u03b1 and CTCF activities around the regulated exons and a putative DNA binding site for HP1\u03b1.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25934638"}, {"offsetInBeginSection": 664, "offsetInEndSection": 1025, "text": "RESULTS: Using chromatin immunoprecipitation sequencing (ChIP-Seq) data for CTCF, AGO1, HP1\u03b1, H3K27me3, H3K9me2, H3K36me3, RNAPII, total H3 and 5metC and alternative splicing arrays from two cell lines, we have analyzed the combinatorial code of their binding to chromatin in relation to the alternative splicing patterns between two cell lines, MCF7 and MCF10.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25934638"}, {"offsetInBeginSection": 0, "offsetInEndSection": 101, "text": "TET-catalyzed oxidation of intragenic 5-methylcytosine regulates CTCF-dependent alternative splicing.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26711177"}]}, {"id": "5a43b2d7966455904c00000c", "body": "Which are the best methods for the prediction of circular RNA (circRNA)?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/26846540", "http://www.ncbi.nlm.nih.gov/pubmed/29165116", "http://www.ncbi.nlm.nih.gov/pubmed/27493192", "http://www.ncbi.nlm.nih.gov/pubmed/28346469", "http://www.ncbi.nlm.nih.gov/pubmed/27241756", "http://www.ncbi.nlm.nih.gov/pubmed/27097056", "http://www.ncbi.nlm.nih.gov/pubmed/28744405", "http://www.ncbi.nlm.nih.gov/pubmed/28977896", "http://www.ncbi.nlm.nih.gov/pubmed/28082450", "http://www.ncbi.nlm.nih.gov/pubmed/28265491"], "snippets": [{"offsetInBeginSection": 335, "offsetInEndSection": 765, "text": "RESULTS: A circRNA prediction software for plants (termed PcircRNA_finder) was developed that is more sensitive in detecting circRNAs than other frequently used programs (such as find_circ and CIRCexplorer), Based on analysis of simulated and real rRNA-/RNAase R RNA-Seq data from Arabidopsis thaliana and rice PcircRNA_finder provides a more comprehensive sensitive, precise prediction method for plants circRNAs.AVAILABILITY AND", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27493192"}, {"offsetInBeginSection": 109, "offsetInEndSection": 268, "text": "Recently, circular RNA (circRNA), a class of endogenous non-protein coding RNAs that contain a circular loop, was found to exhibit multiple biological effects.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/29165116"}, {"offsetInBeginSection": 260, "offsetInEndSection": 650, "text": "While independent studies confirm the expression of circRNA in various tissue types, genome-wide circRNA expression in the heart has yet to be described in detail.Methods and results: We performed deep RNA-sequencing on ribosomal-depleted RNA isolated from 12 human hearts, 25 mouse hearts and across a 28-day differentiation time-course of human embryonic stem cell-derived cardiomyocytes.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28082450"}, {"offsetInBeginSection": 0, "offsetInEndSection": 259, "text": "Aims: Circular RNA (circRNA) is a newly validated class of single-stranded RNA, ubiquitously expressed in mammalian tissues and possessing key functions including acting as microRNA sponges and as transcriptional regulators by binding to RNA-binding proteins.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28082450"}, {"offsetInBeginSection": 0, "offsetInEndSection": 126, "text": "MOTIVATION: Recent studies reveal an important role of non-coding circular RNA (circRNA) in the control of cellular processes.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27493192"}, {"offsetInBeginSection": 0, "offsetInEndSection": 272, "text": "Deregulated expression of circular RNA (circRNA) has been determined to be important in carcinogenesis and progression; however, in the most common type of primary malignant bone tumor osteosarcoma, the roles of circRNA in cancer development still remain to be elucidated.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28977896"}, {"offsetInBeginSection": 0, "offsetInEndSection": 104, "text": "Circular RNA circ-ABCB10 promotes breast cancer proliferation and progression through sponging miR-1271.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28744405"}, {"offsetInBeginSection": 0, "offsetInEndSection": 273, "text": "OBJECTIVE: To determine the expression of circular RNA (circRNA) in blood corpuscles of pregnant women before 20\u00a0weeks of pregnancy and to create a new model to identify the performance of circRNA combined with protein factors for the early diagnosis of pre-eclampsia (PE).", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26846540"}, {"offsetInBeginSection": 0, "offsetInEndSection": 145, "text": "Recent improvements in high-throughput sequencing technologies underscore the pervasiveness of circular RNA (circRNA) expression in animal cells.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27241756"}, {"offsetInBeginSection": 0, "offsetInEndSection": 107, "text": "Circular RNA in blood corpuscles combined with plasma protein factor for early prediction of pre-eclampsia.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26846540"}]}, {"id": "5a468785966455904c00000d", "body": "Does RNA polymerase II have RNA cleavage activity?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/1371280", "http://www.ncbi.nlm.nih.gov/pubmed/1379232", "http://www.ncbi.nlm.nih.gov/pubmed/8312968", "http://www.ncbi.nlm.nih.gov/pubmed/17535246", "http://www.ncbi.nlm.nih.gov/pubmed/9869639", "http://www.ncbi.nlm.nih.gov/pubmed/8090778", "http://www.ncbi.nlm.nih.gov/pubmed/7503982", "http://www.ncbi.nlm.nih.gov/pubmed/12692127", "http://www.ncbi.nlm.nih.gov/pubmed/9037112", "http://www.ncbi.nlm.nih.gov/pubmed/25764335"], "snippets": [{"offsetInBeginSection": 866, "offsetInEndSection": 1088, "text": "We propose that C11 allows the enzyme to switch between an RNA elongation and RNA cleavage mode and that the essential role of the Pol III RNA cleavage activity is to remove the kinetic barriers to the termination process.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/9869639"}, {"offsetInBeginSection": 0, "offsetInEndSection": 142, "text": "The RNA cleavage activity of RNA polymerase III is mediated by an essential TFIIS-like subunit and is important for transcription termination.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/9869639"}, {"offsetInBeginSection": 520, "offsetInEndSection": 623, "text": "In vitro reconstitution experiments demonstrated that Pol III RNA cleavage activity is mediated by C11.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/9869639"}, {"offsetInBeginSection": 0, "offsetInEndSection": 148, "text": "The transcription elongation factor S-II, also designated TFIIS, stimulates the nascent transcript cleavage activity intrinsic to RNA polymerase II.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17535246"}, {"offsetInBeginSection": 430, "offsetInEndSection": 519, "text": "Remarkably, Pol III Delta lacked the intrinsic RNA cleavage activity of complete Pol III.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/9869639"}, {"offsetInBeginSection": 159, "offsetInEndSection": 395, "text": "By site-directed mutagenesis, we have demonstrated that invariant residues Asp-261 and Glu-262 of the nucleic acid-binding TFIIS Zn ribbon are critical for stimulation of both elongation and RNA cleavage activities of RNA polymerase II.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/8090778"}, {"offsetInBeginSection": 326, "offsetInEndSection": 634, "text": "Here we show that a single amino-acid substitution in the trigger loop (TL) of Saccharomyces RNAP II, Rpb1 H1085Y, engenders a gain of intrinsic cleavage activity where the substituted tyrosine appears to participate in acid-base chemistry at alkaline pH for both intrinsic cleavage and nucleotidyl transfer.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25764335"}, {"offsetInBeginSection": 848, "offsetInEndSection": 996, "text": "These results suggest that both S-II and Rpb9 maintain transcriptional fidelity by stimulating the cleavage activity intrinsic to RNA polymerase II.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17535246"}, {"offsetInBeginSection": 151, "offsetInEndSection": 348, "text": "Bypass of many of these impediments is facilitated by elongation factor TFIIS through a mechanism that involves cleavage of the nascent transcript by the RNA polymerase II/TFIIS elongation complex.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/12692127"}, {"offsetInBeginSection": 149, "offsetInEndSection": 244, "text": "Rpb9, a small subunit of RNA polymerase II, enhances the cleavage stimulation activity of S-II.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17535246"}]}, {"id": "5a4df811966455904c00000e", "body": "Which RNA polymerase II subunit carries RNA cleavage activity?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/9869639", "http://www.ncbi.nlm.nih.gov/pubmed/17535246", "http://www.ncbi.nlm.nih.gov/pubmed/21454497", "http://www.ncbi.nlm.nih.gov/pubmed/22396529", "http://www.ncbi.nlm.nih.gov/pubmed/8090778", "http://www.ncbi.nlm.nih.gov/pubmed/23847103", "http://www.ncbi.nlm.nih.gov/pubmed/7678416", "http://www.ncbi.nlm.nih.gov/pubmed/9037112", "http://www.ncbi.nlm.nih.gov/pubmed/9150890", "http://www.ncbi.nlm.nih.gov/pubmed/10777522"], "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 142, "text": "The RNA cleavage activity of RNA polymerase III is mediated by an essential TFIIS-like subunit and is important for transcription termination.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/9869639"}, {"offsetInBeginSection": 560, "offsetInEndSection": 869, "text": "In the resulting model of Pol I, the C-terminal ribbon (C-ribbon) domain of A12.2 reaches the active site via the polymerase pore, like the C-ribbon of the Pol II cleavage factor TFIIS, explaining why the intrinsic RNA cleavage activity of Pol I is strong, in contrast to the weak cleavage activity of Pol II.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22396529"}, {"offsetInBeginSection": 866, "offsetInEndSection": 1088, "text": "We propose that C11 allows the enzyme to switch between an RNA elongation and RNA cleavage mode and that the essential role of the Pol III RNA cleavage activity is to remove the kinetic barriers to the termination process.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/9869639"}, {"offsetInBeginSection": 520, "offsetInEndSection": 623, "text": "In vitro reconstitution experiments demonstrated that Pol III RNA cleavage activity is mediated by C11.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/9869639"}, {"offsetInBeginSection": 0, "offsetInEndSection": 148, "text": "The transcription elongation factor S-II, also designated TFIIS, stimulates the nascent transcript cleavage activity intrinsic to RNA polymerase II.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17535246"}, {"offsetInBeginSection": 149, "offsetInEndSection": 244, "text": "Rpb9, a small subunit of RNA polymerase II, enhances the cleavage stimulation activity of S-II.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17535246"}, {"offsetInBeginSection": 159, "offsetInEndSection": 395, "text": "By site-directed mutagenesis, we have demonstrated that invariant residues Asp-261 and Glu-262 of the nucleic acid-binding TFIIS Zn ribbon are critical for stimulation of both elongation and RNA cleavage activities of RNA polymerase II.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/8090778"}, {"offsetInBeginSection": 403, "offsetInEndSection": 599, "text": "In vitro transcription experiments with paused elongation complexes at position +25 showed that TFS is able to induce cleavage activity in the archaeal RNA polymerase in a similar manner to TFIIS.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/10777522"}, {"offsetInBeginSection": 0, "offsetInEndSection": 141, "text": "The transcription factor TFIIS zinc ribbon dipeptide Asp-Glu is critical for stimulation of elongation and RNA cleavage by RNA polymerase II.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/8090778"}, {"offsetInBeginSection": 868, "offsetInEndSection": 1164, "text": "Involvement of the vaccinia RNA polymerase subunit rpo30 in the transcript-shortening reaction is suggested based on sequence similarity of rpo30 to mammalian protein SII (TFIIS), an extrinsic transcription factor required for nascent RNA cleavage by RNA polymerase II (Reines, D. (1991) J. Biol.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/7678416"}]}, {"id": "5a4e1882966455904c00000f", "body": "Is there a sequence bias in MNase digestion patterns?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/21206756", "http://www.ncbi.nlm.nih.gov/pubmed/26080409", "http://www.ncbi.nlm.nih.gov/pubmed/22559821", "http://www.ncbi.nlm.nih.gov/pubmed/23458408", "http://www.ncbi.nlm.nih.gov/pubmed/29073207", "http://www.ncbi.nlm.nih.gov/pubmed/22310051", "http://www.ncbi.nlm.nih.gov/pubmed/27185945", "http://www.ncbi.nlm.nih.gov/pubmed/22183607", "http://www.ncbi.nlm.nih.gov/pubmed/1988681", "http://www.ncbi.nlm.nih.gov/pubmed/29052192"], "snippets": [{"offsetInBeginSection": 849, "offsetInEndSection": 1065, "text": "RESULTS: In this study we use MNase digestion simulations to demonstrate how MNase-seq signals can vary for different nucleosome configuration when experiments are performed with different extents of MNase digestion.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22559821"}, {"offsetInBeginSection": 188, "offsetInEndSection": 403, "text": "Here, we show that the MNase digestion of nucleosomes assembled on a strong nucleosome positioning sequence, Widom's clone 601, releases nucleosome cores whose sizes are strongly affected by the linker DNA sequence.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23458408"}, {"offsetInBeginSection": 953, "offsetInEndSection": 1147, "text": "The differentiation related changes in the DNase I and MNase digestion pattern in the 5' region of the gene suggest that sequences present in the first intron may be involved in gene regulation.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/1988681"}, {"offsetInBeginSection": 228, "offsetInEndSection": 411, "text": "Here we illustrate how to profile nucleosome occupancy at genome-wide scale using micrococcal nuclease (MNase) digestion combined with high throughput Illumina sequencing (MNase-seq).", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/29052192"}, {"offsetInBeginSection": 1066, "offsetInEndSection": 1213, "text": "Signal variation in these simulations reveals an important DNA sampling bias that results from a neighborhood effect of MNase digestion techniques.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22559821"}, {"offsetInBeginSection": 414, "offsetInEndSection": 639, "text": "Here, we established a gel-based method to map nucleosome positions in Saccharomyces cerevisiae, using isolated nuclei as the substrate for the histone H4 S47C-site-directed chemical cleavage in parallel with MNase digestion.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/29073207"}, {"offsetInBeginSection": 222, "offsetInEndSection": 389, "text": "In this study, we use a differential nuclease sensitivity assay based on micrococcal nuclease (MNase) digestion to discover open chromatin regions in the maize genome.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27185945"}, {"offsetInBeginSection": 477, "offsetInEndSection": 633, "text": "To determine nucleosome organization genome-wide, DNA remaining from MNase digestion is sequenced using high-throughput sequencing technologies (MNase-seq).", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22559821"}, {"offsetInBeginSection": 286, "offsetInEndSection": 462, "text": "Short sequence reads (25-36 bp) from ends of mononucleosome-sized DNA generated from MNase digestion of chromatin can be determined using next-generation sequencing techniques.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22183607"}, {"offsetInBeginSection": 130, "offsetInEndSection": 285, "text": "The nucleosome structure protects DNA from microccocal nuclease (MNase) digestion and leaves a footprint on DNA that indicates the position of nucleosomes.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22183607"}]}, {"id": "5a4e50b242878bf97d000001", "body": "Which topoisomerase is essential in yeast?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/10497270", "http://www.ncbi.nlm.nih.gov/pubmed/2842762", "http://www.ncbi.nlm.nih.gov/pubmed/1332607", "http://www.ncbi.nlm.nih.gov/pubmed/11350066", "http://www.ncbi.nlm.nih.gov/pubmed/11353773", "http://www.ncbi.nlm.nih.gov/pubmed/10075939", "http://www.ncbi.nlm.nih.gov/pubmed/2989818", "http://www.ncbi.nlm.nih.gov/pubmed/2840207", "http://www.ncbi.nlm.nih.gov/pubmed/6323017", "http://www.ncbi.nlm.nih.gov/pubmed/18570880"], "snippets": [{"offsetInBeginSection": 720, "offsetInEndSection": 856, "text": "A topoisomerase activity is involved in this process, since expression of bacterial TopA in yeast top3Delta mutants permits sporulation.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/10075939"}, {"offsetInBeginSection": 0, "offsetInEndSection": 82, "text": "A distinct subnuclear localization of mammalian DNA topoisomerase IIbeta in yeast.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/11350066"}, {"offsetInBeginSection": 0, "offsetInEndSection": 242, "text": "Since DNA topoisomerase II (EC 5.99.1.3) is an essential enzyme in yeast, heterologous topoisomerase II gene expression in yeast cells can provide a system for analyzing the structure and function of topoisomerase II genes from other species.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/2842762"}, {"offsetInBeginSection": 270, "offsetInEndSection": 414, "text": "Seven top1 (mak1) mutants including gene disruptions are viable, demonstrating that DNA topoisomerase I is not essential for viability in yeast.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/2989818"}, {"offsetInBeginSection": 0, "offsetInEndSection": 153, "text": "Studies with yeast DNA topoisomerase mutants indicate that neither topoisomerase I nor II appears to be essential for transcription by RNA polymerase II.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/2840207"}, {"offsetInBeginSection": 505, "offsetInEndSection": 799, "text": "Deletion analysis revealed that two regions (amino acids 1207-1234 and 1513-1573) of the topoisomerase IIbeta-CTD are essential for specific localization of the beta isoform: if either of the two regions is removed, the mutant topoisomerase IIbeta-CTD distributes evenly throughout the nucleus.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/11350066"}, {"offsetInBeginSection": 0, "offsetInEndSection": 90, "text": "Topoisomerase III is essential for accurate nuclear division in Schizosaccharomyces pombe.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/10497270"}, {"offsetInBeginSection": 152, "offsetInEndSection": 331, "text": "In this study, mammalian topoisomerase IIalpha-CTD and IIbeta-CTD were tagged with yellow fluorescent protein (YFP), expressed in yeast cells, and their localization was examined.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/11350066"}, {"offsetInBeginSection": 1467, "offsetInEndSection": 1695, "text": "Our data are consistent with a model in which the association of a RecQ helicase and topoisomerase III is important for facilitating decatenation of late stage replicons to permit faithful chromosome segregation during anaphase.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/10497270"}, {"offsetInBeginSection": 0, "offsetInEndSection": 179, "text": "The gene TOP2 encoding yeast topoisomerase II has been cloned by immunological screening of a yeast genomic library constructed in the phage lambda expression vector, lambda gt11.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/6323017"}]}, {"id": "5a82fc89faa1ab7d2e000028", "body": "Which yeast nucleosomes are preferentially marked by H2A.Z?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/24613878", "http://www.ncbi.nlm.nih.gov/pubmed/18268003", "http://www.ncbi.nlm.nih.gov/pubmed/17671089", "http://www.ncbi.nlm.nih.gov/pubmed/21266479", "http://www.ncbi.nlm.nih.gov/pubmed/21187892", "http://www.ncbi.nlm.nih.gov/pubmed/26116819", "http://www.ncbi.nlm.nih.gov/pubmed/22393239", "http://www.ncbi.nlm.nih.gov/pubmed/16543223", "http://www.ncbi.nlm.nih.gov/pubmed/16248679", "http://www.ncbi.nlm.nih.gov/pubmed/26974124"], "snippets": [{"offsetInBeginSection": 187, "offsetInEndSection": 568, "text": "We report the successful implementation of single molecule tools constituting fluorescence correlation spectroscopy (FCS), pulse interleave excitation-based F\u00f6rster resonance energy transfer (PIE-FRET) and fluorescence lifetime imaging-based FRET (FLIM-FRET) to elucidate the composition of single nucleosomes containing histone variant H2A.Z (Htz1p in yeast) in vitro and in vivo.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22393239"}, {"offsetInBeginSection": 341, "offsetInEndSection": 502, "text": "Here, we report the crystal structure of the H2A.Z-binding domain of Drosophila melanogaster YL1 (dYL1-Z) in complex with an H2A.Z-H2B dimer at 1.9-\u00c5 resolution.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26974124"}, {"offsetInBeginSection": 503, "offsetInEndSection": 717, "text": "The dYL1-Z domain adopts a new whip-like structure that wraps over H2A.Z-H2B, and preferential recognition is largely conferred by three residues in loop 2, the hyperacidic patch and the extended \u03b1C helix of H2A.Z.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26974124"}, {"offsetInBeginSection": 402, "offsetInEndSection": 574, "text": "Anp32e preferentially associates with H2A.Z-H2B dimers rather than H2A-H2B dimers in vitro and in vivo and dissociates non-nucleosomal aggregates formed by DNA and H2A-H2B.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24613878"}, {"offsetInBeginSection": 0, "offsetInEndSection": 125, "text": "H2A.Z demarcates intergenic regions of the plasmodium falciparum epigenome that are dynamically marked by H3K9ac and H3K4me3.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21187892"}, {"offsetInBeginSection": 1005, "offsetInEndSection": 1191, "text": "Cells overexpressing Anp32e displayed a strong global H2A.Z loss at the +1 nucleosomes, whereas cells depleted of Anp32e displayed a moderate global H2A.Z increase at the +1 nucleosomes.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24613878"}, {"offsetInBeginSection": 125, "offsetInEndSection": 336, "text": "The chromatin remodeler SWR1 mediates site-specific incorporation of H2A.Z by a multi-step histone replacement reaction, evicting histone H2A-H2B from the canonical nucleosome and depositing the H2A.Z-H2B dimer.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26116819"}, {"offsetInBeginSection": 213, "offsetInEndSection": 340, "text": "The YL1 (Swc2) subunit of SRCAP (SWR1) plays an essential role in H2A.Z recognition, but how it achieves this has been unclear.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26974124"}, {"offsetInBeginSection": 899, "offsetInEndSection": 1053, "text": "The almost perfect colocalisation of H2A.Z with H3K9ac and H3K4me3 suggests that these marks are preferentially deposited on H2A.Z-containing nucleosomes.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21187892"}, {"offsetInBeginSection": 1192, "offsetInEndSection": 1419, "text": "This suggests that Anp32e may help to resolve the non-nucleosomal H2A.Z aggregates and also facilitate the removal of H2A.Z at the +1 nucleosomes, and the latter may help RNA polymerase II to pass the first nucleosomal barrier.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24613878"}]}, {"id": "5a855585faa1ab7d2e000029", "body": "What is the origin of XUT transcripts in yeast?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/26805575", "http://www.ncbi.nlm.nih.gov/pubmed/21697827", "http://www.ncbi.nlm.nih.gov/pubmed/29114019", "http://www.ncbi.nlm.nih.gov/pubmed/20962350", "http://www.ncbi.nlm.nih.gov/pubmed/26184436", "http://www.ncbi.nlm.nih.gov/pubmed/28557013", "http://www.ncbi.nlm.nih.gov/pubmed/21421781", "http://www.ncbi.nlm.nih.gov/pubmed/28981695", "http://www.ncbi.nlm.nih.gov/pubmed/6270142", "http://www.ncbi.nlm.nih.gov/pubmed/12844360"], "snippets": [{"offsetInBeginSection": 656, "offsetInEndSection": 891, "text": "In contrast to human mitochondrial RNA polymerase, which primes DNA polymerase \u03b3 using transcripts from the light-strand and heavy-strand origins of replication, Rpo41 primes Mip1 at replication origins and promoter sequences in vitro.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26184436"}, {"offsetInBeginSection": 1041, "offsetInEndSection": 1238, "text": "This study reports the first molecular characterization of the annotated XUT genes of Scheffersomyces stipitis and open reading frames from the yeasts Yarrowia lipolytica and Debaryomyces hansenii.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21421781"}, {"offsetInBeginSection": 660, "offsetInEndSection": 780, "text": "RNA profiling revealed that the resulting aslncRNAs mainly correspond to cryptic Xrn1/Exo2-sensitive transcripts (XUTs).", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/29114019"}, {"offsetInBeginSection": 0, "offsetInEndSection": 80, "text": "XUTs are a class of Xrn1-sensitive antisense regulatory non-coding RNA in yeast.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21697827"}, {"offsetInBeginSection": 227, "offsetInEndSection": 440, "text": "To systematically understand the general features of de novo genes, we established a robust pipeline to analyze >20,000 transcript-supported coding sequences (CDSs) from the budding yeast Saccharomyces cerevisiae.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28981695"}, {"offsetInBeginSection": 1641, "offsetInEndSection": 1775, "text": "Our results demonstrate that antisense ncRNA-mediated regulation is a general regulatory pathway for gene expression in S. cerevisiae.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21697827"}, {"offsetInBeginSection": 0, "offsetInEndSection": 151, "text": "Antisense long non-coding (aslnc)RNAs represent a\u00a0substantial part of eukaryotic transcriptomes that are, in yeast, controlled by the Xrn1 exonuclease.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26805575"}, {"offsetInBeginSection": 0, "offsetInEndSection": 216, "text": "Three proteins phylogenetically grouped with proteins from the T7 replisome localize to yeast mitochondria: DNA polymerase \u03b3 (Mip1), mitochondrial RNA polymerase (Rpo41), and a single-stranded binding protein (Rim1).", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26184436"}, {"offsetInBeginSection": 0, "offsetInEndSection": 105, "text": "Nonsense-Mediated Decay Restricts LncRNA Levels in Yeast Unless Blocked by Double-Stranded RNA Structure.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26805575"}, {"offsetInBeginSection": 1132, "offsetInEndSection": 1338, "text": "Notably, RNAPII chromatin immunoprecipitation followed by DNA sequencing (ChIP-seq) analysis of Xrn1-deficient strains revealed a significant decrease of RNAPII occupancy over 273 genes with antisense XUTs.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21697827"}]}, {"id": "5a859184faa1ab7d2e000031", "body": "How are cryptic unstable transcripts (CUTs) defined?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/19169244", "http://www.ncbi.nlm.nih.gov/pubmed/16973436", "http://www.ncbi.nlm.nih.gov/pubmed/16973437", "http://www.ncbi.nlm.nih.gov/pubmed/27113450", "http://www.ncbi.nlm.nih.gov/pubmed/21863483", "http://www.ncbi.nlm.nih.gov/pubmed/18022358", "http://www.ncbi.nlm.nih.gov/pubmed/22567365", "http://www.ncbi.nlm.nih.gov/pubmed/18775327", "http://www.ncbi.nlm.nih.gov/pubmed/18660821", "http://www.ncbi.nlm.nih.gov/pubmed/18316478"], "snippets": [{"offsetInBeginSection": 189, "offsetInEndSection": 378, "text": "Most of these ncRNAs (ncRNAs) are subject to termination by the Nrd1-dependent pathway and rapid degradation by the nuclear exosome and have been dubbed cryptic unstable transcripts (CUTs).", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22567365"}, {"offsetInBeginSection": 0, "offsetInEndSection": 163, "text": "Cryptic unstable transcripts (CUTs) are short, 300-600-nucleotide (nt) RNA polymerase II transcripts that are rapidly degraded by the nuclear RNA exosome in yeast.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/18660821"}, {"offsetInBeginSection": 0, "offsetInEndSection": 210, "text": "Cryptic unstable transcripts (CUTs) are synthesized from intra- and intergenic regions in Saccharomyces cerevisiae and are rapidly degraded by RNA surveillance pathways, but their function(s) remain(s) elusive.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/18316478"}, {"offsetInBeginSection": 129, "offsetInEndSection": 275, "text": "Cryptic unstable transcripts (CUTs) are generated by RNA polymerase II (Pol II) and rapidly degraded after transcription in wild-type yeast cells.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/18775327"}, {"offsetInBeginSection": 0, "offsetInEndSection": 90, "text": "Cryptic unstable transcripts (CUTs) are widely distributed in the genome of S. cerevisiae.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16973437"}, {"offsetInBeginSection": 0, "offsetInEndSection": 190, "text": "There is extensive transcription throughout the eukaryotic genome resulting in both antisense transcripts from coding regions and cryptic unstable transcripts (CUTs) from intergenic regions.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/18022358"}, {"offsetInBeginSection": 118, "offsetInEndSection": 204, "text": "These cryptic unstable transcripts (CUTs) are rapidly degraded by the nuclear exosome.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16973436"}, {"offsetInBeginSection": 171, "offsetInEndSection": 313, "text": "Cryptic unstable transcripts (CUTs) were recently described as a principal class of RNA polymerase II transcripts in Saccharomyces cerevisiae.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19169244"}, {"offsetInBeginSection": 0, "offsetInEndSection": 141, "text": "BACKGROUND: Cryptic unstable transcripts (CUTs) are a largely unexplored class of nuclear exosome degraded, non-coding RNAs in budding yeast.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27113450"}, {"offsetInBeginSection": 0, "offsetInEndSection": 101, "text": "Cryptic unstable transcripts (CUTs) have been recently described as a major class of non-coding RNAs.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21863483"}]}]}